

## CURRICULUM VITAE

### TERENCE ARTHUR KETTER, M.D.

**OFFICE ADDRESS:** Department of Psychiatry and Behavioral Sciences  
Stanford University School of Medicine  
Stanford, California 94305-5723  
Telephone: (650) 723-2515  
Fax: (650) 723-2507

**BORN:** April 20, 1950. Toronto, Ontario, Canada

**CITIZEN OF:** United States of America

#### EDUCATION AND TRAINING:

1969-1973	University of Toronto, Toronto, Canada B.Sc. (Mathematics) 1973
1974-1976	University of Sydney, Sydney, Australia M.Sc. (Mathematics) 1976
1980-1984	University of Toronto, Toronto, Canada M.D. 1984
1984-1985	University of California, San Francisco Department of Psychiatry, Internship
1985-1988	University of California, San Francisco Department of Psychiatry, Residency
1988-1995	National Institute of Mental Health, Bethesda Intramural Research Program Biological Psychiatry Branch, Senior Staff Fellow

#### CURRENT POSITIONS:

2004-Present	Professor Department of Psychiatry and Behavioral Sciences Stanford University School of Medicine, Stanford, California
1995-Present	Chief, Bipolar Disorders Clinic Department of Psychiatry and Behavioral Sciences Stanford University School of Medicine, Stanford, California

#### PROFESSIONAL EXPERIENCE:

1997-2004	Associate Professor Department of Psychiatry and Behavioral Sciences Stanford University School of Medicine, Stanford, California
1999-2006	Voting Member Administrative Panel on Human Subjects in Medical Research Stanford University School of Medicine, Stanford, California

1995-1996 Acting Associate Professor  
Department of Psychiatry and Behavioral Sciences  
Stanford University School of Medicine, Stanford, California

1992-1995 Chief, Unit on Brain Imaging  
Section on Psychobiology  
Biological Psychiatry Branch  
National Institute of Mental Health, Bethesda

1990-1995 Chief, 3 West Clinical Research Unit  
Section on Psychobiology  
Biological Psychiatry Branch  
National Institute of Mental Health, Bethesda

1988-1995 Private Medical Practice  
Pharmacotherapy of Mood and Anxiety Disorders  
Washington, D.C., and Bethesda, MD

1993-1994 Chair, Physician-Nurse Committee  
National Institutes of Health Clinical Center, Bethesda

1992-1995 Member, Physician-Nurse Committee  
National Institutes of Health Clinical Center, Bethesda

1988-1990 Unit Administrator  
3 West Clinical Research Unit  
Section on Psychobiology  
Biological Psychiatry Branch  
National Institute of Mental Health, Bethesda

1988-1989 Psychiatric Consultant  
Clinical Epilepsy Section  
Medical Neurology Branch  
National Institute of Neurological Disorders  
and Stroke, Bethesda

1987-1988 Senior Resident  
Behavioral Neurosciences Service  
Langley Porter Psychiatric Institute  
Department of Psychiatry  
University of California, San Francisco

1987-1988 Psychiatric Consultant  
Northern California Epilepsy Center  
Department of Neurology  
University of California, San Francisco

1987-1988 Resident Representative  
Executive Medical Board  
Department of Psychiatry  
University of California, San Francisco

1987-1988 Vice-President, Residents' Association  
Department of Psychiatry  
University of California, San Francisco

## **HONORS AND FELLOWSHIPS:**

Undergraduate	University of Toronto Varsity Fund Scholarship 1969-73 Governor General's Silver Medal (First standing in graduating class in Erindale College, University of Toronto)
Graduate	Commonwealth of Australia Research Fellowship 1974-76
Pre-medical	Carl Manning Book Prize 1980 (First standing in organic chemistry in Erindale College, University of Toronto)
Medical School	Walter F. Watkins Scholarship 1982
Residency	Creative Resident Award 1987-88 (Creative achievement by a resident in psychiatry, University of California, San Francisco)
Fellowship	American College of Neuropsychopharmacology Mead Johnson Travel Award Fellow 1994
Faculty	Independent Investigator Award Stanley Foundation Research Award Program 1996-2000  Independent Investigator Award National Alliance for Research in Schizophrenia and Depression 1999-2001  Outstanding Faculty Physician Award Vaden Health Center, Stanford University 2002  Independent Investigator Award National Alliance for Research in Schizophrenia and Depression 2003-2005  Fellow Collegium Internationale Neuro-Psychopharmacologicum 2006  Distinguished Fellow American Psychiatric Association 2006  Bruce E. Hedges Memorial Lecturer Weill Medical College of Cornell University 2007

## **SOCIETY MEMBERSHIPS:**

1987 - Present	American Psychiatric Association
1987 - 1988 1996 - Present	Northern California Psychiatric Society
1988 - 1995	Washington Psychiatric Society
1992 - Present	Society of Biological Psychiatry
1994 - Present	American Society of Clinical Psychopharmacology

1994 - Present	American Academy of Clinical Psychiatrists
1995 - Present	American Epilepsy Society
1996 - Present	West Coast College of Biological Psychiatry
1997 - Present	Canadian Psychiatric Association
1998 - Present	International Society for Magnetic Resonance Imaging in Medicine
1999 - Present	International Society for Bipolar Disorders
2005 - Present	World Federation of Societies of Biological Psychiatry
2006 - Present	Collegium Internationale Neuro-Psychopharmacologicum

**MEDICAL LICENSES:**

California	March 10, 1986	#G56822
District of Columbia	September 20, 1988	#17541
Maryland	October 13, 1988	#D37533

**BOARD CERTIFICATION:**

1988	Specialist Certificate in Psychiatry (# 370484) Royal College of Physicians and Surgeons of Canada
1989	Specialist Certificate in Psychiatry (# 31895) American Board of Psychiatry and Neurology
1989	Fellow of Royal College of Physicians & Surgeons of Canada (F.R.C.P.C.)

**JOURNAL REFEREE:**

1991-Present	Neuropsychiatry, Neuropsychology, and Behavioral Neurology
1993-Present	Biochemical Pharmacology
1995-Present	Journal of Clinical Psychopharmacology
1996-Present	Drug Safety
1996-Present	Human Psychopharmacology
1996-Present	Journal of Affective Disorders
1997-Present	Psychiatric Times
1997-Present	Journal of Neuropsychiatry and Clinical Neurosciences
1997-Present	Archives of General Psychiatry
1997 - Present	Psychiatry Research

1997 - Present	Biological Psychiatry
1998-Present	Life Sciences
1998 - Present	Journal of Psychiatric Research
1998 - Present	Journal of Clinical Psychiatry
1998 - Present	Bipolar Disorders
1999 - Present	Harvard Review of Psychiatry
1999 - Present	Expert Opinion on Pharmacotherapy
2000 – Present	Southern Medical Journal
2000 – Present	Depression and Anxiety
2000 – Present	Schizophrenia Research
2000 – Present	Neuropsychopharmacology

#### **EDITORIAL BOARDS**

2000-Present	Bipolar Disorders
2000-Present	Journal of Psychiatric Research
2001-Present	Journal of Affective Disorders
2006-Present	Psychiatry 2006
2006-Present	Acta Neuropsychiatrica

#### **EXTERNAL GRANT REVIEWER**

1993-Present	Ontario Mental Health Foundation
1997-Present	Canadian Psychiatric Research Foundation
1997-1999	Veterans' Administration Merit Review Committee (ad hoc)
1998	American Psychiatric Association (1998 Annual Meeting, Research Colloquium for Junior Investigators Applications)
2000-Present	Medical Research Council of Canada
2002-Present	National Institute of Mental Health

#### **STUDY SECTIONS**

2000-2001	Veterans' Administration Merit Review Committee (Member)
2001-2003	Veterans' Administration Merit Review Committee (Chair)

## BIBLIOGRAPHY OF TERENCE A. KETTER, M.D.

### PART I: ABSTRACTS AND PRESENTATIONS

### PART II: PUBLICATIONS

#### PART I: ABSTRACTS AND PRESENTATIONS

- 1) **Ketter TA**: Complex partial seizures and panic disorder. UCSF symposium: The medical / psychiatric interface of panic. 8<sup>th</sup> Annual National Conference on Phobias and Related Anxiety Disorders, San Francisco, Oct. 22-25, 1987. Abstract.
- 2) Kanas N, Deri J, **Ketter T**, and Fein G: Outcome of short-term outpatient groups for schizophrenics. American Group Psychotherapy Association Annual Meeting, San Francisco, Feb. 21-25, 1989. Abstract.
- 3) Bromfield EB, **Ketter TA**, Balish M, Sato S, Leiderman DB, and Theodore WH: Simple partial status epilepticus with psychosensory and psychoaffective manifestations. American Epilepsy Society Annual Meeting, Boston, December 3-6, 1989. Abstract. *Epilepsia* 1989;30(5):737.
- 4) **Ketter TA**, Laxer KD: Psychopathology in pseudoepileptic seizures and epilepsy. Pseudoepileptic Seizure Symposium, Fort Lauderdale, March 1-3, 1990. Abstract.
- 5) Bromfield EB, Altshuler L, Leiderman DB, Balish M, **Ketter TA**, Devinsky O, Post RM, Theodore WH: Cerebral metabolism and depression in patients with complex partial seizures. American Epilepsy Society Annual Meeting, San Diego, November 12-14, 1990. Abstract. *Epilepsia* 1990;31(5):625-626.
- 6) **Ketter TA**: Psychiatric aspects of epilepsy. American College of Neuropsychiatrists Spring Meeting, Scottsdale, March 21-24, 1991. Abstract.
- 7) Post RM, Weiss SR, **Ketter TA**, George MS, Clark M, Rosen J: The temporal lobes and affective disorders. The Temporal Lobes and Limbic System - Basic and Clinical Perspectives. Copenhagen, Denmark, September 19-20, 1991. Abstract.
- 8) Post RM, Weiss SR, **Ketter TA**, Pazzaglia PJ, Denicoff K: Impact of affective illness on gene expression: rationale for long-term prophylaxis. . 4<sup>th</sup> European College of Neuropsychopharmacology Congress, Monte Carlo, Monaco, October 6-9, 1991. *European Neuropsychopharmacology* 1991;1:214-216.
- 9) Post RM, George MS, **Ketter TA**, Denicoff K, Leverich G, Mikaluskas K: Mechanisms underlying recurrence and cycle acceleration in affective disorders: implications for long-term treatment. British Association for Pharmacology Meeting, London, November 21, 1991. Abstract.
- 10) **Ketter TA**, Barnett J, Schroeder DH, Hinton ML, Chao J, Post RM: Carbamazepine induces bupropion metabolism. 145<sup>th</sup> Annual Meeting of the American Psychiatric Association, Washington, May 2-7, 1992. Abstract NR563. Page 186.
- 11) **Ketter TA**, Malow BA, White SR, Post RM, Theodore WH: Anticonvulsant withdrawal-emergent psychopathology. 44<sup>th</sup> Annual Meeting of the American Academy of Neurology, San Diego, May 3-9, 1992. Abstract 1029P. *Neurology* 1992;42(Suppl 3):450.

- 12) Post RM, **Ketter TA**, Pazzaglia PJ, Denicoff K, George MS, Marangell L, Weiss SR: Anticonvulsants in refractory mood disorders. 2<sup>nd</sup> International Conference on Refractory Depression, The Hague and Amsterdam, June 24-26, 1992. Abstract.
- 13) **Ketter TA**, Potter WZ: Pharmacologic issues in the treatment of bipolar disorder. 42<sup>nd</sup> Annual Meeting of the Canadian Psychiatric Association, Montreal, September 16-18, 1992. Abstract.
- 14) Post RM, **Ketter TA**, Pazzaglia PJ, George MS, Marangell L, Weiss SR: Receptor, ion channel, and neuropeptide targets for drug development: implications from the anticonvulsant model. 31<sup>st</sup> Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 14-18, 1992. Abstract. Page 9.
- 15) Post RM, **Ketter TA**, Pazzaglia PJ, George MS, Marangell L, Denicoff K: New developments in the use of anticonvulsants as mood stabilizers Symposium on antiepileptic drugs in psychiatry, Freiberg, Germany, January 29-30, 1993. Abstract.
- 16) **Ketter TA**, Malow BA, Flamini R, White SR, Post RM, Theodore WH: Carbamazepine withdrawal-emergent psychopathology. 45<sup>th</sup> Annual Meeting of the American Academy of Neurology, New York, April 25-May 1, 1993. Abstract 163S. Neurology 1993;43(Suppl 2):A194.
- 17) Post RM, **Ketter TA**, George MS: Psychiatric syndromes and the limbic system. 45<sup>th</sup> Annual Meeting of the American Academy of Neurology, New York, April 25-May 1, 1993. Abstract.
- 18) **Ketter TA**, Andreason PJ, George MS, Herscovitch P, Post RM: Paralimbic rCBF increases during procaine-induced psychosensory & emotional experiences. 48<sup>th</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry, San Francisco, May 19-23, 1993. Abstract 107. Biol Psychiatry 1993;33(Suppl 6A):66A.
- 19) George MS, **Ketter TA**, Gill D, Herscovitch P, Post RM: The neuroanatomy of facial emotion recognition. 146<sup>th</sup> Annual Meeting of the American Psychiatric Association, San Francisco, May 22-27, 1993. Abstract NR16. Page 63.
- 20) **Ketter TA**, Andreason PJ, George MS, Marangell LB, Pazzaglia PJ, Post RM: Reduced resting frontal lobe CBF in mood disorders. 146<sup>th</sup> Annual Meeting of the American Psychiatric Association, San Francisco, May 22-27, 1993. Abstract NR298. Page 135.
- 21) George MS, **Ketter TA**, Gill D, Marangell LB, Pazzaglia PJ, Post RM: Blunted CBF with emotion recognition in depression. 146<sup>th</sup> Annual Meeting of the American Psychiatric Association, San Francisco, May 22-27, 1993. Abstract NR114. Page 88.
- 22) **Ketter TA**, Andreason PJ, George MS, Pazzaglia PJ, Marangell LB, Post RM: Blunted CBF response to procaine in mood disorders. 146<sup>th</sup> Annual Meeting of the American Psychiatric Association, San Francisco, May 22-27, 1993. Abstract NR297. Pages 134-135.
- 23) Pazzaglia PJ, Post RM, **Ketter TA**, George MS, Marangell LB: Nimodipine in affective illness. 146<sup>th</sup> Annual Meeting of the American Psychiatric Association, San Francisco, May 22-27, 1993. Abstract NR714. Page 239.
- 24) Post RM, Pazzaglia PJ, **Ketter TA**, George MS, Marangell LB: Carbamazepine and nimodipine in refractory bipolar illness: efficacy and mechanisms. 1<sup>st</sup> International

Congress on Hormones, Brain, and Neuropsychopharmacology, Rhodes, Greece, September 13-17, 1993. Abstract.

- 25) Parekh P, Spencer J, George MS, Gill DS, **Ketter TA**, Post RM: rCBF correlates of EEG frequencies before and after i.v. procaine. Society of Neuroscience Annual Meeting, November 7-12, 1993. Abstract 501.9, M-46. Page 239.
- 26) George MS, **Ketter TA**, Parekh PI, Ring, HA, Rosinsky N, Pazzaglia PJ, Marangell LB, Post RM: Differences in performance and regional brain activation in controls and mood disordered subjects while performing a classic and emotional Stroop. 32<sup>nd</sup> Annual Meeting of the American College of Neurosychopharmacology, Honolulu, December 13-17, 1993. Abstract.
- 27) Post RM, Pazzaglia PJ, **Ketter TA**, Marangell LB, George MS: Efficacy of the L-type calcium channel blocker nimodipine in recurrent affective disorders. 32<sup>nd</sup> Annual Meeting of the American College of Neurosychopharmacology, Honolulu, December 13-17, 1993. Abstract.
- 28) George MS, **Ketter TA**, Post RM: An overview of brain activation studies in mood disorders. 49<sup>th</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry, Philadelphia, May 18-22, 1994. Abstract 157. Biol Psychiatry 1994;35(9):658.
- 29) **Ketter TA**, George MS, Andreason PJ, Herscovitch P, Post RM: Blunted paralimbic resting & procaine-activated rCBF in healthy females compared to males. 49<sup>th</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry, Philadelphia, May 18-22, 1994. Abstract 120. Biol Psychiatry 1994;35(9):648.
- 30) George MS, **Ketter TA**, Parekh P, Post RM: Regional blood flow correlates of transient self-induced sadness or happiness. 49<sup>th</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry, Philadelphia, May 18-22, 1994. Abstract 119. Biol Psychiatry 1994;35(9):647.
- 31) **Ketter TA**, George MS, Pazzaglia PJ, Marangell LB, Andreason PJ, Post RM: PET activation studies in mood disorders. 147<sup>th</sup> Annual Meeting of the American Psychiatric Association, Philadelphia, May 21-26, 1994. Abstract. Symposium 105D. Page 184.
- 32) George MS, **Ketter TA**, Post RM: Brain imaging in mania. 147<sup>th</sup> Annual Meeting of the American Psychiatric Association, Philadelphia, May 21-26, 1994. Abstract. Symposium 73C. Page 142.
- 33) **Ketter TA**, George MS, Andreason PJ, Parekh P, Pazzaglia PJ, Marangell LB, Callahan AM, Cohen RM, Herscovitch P, Post RM: rCMRglu in unipolar versus bipolar depression. 147<sup>th</sup> Annual Meeting of the American Psychiatric Association, Philadelphia, May 21-26, 1994. Abstract NR444. Page 172.
- 34) Callahan AM, **Ketter TA**, George MS, Marangell LB, Pazzaglia PJ, Andreason PJ, Parekh P, Horwitz B, Herscovitch P, Post RM: Cholesterol and cerebral metabolism in mood disorders. 147<sup>th</sup> Annual Meeting of the American Psychiatric Association, Philadelphia, May 21-26, 1994. Abstract NR188. Page 104.
- 35) George MS, **Ketter TA**, Parekh PI, Horwitz B, Herscovitch P, Cloninger CR, Post RM: Personality traits correlate with resting rCBF. 147<sup>th</sup> Annual Meeting of the American Psychiatric Association, Philadelphia, May 21-26, 1994. Abstract NR450. Page 173.
- 36) **Ketter TA**, George MS, Andreason PJ, Horwitz B, Parekh P, Pazzaglia PJ,



- Marangell LB, Callahan AM, Cohen RM, Herscovitch P, Post RM: Depression and frontal rCMRglu correlate inversely. 147<sup>th</sup> Annual Meeting of the American Psychiatric Association, Philadelphia, May 21-26, 1994. Abstract NR443. Pages 171-172.
- 37) Marangell LB, **Ketter TA**, George MS, Pazzaglia PJ, Callahan AM, Andreason PJ, Parekh P, Horwitz B, Herscovitch P, Post RM: Thyroid indices and cerebral metabolism in mood disorders. 147<sup>th</sup> Annual Meeting of the American Psychiatric Association, Philadelphia, May 21-26, 1994. Abstract NR187. Page 104.
- 38) Post RM, **Ketter TA**, Denicoff, K, Pazzaglia PJ, Marangell LB, George MS, Callahan, A: Anticonvulsants: state of the art. 1<sup>st</sup> International Conference on Bipolar Disorder, Pittsburgh, June 23-34, 1994. Abstract.
- 39) **Ketter TA**, George MS, Andreason PJ, Horwitz B, Herscovitch P, Post RM: Positive correlations between procaine-induced paralimbic rCBF increases and psychosensory and emotional experiences. 19<sup>th</sup> Congress of Collegium Internationale Neuro-Psychopharmacologicum, Washington, June 27-July 1, 1994. Abstract O-84-107. *Neuropsychopharmacology* 1994;10(3S Part 2):28S.
- 40) Post RM, Leverich, GS, **Ketter TA**, Denicoff, K, Marangell LB, George MS, Pazzaglia PJ, Callahan, A, Weiss, SRB: The empirical and theoretical rationales for lifetime prophylaxis in bipolar affective disorder. 19<sup>th</sup> Congress of Collegium Internationale Neuro-Psychopharmacologicum, Washington, June 27-July 1, 1994. Abstract S-30-128. *Neuropsychopharmacology* 1994;10(3S Part 1):160S.
- 41) George MS, **Ketter TA**, Davis CL, Rubinow DR, Andreason PJ, Pazzaglia PJ, Marangell LB, Callahan, Herscovitch P, Horwitz B, Post RM: CSF somatostatin correlates with regional cerebral metabolism in mood disorder subjects. 19<sup>th</sup> Congress of Collegium Internationale Neuro-Psychopharmacologicum, Washington, June 27-July 1, 1994. Abstract P-117-101. *Neuropsychopharmacology* 1994;10(3S Part 2):178S.
- 42) **Ketter TA**, George MS, Andreason PJ, Marangell LB, Pazzaglia PJ, Callahan AM, Parekh P, Herscovitch P, Post RM: Carbamazepine-induced decreases in regional cerebral glucose metabolism in affective disorders are influenced by mood states. 19<sup>th</sup> Congress of Collegium Internationale Neuro-Psychopharmacologicum, Washington, June 27-July 1, 1994. Abstract O-225-326. *Neuropsychopharmacology* 1994;10(3S Part 2):83S.
- 43) Marangell LB, George MS, Callahan AM, Pazzaglia PJ, **Ketter TA**, Post RM: Intrathecal thyrotropin-releasing hormone in the treatment of affective disorders: preliminary results of a clinical trial. 19<sup>th</sup> Congress of Collegium Internationale Neuro-Psychopharmacologicum, Washington, June 27-July 1, 1994. Abstract P-174-35. *Neuropsychopharmacology* 1994;10(3S Part 2):221S.
- 44) George MS, **Ketter TA**, Parekh PI, Herscovitch P, Post RM: Gender differences in rCBF during transient self-induced sadness or happiness in healthy women. American Neuropsychiatric Association Annual Meeting, Newport, R.I., July 23, 1994.
- 45) Lee C, Unser M, **Ketter TA**: A global approach to multivariate correlation analysis of PET brain images. Society of Photo- Optical Instrumentation Engineers (SPIE): Mathematical Methods in Imaging III Conference, San Diego, July 25-26, 1994. Abstract.
- 46) Post RM, **Ketter TA**, Callahan AM, Denicoff KD, Marangell L, George MS: Rational polypharmacy in bipolar affective disorder: a focus on prophylaxis. Rational Polypharmacy Conference, Durango, September 10-12, 1994. Abstract.

- 47) **Ketter TA**: Clinical pharmacology and pharmacokinetics of mood stabilizers. 44<sup>th</sup> Annual Meeting of the Canadian Psychiatric Association, Ottawa, September 21-23,1994. Abstract. CPA Annual Meeting Selected Symposia Highlights 1994:11-12.
- 48) **Ketter TA**: Anatomy and pharmacology of depression. 20<sup>th</sup> Annual Postgraduate Course of the American Academy of Clinical Psychiatrists , Washington, October 6-8,1994.
- 49) **Ketter TA**, Malow BA, Flamini R, Ko D, White SR, Stertz BE, Post RM, Theodore WH: Psychotropic effects of felbamate monotherapy in patients with epilepsy. American Epilepsy Society Annual Meeting, New Orleans, December 2-8,1994. Abstract C.06. *Epilepsia* 1994;35(Suppl 8):32.
- 50) Post RM, **Ketter TA**: Psychiatric effects of the anticonvulsant drugs: a focus on affective illness. In: Ferrendelli J: Psychiatric Aspects of Epilepsy. American Epilepsy Society Annual Meeting, New Orleans, December 2-8,1994.
- 51) **Ketter TA**, Pazzaglia PJ, George MS, Marangell LB, Callahan AM, Kimbrell T, Frye MA, Parekh PI, Andreason PJ, Herscovitch P, Post RM: Baseline cerebral hypometabolism may predict response to nimodipine in mood disorders. 33<sup>rd</sup> Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 12 - 16, 1994. Abstract. Page 149.
- 52) George MS, Parekh PI, Rosinsky N, **Ketter TA**, Kimbrell TA, Herscovitch P, Post RM: Right hemisphere activation when listening for emotional prosody: an O-15 water PET study in healthy volunteers. 47<sup>th</sup> Annual Meeting of the American Academy of Neurology, Seattle, May 6-13, 1995. Abstract 817S. *Neurology* 1995;45(Suppl 4):A389.
- 53) Theodore WH, Albert P, Stertz BE, Malow BA, Ko D, White SR, Flamini R, **Ketter TA**: Felbamate monotherapy: implications for antiepileptic drug development. 47<sup>th</sup> Annual Meeting of the American Academy of Neurology, Seattle, May 6-13, 1995. Abstract 718P. *Neurology* 1995;45(Suppl 4):A360.
- 54) Callahan AM, Frye MA, Marangell LB, George MS, **Ketter TA**, Kimbrell T, L'Herrou T, Pazzaglia PJ, Post RM: Differential mood and endocrine effects of intravenous versus intrathecal TRH. 50<sup>th</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry, Miami, May 17-20, 1995. Abstract 63. *Biol Psychiatry* 1995;37(9):609.
- 55) Kimbrell TA, George MS, Parekh PI, **Ketter TA**, Parekh PI, Herscovitch P, Post RM: Regional brain activity during self-induced anger and anxiety. 50<sup>th</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry, Miami, May 17-20, 1995. Abstract 93. *Biol Psychiatry* 1995;37(9):617.
- 56) Parekh PI, George MS, Willis M, Lalonde F, **Ketter TA**, Post RM: A functional MRI study of transient sadness in healthy adult women: brain activity due to mood versus the effort of changing mood. 148<sup>th</sup> Annual Meeting of the American Psychiatric Association, Miami, May 20-25, 1995. Abstract NR522. Page 195.
- 57) George MS, Kimbrell TA, Parekh PI, **Ketter TA**, Pazzaglia PJ, Callahan A, Frye M, Marangell L, Herscovitch P, Post RM: Actively depressed subjects have difficulty inducing, and blunted limbic rCBF during, transient sadness. 148<sup>th</sup> Annual Meeting of the American Psychiatric Association, Miami, May 20-25, 1995. Abstract NR167. Pages 99-100.
- 58) **Ketter TA**, George MS, Parekh PI, Pazzaglia PJ, Marangell LB, Callahan AM, Kimbrell T, Frye MA, Herscovitch P, Post RM: PET imaging and psychotropic response prediction in

- mood disorders. 148<sup>th</sup> Annual Meeting of the American Psychiatric Association, Miami, May 20-25, 1995. Paper Session 19, Paper 58. Pages 23-24.
- 59) George MS, Wassermann ES, Williams WA, Kimbrell TA, Pazzaglia PJ, Callahan A, Frye M, **Ketter TA**, Hallett M, Post RM: Differential prefrontal rapid transcranial magnetic stimulation (rTMS) in depression: preliminary observations. 148<sup>th</sup> Annual Meeting of the American Psychiatric Association, Miami, May 20-25, 1995. Abstract NR313. Page 139.
- 60) Lee C, Unser M, **Ketter TA**: Automated recognition of corpus callosum from sagittal brain MR images. Society of Photo- Optical Instrumentation Engineers (SPIE): Applications of Digital Image Processing XVIII Conference, San Diego, July 12-14, 1995. Abstract.
- 61) George MS, **Ketter TA**, Kimbrell TA, Post RM: Functional neuroimaging and mood. In: Physiology and pharmacology of emotion symposium. Annual Meeting of the American EEG Society, Washington, September 9-12, 1995. Abstract.
- 62) Heynen TLP, Nierenberg J, RM, **Ketter TA**, Weiss SRB, Post RM: Cholinergic modulation of local anesthetic kindling. National Institutes of Health Research Festival '95, Bethesda MD, September 18-22, 1995. Abstract A-25.
- 63) Wassermann ES, Hallett M, George MS, **Ketter TA**, Kimbrell TA, Herscovitch P, Post RM: Changes in global and regional cerebral metabolism after chronic treatment with and during repetitive transcranial magnetic stimulation (rTMS) in depression. 10<sup>th</sup> International Congress of EMG and Clinical Neurophysiology, Kyoto, October 15-19, 1995. Abstract. *Electroencephalography and Clinical Neurophysiology/Electromyography and Motor Control* 1995;97(4):S251. Abstract PS-62-2.
- 64) **Ketter TA**, Kimbrell TA, George MS, Post RM: PET studies of illness heterogeneity and baseline markers of therapeutic responses in refractory depression. 3<sup>rd</sup> International Conference on Refractory Depression, Napa Valley CA, October 18-21, 1995. Abstract.
- 65) Marangell LB, Callahan AM, George MS, **Ketter TA**, Pazzaglia PJ, L'Herrou TA, Post RM: Effects of intrathecal TRH in patients with affective disorders. 3<sup>rd</sup> International Conference on Refractory Depression, Napa Valley CA, October 18-21, 1995. Abstract.
- 66) Callahan AM, Frye MA, Marangell LB, George MS, **Ketter TA**, L'Herrou TA, Post RM: Clinical case experiences comparing intrathecal and intravenous TRH: confounding effects of tolerance and implications for therapeutics. 3<sup>rd</sup> International Conference on Refractory Depression, Napa Valley CA, October 18-21, 1995. Abstract.
- 67) George MS, **Ketter TA**, Williams W, Wasserman E, Kimbrell TA, Post RM: Functional neuroimaging of brain correlates of depression. 34<sup>th</sup> Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 11 - 15, 1995. Abstract. Page 65.
- 68) **Ketter TA**, George MS, Kimbrell TA, Stein RM, Willis MW, Little JT, Frye MA, Corá- Locatelli G, Benson BE, Herscovitch P, Post RM: Assessment of PET data in individual patients with mood disorders. 34<sup>th</sup> Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 11 - 15, 1995. Abstract. Page 230.
- 69) Callahan AM, Marangell LB, Frye MA, George MS, **Ketter TA**, L'Herrou TA, Pazzaglia PJ, Post RM: Comparative mood and endocrine effects of intravenous versus intrathecal TRH. 34<sup>th</sup> Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 11 - 15, 1995. Abstract. Page 153.

- 70) George MS, **Ketter TA**, Mathe AA, Kimbrell TA, Frye MA, Willis MW, Benson BE, Little JT, Stein RM, Post RM: Mapping neurochemistry onto neuroanatomy: correlation between resting rCBF and CSF monoamine metabolites. 34<sup>th</sup> Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 11 - 15, 1995. Abstract. Page 226.
- 71) Lee C, **Ketter TA**, Unser M: Automated connectivity-based thresholding segmentation of midsagittal brain MR images. Society of Photo- Optical Instrumentation Engineers (SPIE): Visual Communications and Image Processing Conference, Orlando , March 17-20,1996. Abstract.
- 72) Marangell LB, Callahan AM, **Ketter TA**: What you need to know about the cytochrome P450 system. 149<sup>th</sup> Annual Meeting of the American Psychiatric Association, New York, May 4-9, 1996. Industry Symposium Abstract 21A. Page 306.
- 73) Kimbrell TA, **Ketter TA**, Willis MW, George MS, Andreason PJ, Post RM: Increased basal ganglia, thalamic, and anterior cingulate glucose metabolism in women compared to men. 149<sup>th</sup> Annual Meeting of the American Psychiatric Association, New York, May 4-9, 1996. Abstract NR463. Page 196.
- 74) Kimbrell TA, **Ketter TA**, George MS, Stein RM, Danielson A, Post RM: Anterior paralimbic hypometabolism in patients with unipolar depression in remission. 149<sup>th</sup> Annual Meeting of the American Psychiatric Association, New York, May 4-9, 1996. Abstract NR462. Page 196.
- 75) **Ketter TA**, George MS, Kimbrell TA, Stein RM, Frye MA, Corá-Locatelli G, Post RM: Anterior paralimbic dysfunction in mood disorders. 149<sup>th</sup> Annual Meeting of the American Psychiatric Association, New York, May 4-9, 1996. Symposium 113E. Page 187.
- 76) Frye MA, **Ketter TA**, Corá-Locatelli G, Grothe DR, Kimbrell TA, Piscitelli SC, Little JT, Post RM: Gabapentin does not alter lithium pharmacokinetics. 149<sup>th</sup> Annual Meeting of the American Psychiatric Association, New York, May 4-9, 1996. Abstract NR311. Page 151.
- 77) Frye MA, **Ketter TA**, Leverich GS, Denicoff K, Kimbrell TA, Little JT, Corá-Locatelli G, Stein R, Lantz C, Post RM: The increasing use of polypharmacy for refractory mood disorders: twenty-five years of study. 149<sup>th</sup> Annual Meeting of the American Psychiatric Association, New York, May 4-9, 1996. Abstract NR312. Pages 151-152.
- 78) Corá-Locatelli G, Frye MA, Kimbrell TA, Denicoff K, **Ketter TA**, Post RM: Carbamazepine induces escape from dexamethasone suppression across mood and anxiety disorder subtypes. 149<sup>th</sup> Annual Meeting of the American Psychiatric Association, New York, May 4-9, 1996. Abstract NR444. Page 191.
- 79) George MS, Kimbrell TA, **Ketter TA**, Post RM: Transient sadness in depression and health. 149<sup>th</sup> Annual Meeting of the American Psychiatric Association, New York, May 4-9, 1996. Symposium 47D. Page 103.
- 79) George MS, **Ketter TA**, Kimbrell TA, Post RM: Functional brain imaging in women with respect to mood and depression. 149<sup>th</sup> Annual Meeting of the American Psychiatric Association, New York, May 4-9, 1996. Symposium 12G. Page 59.
- 80) Little JT, **Ketter TA**, Kimbrell TA, Stein RM, Danielson A, Benson BE, Willis MW, Post RM: Venlafaxine and bupropion responders in contrast to nonresponders have baseline prefrontal and paralimbic hypometabolism. 36<sup>th</sup> Annual Meeting of the New Clinical Drug

Evaluation Unit of the National Institute of Mental Health. Boca Raton, May 28-June 1, 1996. Abstract.

- 81) **Ketter TA**, Frye MA, Callahan AM, Marangell LB, Post RM: Clinical pharmacokinetic update on anticonvulsants. 20<sup>th</sup> Congress of Collegium Internationale Neuro-Psychopharmacologicum, Melbourne, June 23-27, 1996. Abstract S-20-2. *Eur Neuropsychopharmacol* 1996;6(Suppl 3):81.
- 82) **Ketter TA**, Kimbrell TA, George MS, Stein RM, Willis MW, Benson BE, Frye MA, Corá-Locatelli G, Post RM: Baseline hypermetabolism may predict carbamazepine response, and hypometabolism nimodipine response in mood disorders. 20<sup>th</sup> Congress of Collegium Internationale Neuro-Psychopharmacologicum, Melbourne, June 23-27, 1996. Abstract O-5-6. *Eur Neuropsychopharmacol* 1996;6(Suppl 3):10.
- 83) **Ketter TA**, George MS, Kimbrell TA, Stein RM, Willis MW, Benson BE, Frye MA, Corá-Locatelli G, Post RM: Prefrontal and anterior paralimbic dysfunction in primary and secondary mood disorders: evidence of common neural substrates. 8<sup>th</sup> Congress of the Association of European Psychiatrists, London, July 7-12, 1996. Abstract. *Eur Psychiatry* 1996;11(Suppl 4):167s-168s.
- 84) **Ketter TA**, George MS, Kimbrell T, Little JT, Frye MA, Corá-Locatelli G, Post RM: Preliminary evidence of prefrontal and anterior paralimbic baseline markers of psychotropic responses in mood disorders. 35<sup>th</sup> Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 9-13, 1996. Abstract. Page 86.
- 85) George MS, Cloninger CR, Kimbrell TA, Willis MW, Parekh PI, Danielson A, **Ketter TA**, Herscovitch P, Post RM: Toward the neurobiological basis of temperament: PET studies of Cloninger's tridimensional scale in healthy adults.. 35<sup>th</sup> Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 9-13, 1996. Abstract. Page 274.
- 86) **Ketter TA**, Kling MA, George MS, Kimbrell T, Lefter L, Willis MW, Benson BE, Herscovitch P, Post RM: Relationships between procaine-induced increases in CBF and cortisol, ACTH, and prolactin in healthy volunteers. 35<sup>th</sup> Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 9-13, 1996. Abstract. Page 277.
- 87) Dunn RT, Kimbrell TA, Frye MA, **Ketter TA**, Danielson AL, Little JT, Benson BE, Willis MW, Post RM: Baseline cerebral metabolism differs in responders to lamotrigine or gabapentin. 52<sup>nd</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry, San Diego, May 14-18, 1997. Abstract 60. *Biol Psychiatry* 1997;41(Suppl 7S):18S-19S.
- 88) Kimbrell TA, **Ketter TA**, Danielson AL, Benson BE, Dunn RT, Little JT, Willis MW, Herscovitch P, Post RM: Serial resting cerebral blood flow measurement in healthy volunteers. 52<sup>nd</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry, San Diego, May 14-18, 1997. Abstract 61. *Biol Psychiatry* 1997;41(Suppl 7S):19S.
- 89) Willis MW, **Ketter TA**, Kimbrell TA, Danielson AL, Benson BE, Little JT, Post RM: Differential changes in cerebral metabolism with age in mood disorder subtypes. 52<sup>nd</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry, San Diego, May 14-18, 1997. Abstract 62. *Biol Psychiatry* 1997;41(Suppl 7S):19S.

- 90) Frye MA, Kimbrell TA, Willis MW, **Ketter TA**, George MS, Pazzaglia PJ, Dunn RT, Luckenbaugh D, Huggins T, Little JT, Vanderham L, Danielson AL, Benson BE, Davis C, Rubinow DR, Post RM: Low CSF somatostatin and cerebral hypometabolism in depression. 52<sup>nd</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry, San Diego, May 14-18, 1997. Abstract 111. Biol Psychiatry 1997;41(Suppl 7S):32S-33S.
- 91) Little JT, **Ketter TA**, Kimbrell TA, Danielson AL, Benson BE, Willis MW, Dunn RT, Frye MA, Post RM: Anterior paralimbic blood flow decreased after venlafaxine response. 52<sup>nd</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry, San Diego, May 14-18, 1997. Abstract 270. Biol Psychiatry 1997;41(Suppl 7S):79S-80S.
- 92) **Ketter TA**, Frye MA, Corá-Locatelli G, Kimbrell T, Post RM: Pharmacology and pharmacokinetics of new anticonvulsants. In the symposium: New Anticonvulsants in Mood Disorders. 150<sup>th</sup> Annual Meeting of the American Psychiatric Association, San Diego, May 17-22, 1997. Symposium 33A. Pages 84-85.
- 93) Frye MA, **Ketter TA**, Kimbrell T, Corá-Locatelli G, Dunn RT, Post RM: Gabapentin and lamotrigine monotherapy in mood disorder. In the symposium: New Anticonvulsants in Mood Disorders. 150<sup>th</sup> Annual Meeting of the American Psychiatric Association, San Diego, May 17-22, 1997. Symposium 33C. Page 85.
- 94) Kimbrell T, **Ketter TA**, Frye MA, Danielson AL, Benson BE, Post RM: Neuroimaging of response to new anticonvulsants. In the symposium: New Anticonvulsants in Mood Disorders. 150<sup>th</sup> Annual Meeting of the American Psychiatric Association, San Diego, May 17-22, 1997. Symposium 33D. Page 85.
- 95) **Ketter TA**, George MS, Kimbrell TA, Little JT, Post RM: Brain imaging in bipolar disorders. In the industry symposium: Diagnostic and Treatment Advances in Manic Depression. 150<sup>th</sup> Annual Meeting of the American Psychiatric Association, San Diego, May 17-22, 1997. Industry Symposium Abstract 12E. Page 277.
- 96) Winsberg ME, DeGolia SG, Strong CM, **Ketter TA**: Divalproex in medication-naive bipolar II depression. 150<sup>th</sup> Annual Meeting of the American Psychiatric Association, San Diego, May 17-22, 1997. Abstract NR113 Page 97.
- 97) Kimbrell TA, **Ketter TA**, Dunn RT, Little JT, Frye MA, Post RM: Differential female and male cerebral glucose metabolism abnormalities in depression. 150<sup>th</sup> Annual Meeting of the American Psychiatric Association, San Diego, May 17-22, 1997. Abstract NR421 Page 182.
- 98) Ali SO, Denicoff K D, **Ketter TA**, Smith-Jackson EE, Post RM: Psychosensory symptoms in patients with bipolar disorder. 150<sup>th</sup> Annual Meeting of the American Psychiatric Association, San Diego, May 17-22, 1997. Abstract NR423. Pages 182-183.
- 99) Benson BE, Kimbrell TA, **Ketter TA**, Little JT, Dunn RT, Post RM: Outpatient antidepressant responders have lower paralimbic rCMRglu than inpatient nonresponders. 150<sup>th</sup> Annual Meeting of the American Psychiatric Association, San Diego, May 17-22, 1997. Abstract NR539 Page 213.
- 100) **Ketter TA**: Clinical pharmacology of carbamazepine. In the course: Anticonvulsants in Child, Adolescent, and Adult Psychiatry. 150<sup>th</sup> Annual Meeting of the American Psychiatric Association, San Diego, May 17-22, 1997. Course 42.

- 101) **Ketter TA**, Winsberg ME, DeGolia SG, Dunai M, Tate DL, Strong CM: Bupropion plus SSRI combination therapy in treatment-resistant bipolar depression. 2<sup>nd</sup> International Conference on Bipolar Disorder, Pittsburgh, June 19-21, 1997. Abstract. Page 95.
- 102) **Ketter TA**, Winsberg ME, Sachs N, Tate DL, Strong CM, Dunai M, Segall GM: Amygdalar metabolism decreases with thirty minute self-induction of depressed mood by recalling sad memories. 36<sup>th</sup> Annual Meeting of the American College of Neuropsychopharmacology, Waikaloa, Hawaii, December 8-12, 1997. Abstract. Page 236.
- 103) Winsberg ME, Sachs N, Tate DL, Dunai M, Strong CM, Spielman DM, **Ketter TA**: Decreased dorsolateral prefrontal *N*-acetyl aspartate in bipolar disorder. 53<sup>rd</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry, Toronto, May 27-31, 1998. Abstract. Abstract 74. Biol Psychiatry 1998;43(Suppl 8S):23S.
- 104) Benson BE, Carson RE, Sandoval W, Linthicum WL, Kimbrell TA, Kieswetter DO, Herscovitch P, Eckleman WC, McCann UD, Weiss SRB, Post RM, **Ketter TA**: A potential cholinergic mechanism of procaine's limbic activation. 53<sup>rd</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry, Toronto, May 27-31, 1998. Abstract 89. Biol Psychiatry 1998;43(Suppl 8S):27S-28S.
- 105) **Ketter TA**, Kennedy SH, Kimbrell TA, Wu JC, Sackeim HA, George MS: Brain imaging studies of treatments in mood disorders. 53<sup>rd</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry, Toronto, May 27-31, 1998. Abstract 206. Biol Psychiatry 1998;43(Suppl 8S):61S.
- 106) **Ketter TA**, Frye MA, Kimbrell T, Post RM: Pharmacology and pharmacokinetics of new anticonvulsants. In the symposium: New Anticonvulsants in Mood Disorders: An Update. 151<sup>st</sup> Annual Meeting of the American Psychiatric Association, Toronto, May 30 - June 4, 1998. Symposium 77A. Page 149.
- 107) Frye MA, **Ketter TA**, Osuch EA, Kimbrell T, Speer AM, Dunn RT, Post RM: Gabapentin and lamotrigine monotherapy in mood disorder: an update. In the symposium: New Anticonvulsants in Mood Disorders. 151<sup>st</sup> Annual Meeting of the American Psychiatric Association, Toronto, May 30 - June 4, 1998. Symposium 77D. Page 150.
- 108) Kimbrell T, **Ketter TA**, Frye MA, Dunn RM, Speer AM, Osuch EA, Post RM: Neuroimaging of response to lamotrigine and gabapentin. In the symposium: New Anticonvulsants in Mood Disorders. 151<sup>st</sup> Annual Meeting of the American Psychiatric Association, Toronto, May 30 - June 4, 1998. Symposium 77E. Page 150.
- 109) **Ketter TA**: Clinical pharmacology of carbamazepine. In the course: Anticonvulsants in Child, Adolescent, and Adult Psychiatry. 151<sup>st</sup> Annual Meeting of the American Psychiatric Association, Toronto, May 30 - June 4, 1998. Course 41.
- 110) Chang KD, **Ketter TA**, Steiner H: Psychiatric morbidity in children of bipolar parents. 151<sup>st</sup> Annual Meeting of the American Psychiatric Association, Toronto, May 30 - June 4, 1998. Abstract NR29. Page 75.
- 111) Dunn RT, Kimbrell TA, **Ketter TA**, Frye MA, Speer AM, Osuch EA, Post RM: Beck depression inventory and regional cerebral metabolism. 151<sup>st</sup> Annual Meeting of the American Psychiatric Association, Toronto, May 30 - June 4, 1998. Abstract NR49. Pages 80-81.

- 112) Winsberg ME, Tate DL, Strong CM, **Ketter TA**: Temperament differences in bipolar disorder patients. 151<sup>st</sup> Annual Meeting of the American Psychiatric Association, Toronto, May 30 - June 4, 1998. Abstract NR140. Page 106.
- 113) Chang KD, **Ketter TA**, Santosa CM, Lee BW, Steiner H: Psychiatric phenomenology in children of bipolar parents. 45<sup>th</sup> Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Anaheim, October 27 - November 1, 1998. Abstract NR-46. Page 97.
- 114) Theodore WH, **Ketter TA**, Kimbrell TA, Dean A, Siegel H, Benson B, Ben-Menachem E: The effect of vigabatrin on psychiatric status assessed by standard rating scales. Annual Meeting of the American Epilepsy Society, San Diego, December 2-8, 1998. Abstract 7.069. *Epilepsia* 1998;39(Suppl 3):240.
- 115) **Ketter TA**, Theodore WH, Kimbrell TA, Dean AC, Siegel H, Benson BE, Ben-Menachem E: Adjunctive vigabatrin decreases anxiety and depression in epilepsy patients. 37<sup>th</sup> Annual Meeting of the American College of Neuropsychopharmacology, Los Croabas, Puerto Rico, December 13-18, 1998. Abstract.
- 116) **Ketter TA**: PET studies in bipolar disorders. In: Charney DS, Anand A. Neural circuitry in bipolar disorder - evidence from brain imaging studies. 54<sup>th</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry, Washington, May 13-15, 1999. Abstract 405. *Biol Psychiatry* 1999;45(Suppl 8):47S.
- 117) Winsberg ME, Sachs N, Tate DL, Spielman DM, **Ketter TA**: Differences in dorsolateral prefrontal cortex *N*-acetyl aspartate in bipolar disorder subtypes using 1H MRS. 54<sup>th</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry, Washington, May 13-15, 1999. Abstract 405. *Biol Psychiatry* 1999;45(Suppl 8):125S.
- 118) Osuch EA, **Ketter TA**, Kimbrell TA, George MS, Benson BE, Willis MW, McCann U, Post RM: Regional cerebral metabolism unique to anxiety symptoms in affective disorder patients. 54<sup>th</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry, Washington, May 13-15, 1999. Abstract 417. *Biol Psychiatry* 1999;45(Suppl 8):129S.
- 119) **Ketter TA**: Clinical pharmacology of carbamazepine. In the course: Anticonvulsants in Child, Adolescent, and Adult Psychiatry. 152<sup>nd</sup> Annual Meeting of the American Psychiatric Association, Washington, May 15 - 20, 1999. Course 55.
- 120) Chang KD, Steiner H, **Ketter TA**: Temperamental characteristics of children and adolescents with bipolar parents. 152<sup>nd</sup> Annual Meeting of the American Psychiatric Association, Washington, May 15 - 20, 1999. Abstract NR108. Page 91.
- 121) Santosa CM, Sachs N, Strong CM, Winsberg ME, **Ketter TA**: Differential creativity assessments in patients with bipolar disorder. 152<sup>nd</sup> Annual Meeting of the American Psychiatric Association, Washington, May 15 - 20, 1999. Abstract NR449. Pages 191-2.
- 122) **Ketter TA**, Kimbrell TA, George MS, Dunn RT, Speer AM, Willis MW, Benson BE, Frye MA, Post RM: Functional brain imaging studies of treatments for bipolar disorders. 22<sup>nd</sup> Annual Meeting of the Canadian College of Neuropsychopharmacology, Halifax, June 12-15, 1999. Symposium 7. Abstract. Page 34.
- 123) Chang KD, Steiner H, **Ketter TA**: Family environment of children and adolescents with bipolar parents. 3<sup>rd</sup> International Conference on Bipolar Disorder, Pittsburgh, June 17-19, 1999. Abstract 23. *Bipolar Disorders* 1999;1(Suppl 1):27.



- 124) **Ketter TA**, Kimbrell TA, George MS, Dunn RT, Speer AM, Willis MW, Benson BE, Danielson A, Frye MA, Herscovitch P, Post RM: Effects of mood state, illness subtype, and course on cerebral glucose metabolism in bipolar disorders. 3<sup>rd</sup> International Conference on Bipolar Disorder, Pittsburgh, June 17-19, 1999. Abstract 62. *Bipolar Disorders* 1999;1(Suppl 1):38.
- 125) Chang, KD, **Ketter TA**, Steiner H: Bipolar Offspring: A window into prodromal bipolar disorder. 46<sup>th</sup> Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Chicago, IL, October 25-31, 1999. Abstract.
- 126) **Ketter TA**, Kimbrell TA, Little JT, George MS, Sachs N, Winsberg ME, Wang PW, Post RM: Differences and commonalities in cerebral function in bipolar compared to unipolar depression. 38<sup>th</sup> Annual Meeting of the American College of Neuropsychopharmacology, Acapulco, Mexico, December 13-17, 1999. Abstract. Page 72.
- 127) **Ketter TA**, Winsberg ME, Wong PW, Tate DL, Strong CM: Olanzapine in nonpsychotic bipolar disorders. 38<sup>th</sup> Annual Meeting of the American College of Neuropsychopharmacology, Acapulco, Mexico, December 13-17, 1999. Abstract. Page 166.
- 128) Little JT, **Ketter TA**, Kimbrell TA, et al.: Antidepressant response and regional cerebral flow. 55<sup>th</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry, Chicago, May 11-13, 2000. Abstract 272. *Biol Psychiatry* 2000;47(8S):82S-83S.
- 129) Lembke A, Sachs N, Ekman P, **Ketter TA**: Impaired facial fear recognition in manic but not euthymic bipolar patients. 55<sup>th</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry, Chicago, May 11-13, 2000. Abstract 276. *Biol Psychiatry* 2000;47(8S):83S-84S.
- 130) Wang PW, Winsberg ME, Santosa CM, Tate DL, Strong CM, **Ketter TA**: Open adjunctive gabapentin effective in bipolar depression. 55<sup>th</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry, Chicago, May 11-13, 2000. Abstract 277. *Biol Psychiatry* 2000;47(8S):84S.
- 131) Benson BE, Willis MW, **Ketter TA**, Kimbrell TA, Osuch EA, Speer AM, Post RM: Altered relationships in rCMRglu associativity in bipolar and unipolar disorders. 55<sup>th</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry, Chicago, May 11-13, 2000. Abstract 357. *Biol Psychiatry* 2000;47(8S):108S.
- 132) Willis MW, Benson BE, **Ketter TA**, Kimbrell TA, Osuch EA, Speer AM, Post RM: Interregional associations of cerebral glucose metabolism in healthy adults, in 55<sup>th</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry. Chicago, May 11-13, 2000. Abstract 358. *Biol Psychiatry* 2000;47(8S):108S.
- 133) **Ketter TA**, Wang PW, Winsberg ME, Sachs N, Tate DL, Strong CM, Segall GM: Baseline hypofrontality and divalproex response in bipolar disorders. 55<sup>th</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry, Chicago, May 11-13, 2000. Abstract 412. *Biol Psychiatry* 2000;47(8S):126S.
- 134) **Ketter TA**, Kimbrell TA, Little JT, George MS, Sachs N, Winsberg ME, Wang PW, Post RM: Cerebral function in bipolar depression. 153<sup>rd</sup> Annual Meeting of the American Psychiatric Association, Chicago, May 13 – 18, 2000. Abstract 8B. Page 54.
- 135) **Ketter TA**: Carbamazepine in bipolar disorder. In the course: Anticonvulsants in Bipolar Disorder. 153<sup>rd</sup> Annual Meeting of the American Psychiatric Association, Chicago, May 2000. Course 97.

- 136) **Ketter TA**, Wang PW, Santosa CM, Tate DL, Strong CM, Sachs N: Baseline cerebral glucose metabolism compared to other potential divalproex response markers. 153<sup>rd</sup> Annual Meeting of the American Psychiatric Association, Chicago, May 13 - 18, 2000. Abstract NR447. Page 178.
- 137) Wang PW, Santosa CM, Tate DL, Strong CM, **Ketter TA**: Gabapentin in bipolar depression. 153<sup>rd</sup> Annual Meeting of the American Psychiatric Association, Chicago, May 13 - 18, 2000. Abstract NR151. Page 97.
- 138) Rennie CM, Strong CM, Santosa CM, Sachs N, Wang PW, Winsberg ME, **Ketter TA**: Personality and temperament in bipolar disorders. 153<sup>rd</sup> Annual Meeting of the American Psychiatric Association, Chicago, May 13 - 18, 2000. Abstract NR479. Page 188.
- 139) Earl NL, Greene P, Ascher JA, Chang CN, Sachs GS, **Ketter TA**, Swann AC: Mood stabilization with lamotrigine in rapid cycling bipolar disorder, in 153<sup>rd</sup> Annual Meeting of the American Psychiatric Association. Chicago, May 13 - 18, 2000 Abstract NR509. Page 196.
- 140) Strong CM, Santosa CM, Sachs N, Rennie CM, Wang PW, Hier AM, **Ketter TA**: Relationships between creativity and temperament in bipolar disorder patients and healthy controls. 153<sup>rd</sup> Annual Meeting of the American Psychiatric Association, Chicago, May 13 - 18, 2000. Abstract NR728. Page 254.
- 141) Santosa CM, Sachs N, Strong CM, Rennie CM, Hier AM, Wang PW, **Ketter TA**: Aging and creativity in bipolar disorder. 153<sup>rd</sup> Annual Meeting of the American Psychiatric Association, Chicago, May 13 - 18, 2000. Abstract NR729. Page 254-5.
- 142) Post RM, **Ketter TA**, Speer AM, Kimbrell T, Dunn RD, Benson B, Willis M: Neurobiology of bipolar disorder: a focus on regional cerebral metabolism, in 22<sup>nd</sup> Congress of Collegium Internationale Neuro-Psychopharmacologicum. Brussels, July 9-13, 2000 Abstract S.31.1. Int J Neuropsychopharmacol 2000;3(Suppl 1):S49.
- 143) Greene P, Earl N, Ascher J, Monaghan E, Smoot T, Bowden C, Calabrese J, **Ketter T**, McElroy S, Post R, Sachs G, Suppes P, Swann A: Mood stabilization with lamotrigine in rapid cycling bipolar disorder: a double-blind placebo-controlled study, in 22<sup>nd</sup> Congress of Collegium Internationale Neuro-Psychopharmacologicum. Brussels, July 9-13, 2000 Abstract P.16.35. Int J Neuropsychopharmacol 2000;3(Suppl 1):S341.
- 144) Earl N, Greene P, Ascher J, Chang C, Evoniuk G, Bowden C, Calabrese J, **Ketter T**, McElroy S, Post R, Sachs G, Suppes P, Swann A: Mood stabilization with lamotrigine in rapid cycling bipolar disorder, in 22<sup>nd</sup> Congress of Collegium Internationale Neuro-Psychopharmacologicum. Brussels, July 9-13, 2000 Abstract P.16.36. Int J Neuropsychopharmacol 2000;3(Suppl 1):S341.
- 145) **Ketter TA**, Kimbrell TA, George MS, Sachs N, Wang PW, Post RM: PET studies of baseline markers or treatment response in bipolar disorders. 22<sup>nd</sup> Congress of Collegium Internationale Neuro-Psychopharmacologicum, Brussels, July 9-13, 2000. Abstract P.16.30. Int J Neuropsychopharmacol 2000;3(Suppl 1):S339.
- 146) **Ketter TA**, Wang PW, Tate DL, Rennie CM, Hier AM, Strong CM: Low dose adjunctive topiramate attenuates weight gain in bipolar disorder patients. 22<sup>nd</sup> Congress of Collegium Internationale Neuro-Psychopharmacologicum, Brussels, July 9-13, 2000. Abstract P.16.46. Int J Neuropsychopharmacol 2000;3(Suppl 1):S344.

- 147) **Ketter TA**, Wang PW, Marangell LB, Post RM: Emerging relationships between thyroid and cerebral function in mood disorders and healthy volunteers. 2<sup>nd</sup> International Congress on Hormones, Brain, and Neuropsychopharmacology, Rhodes, Greece, July 15-19, 2000. *Neuropsychopharmacology* 2000;23(S2):S67.
- 148) Earl, N, Greene P, Ascher J, Fouche N, Chang C, Evoniuk G, Swann A, Pope S, **Ketter T**, McElroy S, Post R, Zajecka J, Altshuler L, Apter J, West S, Risch C, Khan A: Mood stabilisation with lamotrigine in rapid cycling bipolar disorder. 13<sup>th</sup> European College of Neuropsychopharmacology Congress, Munich, Germany, September 9-13, 2000. *Eur Neuropsychopharmacology* 2000;10(Suppl 3):237-8. Abstract P.1.048.
- 149) Sailasuta N, Adalsteinsson E, Sachs N, Wang PW, Spielman D, **Ketter TA**: In vivo determination of cerebral gamma-aminobutyric acid (GABA) by proton magnetic resonance spectroscopy at 3 Tesla. 2<sup>nd</sup> Annual European Stanley Foundation Conference on Bipolar Disorder, Amsterdam, Netherlands, September 21-22, 2000.
- 150) **Ketter TA**, Kimbrell TA, George MS, Sachs N, Wang PW, Post RM: Predictors of treatment response in bipolar disorder: evidence from clinical PET studies. Annual Meeting of the Canadian Psychiatric Association, Victoria, B.C., October 3 - 6, 2000. Abstract S2d. page 77.
- 151) Chang KD, Steiner H, Padilla V, Molbert B, **Ketter TA**: Divalproex in bipolar offspring with mood and behavioral disorders. 47<sup>th</sup> Annual Meeting of the American Academy of Child and Adolescent Psychiatry, New York, NY, October 23–29, 2000. Abstract.
- 152) Glick I, Tandon R, Davis J, Kane J, Casey D, Marder S, Kasper S, **Ketter TA**, Sikich LM, Jeste D, Janowsky D: Atypical antipsychotics: what do we really know? 39<sup>th</sup> Annual Meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico, December 10-14, 2000. Abstract. Page 67.
- 153) **Ketter TA**, Wang P, Sachs N, Rennie CM, Segall GM: Differential anterior paralimbic metabolic decreases with sustained sadness and happiness in healthy volunteers. 39<sup>th</sup> Annual Meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico, December 10-14, 2000. Abstract. Page 131.
- 154) **Ketter TA**, Winsberg ME, Wang PW, Tate DL, Strong CM: Olanzapine in nonpsychotic bipolar disorder patients. Olanzapine Investigator-Initiated Trial Program, Dallas, TX, February 1-3, 2001. Abstract.
- 155) **Ketter TA**: New treatments for bipolar disorders. 42<sup>nd</sup> Annual Meeting of the Northern California Psychiatric Society. Olympic Valley, CA, April 20-22, 2001.
- 156) Chang KD, Adleman N, Dienes K, **Ketter TA**, Reiss A: fMRI of a spatial working memory task in bipolar offspring with bipolar disorder, in 56<sup>th</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry. New Orleans, May 3-5, 2001. Abstract 89. *Biol Psychiatry* 2001;49(8S):25S-26S.
- 157) Wang PW, Sachs N, Sailasuta N, Adalsteinsson E, Spielman D, **Ketter TA**: 3 Tesla 1H-Magnetic Resonance Spectroscopic (MRS) detection of cerebral gamma-aminobutyric acid (GABA) in bipolar disorder patients and healthy volunteers, in 56<sup>th</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry. New Orleans, May 3-5, 2001. Abstract 93. *Biol Psychiatry* 2001;49(8S):27S.
- 158) Obrocea GV, Dunn RT, Frye MA, **Ketter TA**, Luckenbaugh DA, Leverich GS, Speer AM, Osuch EA, Jajodia K, Post RM: Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders, in 56<sup>th</sup> Annual Convention and

Scientific Program of the Society of Biological Psychiatry. New Orleans, May 3-5, 2001. Abstract 175. Biol Psychiatry 2001;49(8S):50S.

- 159) **Ketter TA**, Wang PW, Sachs N, Kimbrell TA, Little JT, George MS, Post RM: Brain imaging studies of medication effects and baseline markers of response in bipolar disorders, in 56<sup>th</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry. New Orleans, May 3-5, 2001. Abstract 280. Biol Psychiatry 2001;49(8S):80S.
- 160) Chang KD, Adleman N, Sachs N, Dienes K, Reiss A, **Ketter TA**: Proton MRS of bipolar offspring with bipolar disorder, in 56<sup>th</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry. New Orleans, May 3-5, 2001. Abstract 318. Biol Psychiatry 2001;49(8S):91S-92S.
- 161) Tohen M, Baker RW, Milton DR, Risser RC, Gilmore JA, Altshuler L, Zarate CA, **Ketter TA**: Olanzapine versus divalproex sodium in the treatment of acute mania, in 56<sup>th</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry. New Orleans, May 3-5, 2001. Abstract 382. Biol Psychiatry 2001;49(8S):109S-110S.
- 162) Janenawasin S, Wang PW, Schumacher M, Das B, Santosa CM, Mongkolkeep J, Strong CM, **Ketter TA**: Rapid improvement with olanzapine in diverse syndromal and subsyndromal exacerbations of bipolar disorders, in 56<sup>th</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry. New Orleans, May 3-5, 2001. Abstract 414. Biol Psychiatry 2001;49(8S):119S.
- 163) Benson BE, Willis MW, **Ketter TA**, Kimbrell TA, Speer AM, Repella JD, Herscovitch P, Post RM: Functional connectivity of the subgenual anterior cingulate in bipolar and unipolar illness, in 56<sup>th</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry. New Orleans, May 3-5, 2001. Abstract 537. Biol Psychiatry 2001;49(8S):156S-157S.
- 164) **Ketter TA**, Wang PW: Emerging treatments for bipolar disorders. 154<sup>th</sup> Annual Meeting of the American Psychiatric Association, New Orleans, May 5 – 10, 2001. In the industry symposium: Treating Psychotic Disorders: What is the State of the Art?. Industry Symposium Abstract 15C. Pages 281-2.
- 165) **Ketter TA**: Clinical and neuroimaging evidence of illness progression in bipolar disorders. 154<sup>th</sup> Annual Meeting of the American Psychiatric Association, New Orleans, May 5 – 10, 2001. In the industry symposium: Plasticity as Efficacy? Neurotrophic Effects of Mood Stabilizers. Industry Symposium Abstract 44B. Page 320-1.
- 166) **Ketter TA**: Carbamazepine and oxcarbazepine in bipolar disorders. In the course: Anticonvulsants in Bipolar Disorder. 154<sup>th</sup> Annual Meeting of the American Psychiatric Association, New Orleans, May 5 – 10, 2001. Course 54.
- 167) Janenawasin S, Wang PW, Schumacher M, Das B, Santosa CM, Mongkolkeep J, **Ketter TA**: Olanzapine yields rapid improvement in diverse syndromal and subsyndromal exacerbations of bipolar disorders. 154<sup>th</sup> Annual Meeting of the American Psychiatric Association, New Orleans, May 5 - 10, 2001. Abstract NR168. Pages 46-7.
- 168) Dieckmann NF, Wang PW, Sachs N, Rennie CM, Tate D, Patwardhan A, **Ketter TA**: Frontal lobe gray matter volume and biochemical differences in bipolar disorder. 154<sup>th</sup> Annual Meeting of the American Psychiatric Association, New Orleans, May 5 - 10, 2001. Abstract NR333. Pages 90-1.

- 169) Das B, Strong CM, Sachs N, Mongkolkeep J, Schumacher M, Wang PW, **Ketter TA**: Creativity enhancement in bipolar patients more specific than in creative discipline graduate students. 154<sup>th</sup> Annual Meeting of the American Psychiatric Association, New Orleans, May 5 - 10, 2001. Abstract NR343. Page 93.
- 170) Strong CM, Das B, Sachs N, Santosa CM, Wang PW, **Ketter TA**: Creativity and temperament relationships in mood disorder and creative subjects. 154<sup>th</sup> Annual Meeting of the American Psychiatric Association, New Orleans, May 5 - 10, 2001. Abstract NR344. Pages 93-4.
- 171) **Ketter, TA**, Santosa CM, Wang PW, Das B, Sachs N, Strong CM, Mongkolkeep J: Mood stabilizer effects on creativity in bipolar disorder patients. 154<sup>th</sup> Annual Meeting of the American Psychiatric Association, New Orleans, May 5 - 10, 2001. Abstract NR370. Pages 100-1.
- 172) Ascher JA, Barnett S, Batey S, **Ketter TA**, Meredith CE, Londborg PD, West SA: Safety and tolerability of lamotrigine in controlled mood disorder trials, in 154<sup>th</sup> Annual Meeting of the American Psychiatric Association. New Orleans, May 5 - 10, 2001 Abstract NR400. Page 109.
- 173) Solvason HB, DeBattista C, Lopez. J, Ghebremichael R, **Ketter T**, Schatzberg A: Low frequency transcranial magnetic stimulation (TMS) in the treatment of resistant depression. 41<sup>st</sup> Annual New Clinical Drug Evaluation Unit Meeting, Phoenix, May 28-31, 2001. Abstract III-15.
- 174) Chang KD, Steiner H, Dienes KD, **Ketter TA**: Divalproex in bipolar offspring with mood and behavioral disorders, in 41<sup>st</sup> Annual New Clinical Drug Evaluation Unit Meeting. Phoenix, May 28-31, 2001. Abstract III-2.
- 175) **Ketter TA**, Janenawasin S, Wang PW, Schumacher M, Das B, Santosa CM, Mongkolkeep J, Strong CM: Olanzapine yields rapid improvement in diverse syndromal and subsyndromal exacerbations of bipolar disorders. In 4<sup>th</sup> International Conference on Bipolar Disorder. Pittsburgh, June 14-16, 2001. Abstract 71. Bipolar Disord 2001;3(Suppl 1):44.
- 176) Emsley R, Brook S, Frangou S, **Ketter T**, Earl N, Ascher JA, Paska W: Safety and tolerability of lamotrigine in controlled mood disorder trials. In 14<sup>th</sup> European College of Neuropsychopharmacology Congress, Istanbul, Turkey, October 13-17, 2001. Eur Neuropsychopharmacology 2001;11(Suppl 3):S204-5. Abstract P.1.054.
- 177) Tohen M, Baker RW, Altshuler L, Zarate CA, Suppes T, **Ketter TA**, Risser R, Juliar BE, Luther MF, Gilmore JA, Schuh LM: Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. In 14<sup>th</sup> European College of Neuropsychopharmacology Congress, Istanbul, Turkey, October 13-17, 2001. Eur Neuropsychopharmacology 2001;11(Suppl 3):S354. Abstract P.6.039
- 178) Chang K, Adleman N, Dienes K, Reiss A, **Ketter TA**: <sup>1</sup>H-MRS of bipolar offspring with and at high risk for bipolar disorder. 48<sup>th</sup> Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Anaheim, October 23 - 28, 2001. Abstract.
- 179) Chang KD, Adleman N, Dienes K, Reiss A, **Ketter TA**: fMRI of viso-spatial working memory in bipolar offspring with and without bipolar disorder. 48<sup>th</sup> Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Anaheim, October 23 - 28, 2001. Abstract.

- 180) **Ketter TA**, Wang PW, Dieckmann N: Brain Imaging in Mood Disorders, in 40<sup>th</sup> Anniversary Meeting of the Taiwanese Society of Psychiatry. Taipei, Taiwan, Republic of China, November 2, 2001
- 181) Chang KD, Adleman N, Dienes K, Reiss A, **Ketter TA**: <sup>1</sup>H-MRS in bipolar offspring with bipolar disorder, in 40<sup>th</sup> Annual Meeting of the American College of Neuropsychopharmacology. Waikaloa, Hawaii, December 9-13, 2001 Abstract. Page 219.
- 182) Sachs G, Altshuler L, **Ketter T**, Suppes T, Rasgon N, Frye M, Collins M: Divalproex versus placebo for the treatment of bipolar depression, in 40<sup>th</sup> Annual Meeting of the American College of Neuropsychopharmacology. Waikaloa, Hawaii, December 9-13, 2001 Abstract. Page 232.
- 183) Baker RW, Tohen M, Altshuler L, Zarate CA, Suppes T, **Ketter TA**, Risser RC, Schuh L: Olanzapine versus divalproex sodium for treatment of acute mania and maintenance of remission: a 47-week study, in 40<sup>th</sup> Annual Meeting of the American College of Neuropsychopharmacology. Waikaloa, Hawaii, December 9-13, 2001 Abstract. Page 247.
- 184) Calabrese JR, Suppes T, Swann A, **Ketter T**, Bowden CL, DeVeaugh-Geiss J, Evoniuk G: Lamotrigine and rash: a review of evidence from double-blind, placebo-controlled trials in bipolar disorder patients, in 40<sup>th</sup> Annual Meeting of the American College of Neuropsychopharmacology. Waikaloa, Hawaii, December 9-13, 2001 Abstract. Page 347.
- 185) **Ketter TA**, Wang PW, Sachs GS, Zarate CA, Marangell LB, Calabrese JR, Goldberg JF: Increased obesity in women with bipolar disorders. 40<sup>th</sup> Annual Meeting of the American College of Neuropsychopharmacology, Waikaloa, Hawaii, December 9-13, 2001. Abstract. Page 359.
- 186) **Ketter TA**: Refractory depression: a management challenge. 4<sup>th</sup> Meeting of the East African Psychiatric Association, Entebbe, Uganda, April 22-23, 2002. Abstract.
- 187) **Ketter TA**: Bipolar affective disorders: diagnostic and management challenges. 4<sup>th</sup> Meeting of the East African Psychiatric Association, Entebbe, Uganda, April 22-23, 2002. Abstract.
- 188) Tohen M, Baker RW, Altshuler L, Zarate CA, Suppes T, **Ketter TA**, Risser RC, Brown E, Luther MF, Gilmore JA, Schuh L: Olanzapine versus divalproex sodium for bipolar mania: a 47-week study. 11<sup>th</sup> Congress of the Association of European Psychiatrists. Stockholm, May 4-8, 2002. Abstract 488. Eur Psychiatry 2002;17(Suppl 1):109.
- 189) Zubieta JK, Bueller JA, Xu Y, Koeppe RA, **Ketter TA**: Anterior cingulate and limbic mu opioid receptors regulate affective states, in 57<sup>th</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry. Philadelphia, May 16-18, 2002 Abstract 150. Biol Psychiatry 2002;51(8S):50S-51S.
- 190) Tohen M, Baker RW, Altshuler L, Zarate CA, Suppes T, **Ketter TA**, Risser RC, Juliar BE, Luther MF, Gilmore JA: Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study, in 57<sup>th</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry. Philadelphia, May 16-18, 2002 Abstract 208. Biol Psychiatry 2002;51(8S):70S.
- 191) Little JT, **Ketter TA**, Kimbrell TA, Dunn RT, B.E. B, Willis MW, Luckenbaugh DA, Post RM: Pretreatment regional cerebral metabolism and antidepressant response to

- bupropion and venlafaxine, in 57<sup>th</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry. Philadelphia, May 16-18, 2002 Abstract 257. Biol Psychiatry 2002;51(8S):87S.
- 192) Wang PW, Dieckmann N, Sailasuta N, Adalsteinsson E, Spielman D, **Ketter TA**: 3 Tesla <sup>1</sup>H-magnetic resonance spectroscopic measurements of prefrontal cortical gamma-aminobutyric acid (GABA) levels in bipolar disorder patients and healthy volunteers., in 57<sup>th</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry. Philadelphia, May 16-18, 2002 Abstract 571. Biol Psychiatry 2002;51(8S):197S.
- 193) Baker RW, Tohen MF, Altshuler LL, Zarate CA, Suppes P, **Ketter TA**, Risser RC: Olanzapine versus divalproex sodium for mania: a 47-week study, in 155<sup>th</sup> Annual Meeting of the American Psychiatric Association. Philadelphia, PA, May 18-23, 2002. Report Session Abstract 37. Page 15.
- 194) **Ketter TA**: Managing common benign and uncommon serious adverse effects. In the industry symposium: Bipolar Depression and Rapid Cycling: Current Management Strategies, in 155<sup>th</sup> Annual Meeting of the American Psychiatric Association. Philadelphia, PA, May 18-23, 2002. Industry Symposium Abstract 31D. Page 284.
- 195) **Ketter TA**: Carbamazepine, oxcarbazepine and zonisamide in bipolar disorders. In the course: Anticonvulsants in Bipolar Disorder, in 155<sup>th</sup> Annual Meeting of the American Psychiatric Association. Philadelphia, PA, May 18-23, 2002. Course 21.
- 196) Schumacher M, Corrigan PW, **Ketter TA**: Stigmatizing attitudes more related to psychotic compared to depressive behaviors. 155<sup>th</sup> Annual Meeting of the American Psychiatric Association, Philadelphia, May 18-23, 200. Abstract NR16. Page 5.
- 197) Wang PW, Dieckmann NF, Becker OV, Sailasuta N, Adalsteinsson E, Spielman D, **Ketter TA**: Increased prefrontal cortical gamma-aminobutyric Acid (GABA) in bipolar disorder patients, compared to healthy controls. 155<sup>th</sup> Annual Meeting of the American Psychiatric Association, Philadelphia, PA, May 18-23, 2002. Abstract NR87. Page 25.
- 198) Dieckmann NF, Wang PW, Becker OV, Sachs N, **Ketter TA**: Decreased left frontal lobe gray matter in men with bipolar I disorder. 155<sup>th</sup> Annual Meeting of the American Psychiatric Association, Philadelphia, May 18-23, 200. Abstract NR181. Page 49-50.
- 199) Strong CM, **Ketter TA**: Negative affective traits and openness have differential relationships to creativity. 155<sup>th</sup> Annual Meeting of the American Psychiatric Association, Philadelphia, PA, May 18-23, 2002. Abstract NR267. Page 73.
- 200) **Ketter TA**, Wang PW, Sachs GS, Zarate CA, Marangell LB, Calabrese JR, Goldberg JF: Increased obesity in women with bipolar disorders. 155<sup>th</sup> Annual Meeting of the American Psychiatric Association, Philadelphia, PA, May 18-23, 2002. Abstract NR291. Page 80.
- 201) Zhu B, Baker RW, Altshuler L, Zarate CA, **Ketter TA**, Lage M, Tunis S, Shi L, Tohen M: Economic outcomes associated with olanzapine versus divalproex treatment for acute mania: results from a randomized clinical trial, in 7<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research. Crystal City, Virginia, May 19-20, 2002. Abstract.
- 202) Tohen M, Vieta E, **Ketter T**, Centorino F, Calabrese C, Sachs G, Bowden C, Risser R, Baker RW, Evans AR, Dube S, Tollefson G, Brier A: Olanzapine in the treatment of bipolar depression, in 42<sup>nd</sup> Annual New Clinical Drug Evaluation Unit Meeting. Boca Raton, June 10-13, 2002 Abstract III-6.

- 203) Chang KD, Dienes K, Blasey C, Reiss A, **Ketter T**: Medication in bipolar offspring: a risk factor for development of bipolar disorder?, in 42<sup>nd</sup> Annual New Clinical Drug Evaluation Unit Meeting. Boca Raton, June 10-13, 2002 Abstract III-12.
- 204) Zhu B, Baker R, Altshuler L, Zarate CA, **Ketter TA**, Lage M, Tunis S, Shi L, Tohen M: Economic outcomes associated with olanzapine versus divalproex treatment for acute mania: results from a randomized clinical trial. 42<sup>nd</sup> Annual New Clinical Drug Evaluation Unit Meeting, Boca Raton, June 10-13, 2002. Abstract.
- 205) **Ketter TA**: Challenge of treating bipolar depression, in 15<sup>th</sup> Congress of the European College of Neuropsychopharmacology. Barcelona, Spain, October 5-9, 2002. Abstract.
- 206) Tohen M, Vieta E, **Ketter T**, Centorino F, Calabrese C, Sachs G, Bowden C, Risser R, Baker RW, Evans AR, Dube S, Tollefson G, Brier A: Olanzapine in the treatment of bipolar depression, in 15<sup>th</sup> Congress of the European College of Neuropsychopharmacology. Barcelona, Spain, October 5-9, 2002. Abstract P.1.169. European Neuropsychopharmacol 2002;12(Suppl 3):S238-S239.
- 207) Tohen M, Baker RW, Altshuler L, Zarate CA, Suppes T, **Ketter TA**, Risser RC, Brown EB, Luther MF, Gilmore JA, Schuh LM: Olanzapine versus divalproex sodium for bipolar mania: a 47-week study, in National Clinical Symposium of the American College of Nurse Practitioners. Albuquerque, October 9-13, 2002. Abstract.
- 208) **Ketter TA**, Wang PW, Sachs N, Jimison JJ, Segall GM: Commonalities and dissociations in anterior paralimbic metabolic decreases with sustained sadness in female unipolar depressives versus bipolar II depressives and healthy volunteers, in 41<sup>st</sup> Annual Meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico, December 8-12, 2002 Abstract. Page 147.
- 209) Goldberg JF, Michaelis BH, Endick CJ, Singer TM, Allen MH, Sagduyu K, Calabrese JR, Sachs GS, Marangell LB, Thase ME, **Ketter TA**, Ghaemi SN: Suicidality and differential pharmacotherapy in the STEP 500 bipolar cohort, in 41<sup>st</sup> Annual Meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico, December 8-12, 2002 Abstract. Page 220
- 210) Baker RW, Vieta E, **Ketter TA**, Centorrino F, Calabrese J, Sachs G, Bowden C, Risser R, Evans AR, Dube S, Tollefson GD, Tohen M: Olanzapine and olanzapine - fluoxetine combination (OFC) in the treatment of bipolar depression, in 41<sup>st</sup> Annual Meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico, December 8-12, 2002 Abstract. Page 220.
- 211) Lembke A, Miklowitz D, Otto M, Wisniewski S, Sachs G, Thase M, **Ketter T**: Psychosocial service utilization by patients with bipolar disorders, in 58<sup>th</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry. San Francisco, May 15-17, 2003 Abstract 147. Biol Psychiatry 2003;53(8S):52S.
- 212) Wang PW, **Ketter TA**, Sachs N, Jimison JJ, Segall GM: Commonalities and dissociations in anterior paralimbic metabolic decreases with sustained sadness in female unipolar depressives versus bipolar II depressives and healthy volunteers, in 58<sup>th</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry. San Francisco, May 15-17, 2003 Abstract 267. Biol Psychiatry 2003;53(8S):95S.
- 213) Nowakowska C, Strong CM, **Ketter TA**: Temperamental similarities and differences among euthymic mood disorders patients, healthy controls, and creative controls, in 58<sup>th</sup>



Annual Convention and Scientific Program of the Society of Biological Psychiatry. San Francisco, May 15-17, 2003 Abstract 442. Biol Psychiatry 2003;53(8S):157S.

- 214) Chang KD, Barnea-Goraly N, Adleman N, Dienes N, **Ketter TA**, Reiss AL: Volumetric MRI of familial pediatric bipolar disorder, in 58<sup>th</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry. San Francisco, May 15-17, 2003 Abstract 550. Biol Psychiatry 2003;53(8S):195S.
- 215) Yang Y, Nowakowska C, Becker OV, Schumacher M, Strong CM, Wang P, **Ketter TA**: Weight loss during first two months of open adjunctive zonisamide for obesity in bipolar disorder patients, in 156<sup>th</sup> Annual Meeting of the American Psychiatric Association. San Francisco, CA, May 17-22, 2003 Abstract NR14. Pages 5-6.
- 216) Alarcon AM, Perlick DA, Menard K, Baloga-Mintz N, Schumacher MR, Strong CM, **Ketter TA**: Enhanced creativity in bipolar disorder patients compared to caregivers, in 156<sup>th</sup> Annual Meeting of the American Psychiatric Association. San Francisco, CA, May 17-22, 2003 Abstract NR126. Pages 46-47.
- 217) Simeonova-Lennon D, Dienes K, Blasey C, **Ketter TA**, Chang KD: Measurement of creativity in bipolar adults and their offspring, in 156<sup>th</sup> Annual Meeting of the American Psychiatric Association. San Francisco, CA, May 17-22, 2003 Abstract NR127. Page 47.
- 218) Chandler RA, O'Keeffe CM, Wang PW, Giri K, Davenport C, Schumacher MR, **Ketter TA**: Low incidence of lamotrigine treatment-emergent rash with dermatology precautions, in 156<sup>th</sup> Annual Meeting of the American Psychiatric Association. San Francisco, CA, May 17-22, 2003 Abstract NR156. Page 58.
- 219) Wang PW, Chandler RA, O'Keeffe CM, Giri K, Davenport C, Schumacher MR, **Ketter TA**: Lamotrigine use in a bipolar disorders clinic, in 156<sup>th</sup> Annual Meeting of the American Psychiatric Association. San Francisco, CA, May 17-22, 2003 Abstract NR158. Pages 58-59.
- 220) **Ketter TA**, Bowden CL, Calabrese JR, Goldberg JF, Suppes P: Clinical predictors of response to maintenance treatment in bipolar I disorder, in 156<sup>th</sup> Annual Meeting of the American Psychiatric Association. San Francisco, CA, May 17-22, 2003 Abstract NR237. Pages 88-89.
- 221) Ginsberg LD, Bowden CL, Calabrese JR, Sachs GS, **Ketter TA**: Effects of mood stabilizers on body weight in bipolar I disorder, in 156<sup>th</sup> Annual Meeting of the American Psychiatric Association. San Francisco, CA, May 17-22, 2003 Abstract NR463. Pages 173-174.
- 222) Perlick DA, Miklowitz DJ, Menard K, Wolff N, Marangell LB, Calabrese JR, Ostacher MJ, Patel JK, **Ketter TA**, Rosenheck RA: Scope and correlates of caregiver burden in bipolar disorder, in 156<sup>th</sup> Annual Meeting of the American Psychiatric Association. San Francisco, CA, May 17-22, 2003 Abstract NR471. Pages 176-177.
- 223) Frye MA, **Ketter TA**, Goldberg JF, Antonijevic Z, Calabrese JR: Previous episode burden and response to treatment in bipolar I disorder, in 156<sup>th</sup> Annual Meeting of the American Psychiatric Association. San Francisco, CA, May 17-22, 2003 Abstract NR483. Page 181.
- 224) Hamner MB, **Ketter TA**: Extended release carbamazepine in bipolar disorder: a six month open trial, in 156<sup>th</sup> Annual Meeting of the American Psychiatric Association. San Francisco, CA, May 17-22, 2003 Abstract NR491. Page 184.

- 225) Tohen MF, **Ketter TA**, Calabrese JR, Andersen SW, Detke HC, Risser RC, Corya SA: Long-term use of olanzapine or olanzapine/fluoxetine combination for bipolar depression, in 156<sup>th</sup> Annual Meeting of the American Psychiatric Association. San Francisco, CA, May 17-22, 2003 Abstract NR510. Page 191.
- 226) Strong CM, Abouadarham JF, **Ketter TA**: Creativity related to dislike of simplicity and symmetry rather than like of complexity and asymmetry, in 156<sup>th</sup> Annual Meeting of the American Psychiatric Association. San Francisco, CA, May 17-22, 2003 Abstract NR625. Page 234.
- 227) **Ketter TA**: Evolving role of novel antipsychotics for the management of acute mania. In the industry symposium: Managing the Spectrum of Psychotic Disorders, in 156<sup>th</sup> Annual Meeting of the American Psychiatric Association. San Francisco, CA, May 17-22, 2003 Industry Symposium Abstract 31B. Page 288.
- 228) **Ketter TA**: Mood stabilizer combinations: multimodal therapy or polypharmacy? In the industry symposium: Combined Pharmacotherapy for Bipolar Disorders, in 156<sup>th</sup> Annual Meeting of the American Psychiatric Association. San Francisco, CA, May 17-22, 2003 Industry Symposium Abstract 49C. Page 311.
- 229) **Ketter TA**, Bowden C, Calabrese J, Goldberg J, Suppes T, Frye M, Antonijevic Z: Clinical predictors of response to treatment in bipolar I disorder, in 43<sup>rd</sup> Annual New Clinical Drug Evaluation Unit Meeting, Boca Raton, May 27-30, 2003. Abstract I-85.
- 230) Frye MA, **Ketter TA**, Goldberg J, Antonijevic Z, Calabrese J. Previous episode burden and response to treatment in bipolar I disorder, in 43<sup>rd</sup> Annual New Clinical Drug Evaluation Unit Meeting, Boca Raton, May 27-30, 2003. Abstract I-87.
- 231) Martinez JM, Marangell LB, **Ketter TA**, Bowden CL, Goldberg JF, Calabrese JR, Thase ME: Lamotrigine use in patients with bipolar disorder: baseline data from the STEP-BD 500, in 43<sup>rd</sup> Annual New Clinical Drug Evaluation Unit Meeting, Boca Raton, May 27-30, 2003. Abstract I-88.
- 232) Kalali A, **Ketter TA**, Weisler RH: A 3-week double-blind placebo-controlled study of extended release carbamazepine in the treatment of acute mania in bipolar disorder: a six month open trial, in 43<sup>rd</sup> Annual New Clinical Drug Evaluation Unit Meeting, Boca Raton, May 27-30, 2003. Abstract II-11.
- 233) **Ketter TA**, Tohen M, Vieta E, Calabrese J, Andersen S, Detke HC, Risser R, Corya S: Open-label maintenance treatment for bipolar depression using olanzapine or olanzapine/fluoxetine combination, in 43<sup>rd</sup> Annual New Clinical Drug Evaluation Unit Meeting, Boca Raton, May 27-30, 2003. Abstract II-14.
- 234) Ginsberg LD, Calabrese JR, Bowden CL, Sachs GS, **Ketter TA**, Antonijevic Z, Ledbetter R: Effects of lamotrigine and lithium on body weight in bipolar I disorder, in 43<sup>rd</sup> Annual New Clinical Drug Evaluation Unit Meeting, Boca Raton, May 27-30, 2003. Abstract II-16.
- 235) Perlick D, Rosenheck A, Menard KR, Woods SW, Sernyak M, Neugebauer SR, Baxter N, Lippman L, Miklowitz DF, Morris C, Schumacher M, Alarcon A, **Ketter TA**: Needs of family caregivers of patients with bipolar illness: preliminary data using the family assessment of need for service (FANS), in 43<sup>rd</sup> Annual New Clinical Drug Evaluation Unit Meeting, Boca Raton, May 27-30, 2003. Abstract II-19.

- 236) **Ketter TA**: Choosing the right patient population. In: Improving the clinical relevance of maintenance designs in bipolar disorder, in 43<sup>rd</sup> Annual New Clinical Drug Evaluation Unit Meeting, Boca Raton, May 27-30, 2003. Panel 1.
- 237) Frye M, **Ketter T**, Goldberg G, Antonijevic Z, Calabrese J: Previous episode burden and response to treatment in bipolar I disorder. 5<sup>th</sup> International Conference on Bipolar Disorder, Pittsburgh, June 12-14, 2003. Abstract P69. *Bipolar Disorders* 2003;5(Suppl 1):48.
- 238) **Ketter TA**, Weisler RH, Kalali AH: Extended release carbamazepine in bipolar disorder. 5<sup>th</sup> International Conference on Bipolar Disorder, Pittsburgh, June 12-14, 2003. Abstract P105. *Bipolar Disorders* 2003;5(Suppl 1):60.
- 239) **Ketter T**, Bowden C, Suppes T, Goldberg J, Antonijevic Z, Leadbetter R: Predictors of response to lithium and lamotrigine prophylaxis in bipolar I disorder. 5<sup>th</sup> International Conference on Bipolar Disorder, Pittsburgh, June 12-14, 2003. Abstract P106. *Bipolar Disorders* 2003;5(Suppl 1):60.
- 240) Schneck CD, Milkowitz DJ, Calabrese JR, Allen MH, Thomas MR, Wisniewski SR, Miyahara S, Shelton MD, **Ketter TA**, Goldberg JF, Bowden CL, Sachs GS: Phenomenology of rapid cycling bipolar disorder: data from the first 500 participants in the systematic treatment enhancement program. 5<sup>th</sup> International Conference on Bipolar Disorder, Pittsburgh, June 12-14, 2003. Abstract P179. *Bipolar Disorders* 2003;5(Suppl 1):82.
- 241) **Ketter T**: Role of atypicals in bipolar depression. 16<sup>th</sup> Congress of the European College of Neuropsychopharmacology. Prague, Czech Republic, September 20-24, 2003. Industry Symposium Abstract.
- 242) Vieta E, Tohen M, **Ketter T**, Calabrese J, Andersen S, Detke H, Risser R, Corya S: Long-term use of olanzapine or olanzapine/fluoxetine for bipolar depression. 16<sup>th</sup> Congress of the European College of Neuropsychopharmacology. Prague, Czech Republic, September 20-24, 2003. Abstract P.1.078. *European Neuropsychopharmacol* 2003;13(Suppl 4):S207-S208.
- 243) **Ketter T**, Bowden C, Vieta E, Goldberg JF, Antonijevic Z, Leadbetter R: Predictors of response to lithium and lamotrigine prophylaxis in bipolar I disorder. 16<sup>th</sup> Congress of the European College of Neuropsychopharmacology. Prague, Czech Republic, September 20-24, 2003. Abstract P.1.217. *European Neuropsychopharmacol* 2003;13(Suppl 4):S267.
- 244) Frye M, Vieta E, **Ketter T**, Goldberg JF, Antonijevic Z, Calabrese J. Previous episode burden and response to lithium and lamotrigine in bipolar I disorder. 16<sup>th</sup> Congress of the European College of Neuropsychopharmacology. Prague, Czech Republic, September 20-24, 2003. Abstract P.1.218. *European Neuropsychopharmacol* 2003;13(Suppl 4):S267.
- 245) Simeonova-Lennon D, Dienes K, Strong C, **Ketter TA**, Chang KD: Measurement of creativity in familial pediatric bipolar disorder, in 50<sup>th</sup> Annual Meeting of the American Academy of Child and Adolescent Psychiatry, October 14-19, 2003. Abstract.
- 246) Tohen M, Vieta E, **Ketter TA**, Calabrese J, Mitchell PB, Corya SA, Detke HC, Risser R, Case M, Baker RW: Acute and long-term efficacy of olanzapine and olanzapine/fluoxetine combination for bipolar depression, in 42<sup>nd</sup> Annual Meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico, December 7-11, 2003 Abstract. Page 48.

- 247) Goldberg JF, Malhotra AK, Calabrese JR, Bowden CL, Suppes T, Frye MA, **Ketter TA**: Life charting of longitudinal mood symptoms with lamotrigine monotherapy versus placebo in rapid cycling bipolar disorder, in 42<sup>nd</sup> Annual Meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico, December 7-11, 2003 Abstract. Page 94.
- 248) Vieta E, Tohen M, Calabrese J, **Ketter TA**, Mitchell PB, Briggs SD, Case M: Clinical predictors of response to olanzapine or olanzapine/fluoxetine combination for bipolar depression, in 42<sup>nd</sup> Annual Meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico, December 7-11, 2003 Abstract. Page 97.
- 249) Bowden C, Calabrese J, Sachs G, **Ketter T**, Antonijevic Z, Evoniuk G: The effects of lamotrigine maintenance therapy on weight change in adults with bipolar I disorder, in 42<sup>nd</sup> Annual Meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico, December 7-11, 2003 Abstract. Page 207.
- 250) **Ketter TA**, Yang Y, Nowakowska C, Becker OV, Wang PW, Chandler RA, Schumacher MR: Open adjunctive zonisamide for obesity in medicated euthymic bipolar disorder patients, in 42<sup>nd</sup> Annual Meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico, December 7-11, 2003 Abstract. Page 225.
- 251) **Ketter TA**: New treatment insights for bipolar disorders. In: International Society for Bipolar Disorders Regional Group Conference. Sydney, Australia, February 5-7, 2004. Abstract 102. *Bipolar Disorders* 2004;6(Suppl 1):11.
- 252) **Ketter TA**: Neuroanatomical substrates of affective processing in health and mood disorders. In: International Society for Bipolar Disorders Regional Group Conference. Sydney, Australia, February 5-7, 2004. Abstract 204. *Bipolar Disorders* 2004;6(Suppl 1):18-19.
- 253) **Ketter TA**, Tohen MF, Vieta E, Calabrese JR, Andersen SW, Detke HC, Risser RC, Corya SA: Open-label maintenance treatment for bipolar depression using olanzapine or olanzapine/fluoxetine combination. In: International Society for Bipolar Disorders Regional Group Conference. Sydney, Australia, February 5-7, 2004. Abstract 309. *Bipolar Disorders* 2004;6(Suppl 1):27.
- 254) **Ketter TA**, Tohen MF, Vieta E, Calabrese JR, Andersen SW, Detke HC, Risser RC, Corya SA: Open-label maintenance treatment for bipolar depression using olanzapine or olanzapine/fluoxetine combination. In: World Federation of Societies of Biological Psychiatry International Congress of Biological Psychiatry. Sydney, Australia, February 9-13, 2004. Abstract 5267. *World J Biol Psychiatry* 2004;5(Suppl 1):51.
- 255) Goldberg JF, Malhotra AK, Calabrese JR, Bowden CI, Suppes T, Frye MA, **Ketter TA**: Weekly mood stability over 6 months with lamotrigine or placebo in bipolar rapid cycling, in 59<sup>th</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry. New York, April 29-May 1, 2004 Abstract 506. *Biol Psychiatry* 2004;54(8S):141S-142S.
- 256) Tohen MF, Vieta E, Calabrese JR, **Ketter TA**, Mitchell P, Briggs SD, Case M: Clinical predictors of response to olanzapine or olanzapine/fluoxetine combination for bipolar depression, in 59<sup>th</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry. New York, April 29-May 1, 2004 Abstract 506. *Biol Psychiatry* 2004;54(8S):231S.

- 257) **Ketter TA**, Kalali AH, Weisler RH: Three-bead extended-release carbamazepine capsule (SPD417) continuation/maintenance therapy in bipolar disorder, in 157<sup>th</sup> Annual Meeting of the American Psychiatric Association. New York, NY, May 1-6, 2004. Scientific and Clinical Report 42. Page 88.
- 258) Sapozhnikova A, Chandler RA, Alarcon AM, Wang PW, Nowakowska C, Marsh WK, **Ketter TA**: Illness severity and longitudinal course in college students with bipolar disorders, in 157<sup>th</sup> Annual Meeting of the American Psychiatric Association. New York, NY, May 1-6, 2004. Abstract NR31. Page 12.
- 259) Fenn R, Wang PW, Sachs N, Nowakowska C, Dieckmann NF, **Ketter TA**: Gender differences in cerebral metabolism during sustained sadness, in 157<sup>th</sup> Annual Meeting of the American Psychiatric Association. New York, NY, May 1-6, 2004. Abstract NR80. Page 30.
- 260) Alarcon AM, Baloga-Mintz N, Jaros S, Perlick DA, Wang PW, Nowakowska C, **Ketter TA**: Enhanced creativity in patients with bipolar disorder compared with caregivers, in 157<sup>th</sup> Annual Meeting of the American Psychiatric Association. New York, NY, May 1-6, 2004. Abstract NR141. Page 52.
- 261) Wang PW, Chandler RA, Alarcon AM, Nowakowska C, Marsh WK, **Ketter TA**: Low incidence of lamotrigine treatment-emergent rash with dermatology precautions, in 157<sup>th</sup> Annual Meeting of the American Psychiatric Association. New York, NY, May 1-6, 2004. Abstract NR348. Page 129.
- 262) Weisler RH, Kalali AH, **Ketter TA**: Carbamazepine extended release treatment of manic and mixed symptoms, in 157<sup>th</sup> Annual Meeting of the American Psychiatric Association. New York, NY, May 1-6, 2004. Abstract NR359. Page 133.
- 263) Goldberg JF, **Ketter TA**, Calabrese JR, Suppes T, Frye MA, White R: Effects of mood stabilizers on relapse and recurrence in bipolar disorder, in 157<sup>th</sup> Annual Meeting of the American Psychiatric Association. New York, NY, May 1-6, 2004. Abstract NR407. Page 152.
- 264) Nowakowska C, Sapozhnikova A, Chandler RA, Alarcon AM, Wang PW, Marsh WK, **Ketter TA**: Effect of first-degree family history in college students with bipolar disorder, in 157<sup>th</sup> Annual Meeting of the American Psychiatric Association. New York, NY, May 1-6, 2004. Abstract NR753. Page 283.
- 265) Ostacher MJ, Rosenheck RA, Wolff N, Perlick DA, Miklowitz D, Eidelman P, Calabrese JR, Fossey MD, Gonzalez J, **Ketter TA**, Marangell LB, Patel JK, Wolff N, Rosenheck R: Patient substance/alcohol abuse and caregiver burden in bipolar disorder, in 157<sup>th</sup> Annual Meeting of the American Psychiatric Association. New York, NY, May 1-6, 2004. Abstract NR794. Page 299.
- 266) Tohen MF, Vieta E, Calabrese JR, **Ketter TA**, Mitchell P, Briggs SD, Case M: Predictors of response to olanzapine and fluoxetine in bipolar depression, in 157<sup>th</sup> Annual Meeting of the American Psychiatric Association. New York, NY, May 1-6, 2004. Abstract NR801. Page 302.
- 267) Jaros S, Schumacher M, Culver J, Alarcon AM, Baloga-Mintz N, Derlick D, **Ketter TA**: Stigma by proxy: exploring caregivers of patients with bipolar illness, in 157<sup>th</sup> Annual Meeting of the American Psychiatric Association. New York, NY, May 1-6, 2004. Abstract NR903. Page 338.

- 268) **Ketter TA**: Efficacy of anticonvulsants in bipolar disorders: novel findings from longitudinal studies, in 44<sup>th</sup> Annual New Clinical Drug Evaluation Unit Meeting, Phoenix, AZ, June 1-4, 2004. Workshop 2. Page 5.
- 269) Tohen M, Vieta E, **Ketter TA**, Centorrino F, Calabrese J, Sachs G, Bowden C, Mitchell PB, Risser R, Baker RW, Evans AR: Olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar depression, in 44<sup>th</sup> Annual New Clinical Drug Evaluation Unit Meeting, Phoenix, AZ, June 1-4, 2004. Panel 1. Page 22.
- 270) **Ketter TA**, Paulsson B, Jones M: Sustained remission/euthymia with quetiapine monotherapy for bipolar mania, in 44<sup>th</sup> Annual New Clinical Drug Evaluation Unit Meeting, Phoenix, AZ, June 1-4, 2004. Abstract 24. Page 78.
- 271) Schneck CD, Miklowitz DJ, Calabrese JR, Allen MH, Thomas MR, Wisniewski SR, Miyahara S, Shelton MD, **Ketter TA**, Goldberg JF, Bowden CL, Sachs GS: Phenomenology of rapid cycling bipolar disorder: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder, in 44<sup>th</sup> Annual New Clinical Drug Evaluation Unit Meeting, Phoenix, AZ, June 1-4, 2004. Abstract 95. Page 149.
- 272) Weisler RH, Keck PE, **Ketter TA**, Swann AC, Kalali AH: Extended release carbamazepine monotherapy for acute manic and mixed symptoms associated with bipolar disorder, in 44<sup>th</sup> Annual New Clinical Drug Evaluation Unit Meeting, Phoenix, AZ, June 1-4, 2004. Abstract 101. Page 155.
- 273) Goldberg JF, **Ketter TA**, Calabrese JR, Suppes T, Frye MA, White R: Effects of mood stabilizer treatment on relapse and recurrence in bipolar disorder, in 44<sup>th</sup> Annual New Clinical Drug Evaluation Unit Meeting, Phoenix, AZ, June 1-4, 2004. Abstract 219. Page 273.
- 274) Calabrese JR, **Ketter TA**: Lamotrigine: a new kind of mood stabilizer, in 24<sup>th</sup> Congress of Collegium Internationale Neuro-Psychopharmacologicum. Paris, June 20-24, 2004 Abstract SP.43.04. Int J Neuropsychopharmacol 2004;7(Suppl 1):S53.
- 275) **Ketter TA**: Treatment of bipolar depression, in 24<sup>th</sup> Congress of Collegium Internationale Neuro-Psychopharmacologicum. Paris, June 20-24, 2004 Abstract SAT.06.03. Int J Neuropsychopharmacol 2004;7(Suppl 1):S97-8.
- 276) **Ketter TA**, Suppes T, Goldberg JF, Frye MA, White R: Effects of mood stabilizer treatment on mood episode relapse and recurrence in bipolar disorder, in 24<sup>th</sup> Congress of Collegium Internationale Neuro-Psychopharmacologicum. Paris, June 20-24, 2004 Abstract P01.071. Int J Neuropsychopharmacol 2004;7(Suppl 1):S153.
- 277) **Ketter TA**, Paulsson B, Jones M: Sustained remission/euthymia with quetiapine monotherapy for bipolar mania, in 24<sup>th</sup> Congress of Collegium Internationale Neuro-Psychopharmacologicum. Paris, June 20-24, 2004 Abstract P02.095. Int J Neuropsychopharmacol 2004;7(Suppl 1):S330.
- 278) Tohen MF, Vieta E, Calabrese JR, **Ketter TA**, Mitchell P, Briggs SD, Case M: Clinical predictors of response to olanzapine or olanzapine/fluoxetine combination for bipolar depression, in 24<sup>th</sup> Congress of Collegium Internationale Neuro-Psychopharmacologicum. Paris, June 20-24, 2004 Abstract P02.098. Int J Neuropsychopharmacol 2004;7(Suppl 1):S331.
- 279) **Ketter TA**, Tohen M, Vieta E, Calabrese JR, Andersen SW, Detke HC, Risser R, Corya S: Long-term use of Olanzapine/fluoxetine for bipolar depression, in 4<sup>th</sup> European

- Stanley Conference on Bipolar Disorders, Aarhus, Denmark, Sept 23-25, 2004. Acta Psychiatrica Scandinavica, Supplementum 2004:110(Suppl 423):23-4.
- 280) Keck PE Jr, **Ketter TA**, Macfadden W, Minkwitz M, Mullen J: Quetiapine in bipolar depression: time-to-event analyses, in 4<sup>th</sup> European Stanley Conference on Bipolar Disorders, Aarhus, Denmark, Sept 23-25, 2004. Acta Psychiatrica Scandinavica, Supplementum 2004:110(Suppl 423):26-7.
- 281) **Ketter TA**, Paulsson B, Jones M: Sustained remission/euthymia with quetiapine monotherapy for bipolar mania, in 4<sup>th</sup> European Stanley Conference on Bipolar Disorders, Aarhus, Denmark, Sept 23-25, 2004. Acta Psychiatrica Scandinavica, Supplementum 2004:110(Suppl 423):31.
- 282) Baloga-Mintz N, Clark AL, Culver JL, Deyo M, Wang PW, **Ketter TA**: A chart review of patients with bipolar disorders receiving individual psychotherapy, in 38<sup>th</sup> Annual Association for the Advancement of Behavior Therapy Convention, New Orleans, LA, November 18-21, 2004. Abstract 15B-1.
- 283) **Ketter TA**, Wang PW, Chandler RA, Culver JL, Alarcon AM: Aripiprazole in treatment-resistant bipolar depression, in 43<sup>rd</sup> Annual Meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico, December 12-16, 2004 Abstract.
- 284) Bowden CL, Yatham LN, Calabrese J, Suppes T, **Ketter T**, Frye M, Thompson T, Adams B: The impact of lamotrigine treatment on depression in bipolar I disorder, in 43<sup>rd</sup> Annual Meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico, December 12-16, 2004 Abstract.
- 285) **Ketter TA**: Recent advances in maintenance treatment in bipolar disorders, in Annual Meeting of the Korean Neuropsychiatric Association. Jeonju, Korea, April 22-23, 2005 Abstract.
- 286) **Ketter TA**: New treatment options for bipolar disorders, in Annual Meeting of the Korean Neuropsychiatric Association. Jeonju, Korea, April 22-23, 2005 Abstract.
- 287) **Ketter TA**, Houston JP, Risser RC, Adams DH, Meyers A, Williamson D, Tohen M: Olanzapine and lithium prophylaxis of bipolar disorder and episode history, in 60<sup>th</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry. Atlanta, May 19-21, 2005 Abstract 190. Biol Psychiatry 2005;57(8S):54S.
- 288) Cookson J, Keck PE, Jr., **Ketter TA**, Macfadden W, Minkwitz MC, Mullen J: Quetiapine in bipolar depression: NNT and time-to-event analyses, in 158<sup>th</sup> Annual Meeting of the American Psychiatric Association. Atlanta, GA, May 21-26, 2005. Abstract NR300. Page 111.
- 289) Yatham LN, Bowden CL, Adams BE, Calabrese JR, Deveaugh-Geiss AM, **Ketter TA**, Thompson TR: Polarity of subsyndromal symptoms in bipolar maintenance studies, in 158<sup>th</sup> Annual Meeting of the American Psychiatric Association. Atlanta, GA, May 21-26, 2005. Abstract NR305. Page 113.
- 290) Weisler RH, Keck PE, Jr., **Ketter TA**, Swann AC, Kalali AH, Cutler AJ: Efficacy of switching to extended-release carbamazepine in bipolar disorder, in 158<sup>th</sup> Annual Meeting of the American Psychiatric Association. Atlanta, GA, May 21-26, 2005. Abstract NR309. Pages 114-5.

- 291) Rasgon NL, Marsh W, Templeton A, **Ketter TA**: Clinical course of bipolar disorder through perimenopause: chart review, in 158<sup>th</sup> Annual Meeting of the American Psychiatric Association. Atlanta, GA, May 21-26, 2005. Abstract NR353. Page 131.
- 292) Houston JP, **Ketter TA**, Risser RR, Adams D, Meyers A, Williamson D, Tohen M: Olanzapine and lithium prophylaxis of bipolar disorder and episode history, in 158<sup>th</sup> Annual Meeting of the American Psychiatric Association. Atlanta, GA, May 21-26, 2005. Abstract NR377. Page 140.
- 293) Culver J, Arnow B, Clark A, Wang PW, **Ketter TA**: DBT skills group for treatment of patients with bipolar disorders: a retrospective chart review, in 158<sup>th</sup> Annual Meeting of the American Psychiatric Association. Atlanta, GA, May 21-26, 2005. Abstract NR785. Page 291.
- 294) **Ketter TA**, Graham J, Roberts J, Deveaugh-Geiss AM, Thompson TR: A 12-week, randomized study of dermatological precautions with lamotrigine in patients with bipolar disorder, in 158<sup>th</sup> Annual Meeting of the American Psychiatric Association. Atlanta, GA, May 21-26, 2005. Abstract NR786. Page 291.
- 295) **Ketter TA**: Optimizing pharmacotherapy in the treatment of acute mania, in 158<sup>th</sup> Annual Meeting of the American Psychiatric Association. Atlanta, GA, May 21-26, 2005. Industry Symposium Abstract 32B, Pages 43-4.
- 296) **Ketter TA**: Clinical strategies for bipolar depression, in 158<sup>th</sup> Annual Meeting of the American Psychiatric Association. Atlanta, GA, May 21-26, 2005. Industry Symposium Abstract 34B, Page 45.
- 297) **Ketter TA**: Bipolar Disorders, in 158<sup>th</sup> Annual Meeting of the American Psychiatric Association. Atlanta, GA, May 21-26, 2005. Section III of Review of Psychiatry, Abstract, Pages 326-7.
- 298) Houston JP, **Ketter TA**, Risser RC, Adams DH, Meyers A, Williamson D, Tohen M: Olanzapine and lithium prophylaxis of bipolar disorder and episode history, in 45<sup>th</sup> Annual New Clinical Drug Evaluation Unit Meeting. Boca Raton, June 6-9, 2005. Abstract II-51.
- 299) **Ketter TA**: Extended-release carbamazepine capsules as monotherapy for bipolar disorder: effect on random cholesterol levels and body weight, in 45<sup>th</sup> Annual New Clinical Drug Evaluation Unit Meeting. Boca Raton, June 6-9, 2005. Abstract II-66.
- 300) **Ketter TA**, Calabrese JR, Bowden CL, Marangell LB, Gyulai L, Wisniewski S, Sachs GS: Differential roles of adjunctive antidepressants in bipolar II compared to bipolar I disorder, in 6<sup>th</sup> International Conference on Bipolar Disorder. Pittsburgh, June 16-18, 2005 Abstract RC4. Bipolar Disorders 2005;7(Suppl 2):23.
- 301) Cookson J, Keck PE, Jr., **Ketter TA**, Macfadden W, Minkwitz M, Mullen J: Quetiapine in bipolar depression: NNT and time-to-event analyses, in 6<sup>th</sup> International Conference on Bipolar Disorder. Pittsburgh, June 16-18, 2005 Abstract P52. Bipolar Disorders 2005;7(Suppl 2):43.
- 302) Graham JA, **Ketter TA**, Roberts J, Deveaugh-Geiss AM, Thompson TR: A 12-week, randomized open-label study of dermatological precautions with lamotrigine in patients with bipolar disorder, in 6<sup>th</sup> International Conference on Bipolar Disorder. Pittsburgh, June 16-18, 2005 Abstract P102. Bipolar Disorders 2005;7(Suppl 2):62.



- 303) Houston JP, **Ketter TA**, Risser RR, Adams DH, Meyers A, Williamson DJ, Tohen M: Olanzapine and lithium prophylaxis of bipolar disorder and episode history, in 6<sup>th</sup> International Conference on Bipolar Disorder. Pittsburgh, June 16-18, 2005 Abstract P113. *Bipolar Disorders* 2005;7(Suppl 2):66
- 304) **Ketter TA**: The efficacy of extended-release carbamazepine therapy in older patients with bipolar disorder, in 6<sup>th</sup> International Conference on Bipolar Disorder. Pittsburgh, June 16-18, 2005 Abstract P119. *Bipolar Disorders* 2005;7(Suppl 2):67-8.
- 305) Marsh WK, Zappert L, Williams EK, Templeton AJ, Reynolds MF, **Ketter TA**, Rasgon NL: Clinical course of bipolar disorder during pregnancy in women receiving minimal or no prescription psychotropic medication, in 6<sup>th</sup> International Conference on Bipolar Disorder. Pittsburgh, June 16-18, 2005 Abstract P148. *Bipolar Disorders* 2005;7(Suppl 2):75-6.
- 306) Suppes T, Dennehy EB, Hirschfeld RM, Altshuler LL, Bowden CL, Calabrese JR, Crismon ML, **Ketter TA**, Sachs G, Swann AC: The Texas Implementation of Medication Algorithms: Update to the algorithms for treatment of bipolar I disorder, in 6<sup>th</sup> International Conference on Bipolar Disorder. Pittsburgh, June 16-18, 2005 Abstract 238. *Bipolar Disorders* 2005;7(Suppl 2):104.
- 307) Yatham LN, Bowden CL, Calabrese JR, **Ketter TA**, Adams BE, Deveaugh-Geiss AM, Thompson TR: The impact of polarity of subsyndromal symptoms in bipolar maintenance studies, in 6<sup>th</sup> International Conference on Bipolar Disorder. Pittsburgh, June 16-18, 2005 Abstract P268. *Bipolar Disorders* 2005;7(Suppl 2):113.
- 308) **Ketter TA**, Graham J, Thompson TR, Nanry K: A 12-week randomized open-label study of dermatological precautions with lamotrigine in bipolar disorder patients, in Joint Annual Meeting of the American Epilepsy Society and the American Clinical Neurophysiology Society. Washington, DC, December 2-6, 2005. Abstract 2.253. *Epilepsia* 2005;46(Suppl 8):176.
- 309) **Ketter TA**, Calabrese JR, Bowden CL, Marangell LB, Gyulai L, Wisniewski S, Sachs GS: Differential roles of adjunctive antidepressants in bipolar II compared to bipolar I disorder, in 44<sup>th</sup> Annual Meeting of the American College of Neuropsychopharmacology. Waikaloa, Hawaii, December 12-16, 2005 Abstract II.84. *Neuropsychopharmacology* 2005;30(Suppl 1):S176.
- 310) **Ketter TA**, Glick I: Industry – the challenge of teaching at the academic-industry interface, in *The Neglected Constituencies: Can Teaching About Psychopharmacology Change Attitudes & Practices?*, in 44<sup>th</sup> Annual Meeting of the American College of Neuropsychopharmacology. Waikaloa, Hawaii, December 12-16, 2005.
- 311) **Ketter TA**: Neuroimaging in mood disorders: what have we learned? In Australasian Society for Bipolar Disorders Conference. Melbourne, Australia, February 23-25, 2006.
- 312) **Ketter TA**: Clinical challenges in the management of rapid cycling bipolar disorder, in Australasian Society for Bipolar Disorders Conference. Melbourne, Australia, February 23-25, 2006.
- 313) **Ketter TA**: Diagnosis of bipolar depression, in Western Regional Collegium Internationale Neuro-Psychopharmacologicum Conference. Belfast, Northern Ireland, April 2-4, 2006.

- 314) **Ketter TA**: Treatment options for acute mania, in Western Regional Collegium Internationale Neuro-Psychopharmacologicum Conference. Belfast, Northern Ireland, April 2-4, 2006.
- 315) Brooks JO, 3<sup>rd</sup>, Wang PW, Bonner JC, **Ketter TA**: Effects of depression on cerebral metabolism in bipolar disorder, in 61<sup>st</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry. Toronto, Canada, May 18-20, 2006 Abstract 547. Biol Psychiatry 2006;59(8S):168S.
- 316) Bonner JC, Rosen AC, Wang PW, **Ketter TA**, Hill SJ, Brooks JO, 3<sup>rd</sup>: Voxel-based morphometric analysis of gray matter in bipolar depression, in 61<sup>st</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry. Toronto, Canada, May 18-20, 2006 Abstract 568. Biol Psychiatry 2006;59(8S):174S.
- 317) Wang PW, Brooks JO, 3<sup>rd</sup>, Bonner JC, Hill S, Chandler RC, **Ketter TA**: Commonalities and dissociations of cerebral metabolism with divalproex response in bipolar disorder, in 61<sup>st</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry. Toronto, Canada, May 18-20, 2006 Abstract 824. Biol Psychiatry 2006;59(8S):252S.
- 318) **Ketter TA**: Diagnosing bipolar disorder and the role of screening instruments, in 159<sup>th</sup> Annual Meeting of the American Psychiatric Association. Toronto, Canada, May 20-25, 2006. Industry Symposium Abstract 18A, Page 27.
- 319) **Ketter TA**: Advances in pharmacotherapy for maintenance treatment in bipolar disorder, in 159<sup>th</sup> Annual Meeting of the American Psychiatric Association. Toronto, Canada, May 20-25, 2006. Industry Symposium Abstract 26D, Page 38.
- 320) **Ketter TA**, Calabrese JR, Hirschfeld RMA: Rate of improvement with quetiapine across different symptoms and symptom clusters in bipolar disorder, in 159<sup>th</sup> Annual Meeting of the American Psychiatric Association. Toronto, Canada, May 20-25, 2006. Scientific and Clinical Report 47. Pages 88-9.
- 321) Champion LM, Nam JY, Culver JL, Wang PW, Marsh WK, Bonner JC, **Ketter TA**: Effectiveness of lamotrigine in a clinical setting, in 159<sup>th</sup> Annual Meeting of the American Psychiatric Association. Toronto, Canada, May 20-25, 2006. Abstract NR73. Page 31.
- 322) Marsh W, **Ketter TA**, Nam J, Culver J, Holland A, Rasgon NL: Gender differences in quetiapine use and response in patients with bipolar disorder, in 159<sup>th</sup> Annual Meeting of the American Psychiatric Association. Toronto, Canada, May 20-25, 2006. Abstract NR114. Page 48.
- 323) Culver JL, Nam JY, Ullal A, Wang PW, Marsh W, **Ketter TA**: Finding a silver lining: benefit finding in bipolar disorder, in 159<sup>th</sup> Annual Meeting of the American Psychiatric Association. Toronto, Canada, May 20-25, 2006. Abstract NR200. Page 83.
- 324) Brooks JO, 3<sup>rd</sup>, Wang PW, Bonner JC, **Ketter TA**: Effects of depression on cerebral metabolism in bipolar disorder, in 159<sup>th</sup> Annual Meeting of the American Psychiatric Association. Toronto, Canada, May 20-25, 2006. Abstract NR471. Pages 195-6.
- 325) Glick I, Rapaport MH, **Ketter TA**, Zisook S: Psychopharmacology and "The Music Man": "Trouble in the River City" residency program, in 46<sup>th</sup> Annual New Clinical Drug Evaluation Unit Meeting. Boca Raton, June 12-15, 2006 Abstract I-73.
- 326) Champion LM, Nam JY, Culver JL, Wang PW, Marsh WK, Bonner JC, **Ketter TA**: Effectiveness of lamotrigine in a clinical setting, in 46<sup>th</sup> Annual New Clinical Drug Evaluation Unit Meeting. Boca Raton, June 12-15, 2006 Abstract II-25.

- 327) Brown E, **Ketter T**, Houston JP, Stensland M, Orth P, Ahl J: Olanzapine/fluoxetine combination versus lamotrigine for bipolar I depression: aggressive behavior and other functional outcomes, in 25<sup>th</sup> Congress of Collegium Internationale Neuro-Psychopharmacologicum. Chicago, July 9-13, 2006.
- 328) Chandler RA, Young HJ, Harmer CJ, **Ketter TA**, Wang PW, Goodwin GM. Symptoms of mood elevation and depression and current medication use in freshmen students at Oxford and Stanford universities. British Association for Psychopharmacology Summer Meeting, Oxford, UK, July 23-26, 2006. Abstract TD12.
- 329) **Ketter TA**: Rates of improvement with quetiapine across dimensions of bipolar disorder. 19<sup>th</sup> Congress of the European College of Neuropsychopharmacology. Paris, France, September 16-20, 2006. Abstract P.2.e.020. European Neuropsychopharmacol 2006;16(Suppl 4):S356.
- 330) Holland AA, **Ketter TA**, Nam JY, Culver JL, Wang PW, Marsh WK, Bonner JC,: Effectiveness of quetiapine in a clinical setting, in 58<sup>th</sup> Institute on Psychiatric Services. New York, October 5-8, 2006. Abstract.
- 331) Gruber JL, Culver JL, Nam JY, Johnson SL, Keltner D, **Ketter TA**: Dispositional positive emotion experience in euthymic bipolar disorder patients, in 40<sup>th</sup> Annual Convention of the Association for Behavioral and Cognitive Therapies. Chicago, November 16-19, 2006. Abstract 11A-9.
- 332) Culver JL, Nam JY, Clark AL, Wang PW, **Ketter TA**: Optimism and well-being in euthymic bipolar disorder patients, in 40<sup>th</sup> Annual Convention of the Association for Behavioral and Cognitive Therapies. Chicago, November 16-19, 2006. Abstract 11A-13.
- 333) Nam JY, Culver JL, Clark AL, Wang PW, **Ketter TA**: Coping strategies of euthymic patients with bipolar disorders, in 40<sup>th</sup> Annual Convention of the Association for Behavioral and Cognitive Therapies. Chicago, November 16-19, 2006. Abstract 11A-18.
- 334) **Ketter TA**, Holland AA, Nam JY, Culver JL, Wang PW, Marsh WK, Bonner JC,: Effectiveness of quetiapine in a clinical setting, in 45<sup>th</sup> Annual Meeting of the American College of Neuropsychopharmacology. Hollywood, Florida, December 3-7, 2006 Abstract III.90. Neuropsychopharmacology 2006;31(Suppl 1):S234.
- 335) Fenn HH, Sommer BR, **Ketter TA**, Alldredge B: Anticonvulsants for psychiatric indications in the elderly: safety and strategies, in 20<sup>th</sup> Annual Meeting of the American Association of Geriatric Psychiatry. New Orleans, LA. March 1-4, 2007.
- 336) Mansour H, Chowdari KV, Wood J, Pless L, McClendon TB, King AJ, Allen M, Bowden CL, Calabrese J, El-Mallakh RS, Fagiolini A, Faraone SV, Fossey MD, Friedman ES, Gyulai L, Hauser P, **Ketter TA**, Loftis JM, Marangell LB, Miklowitz DJ, McQueen MB, Nierenberg AA, Patel J, Sachs GS, Sklar P, Smoller JW, Thase ME, Frank E, Kupfer DJ, Devlin B, Nimgaonkar VL: Circadian gene polymorphism and liability to bipolar I disorder, in 62<sup>nd</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry. San Diego, CA, May 17-19, 2007 Abstract 17. Biol Psychiatry 2006;61(8S):7S.
- 337) Brooks JO, 3<sup>rd</sup>, Bonner JC, Rosen AC, Wang PW, **Ketter TA**: Gray matter density changes associated with bipolar depression, in 62<sup>nd</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry. San Diego, CA, May 17-19, 2007 Abstract 175. Biol Psychiatry 2006;61(8S):56S.

- 338) Bonner JC, **Ketter TA**, Wang PW, Garcia-Amador M, Brooks JO, 3<sup>rd</sup>: Regional cerebral gray matter density changes associated with creativity in healthy volunteers, in 62<sup>nd</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry. San Diego, CA, May 17-19, 2007 Abstract 366. Biol Psychiatry 2006;61(8S):113S-114S.
- 339) Brooks JO, 3<sup>rd</sup>, Hoblyn JC, Woodard S, Rosen AC, Krasnykh O, **Ketter TA**, Schatzberg AF: Relations between delayed memory and cerebral metabolism in older euthymic adults with bipolar disorder, in 62<sup>nd</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry. San Diego, CA, May 17-19, 2007 Abstract 368. Biol Psychiatry 2006;61(8S):114S.
- 340) Hoblyn JC, Brooks JO, 3<sup>rd</sup>, Rosen AC, Woodard S, Krasnykh O, **Ketter TA**, Schatzberg AF: nd Cerebral metabolic correlates of attention in older euthymic adults with bipolar disorder, in 62<sup>nd</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry. San Diego, CA, May 17-19, 2007 Abstract 374. Biol Psychiatry 2006;61(8S):116S.
- 341) Gersing K, Burchett B, Kujawa M, Young R, Turner N, Mahmoud R, Mahalchick L, Frye M, **Ketter T**: Frequently-relapsing bipolar disorder: characterization of psychiatric resource utilization by patients in a large healthcare database, in 62<sup>nd</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry. San Diego, CA, May 17-19, 2007 Abstract 444. Biol Psychiatry 2006;61(8S):136S-137S.
- 342) Wang PW, Sachs N, Brooks JO, 3<sup>rd</sup>, Bonner JC, **Ketter TA**: Differential global cerebral metabolism changes with sadness induction between creative bipolar patients and healthy controls, in 62<sup>nd</sup> Annual Convention and Scientific Program of the Society of Biological Psychiatry. San Diego, CA, May 17-19, 2007 Abstract 741. Biol Psychiatry 2006;61(8S):230S.
- 343) Bonner JC, **Ketter TA**, Wang PW, Garcia-Amador M, Brooks JO, 3<sup>rd</sup>: Regional cerebral gray matter density changes associated with creativity in healthy volunteers, in 160<sup>th</sup> Annual Meeting of the American Psychiatric Association. San Diego, CA, May 19-24, 2007. Abstract NR243. Pages 102-3.
- 344) Hill SJ, Nam JY, Culver J, Keller K, Wang PW, **Ketter TA**: Euthymic but not depressed bipolar II disorder patients have enhanced creativity compared to healthy controls, in 160<sup>th</sup> Annual Meeting of the American Psychiatric Association. San Diego, CA, May 19-24, 2007. Abstract NR340. Page 144.
- 345) Brooks JO, 3<sup>rd</sup>, Bonner JC, Rosen AC, Wang PW, **Ketter TA**: Regional gray matter density changes in bipolar depression, in 160<sup>th</sup> Annual Meeting of the American Psychiatric Association. San Diego, CA, May 19-24, 2007. Abstract NR401. Page 171.
- 346) **Ketter TA**, Warrington L, Loebel AD, Siu C: Early onset of antipsychotic effect and time course in the treatment of acute bipolar mania, in 160<sup>th</sup> Annual Meeting of the American Psychiatric Association. San Diego, CA, May 19-24, 2007. Abstract NR518. Pages 222-3.
- 347) Gersing K, Burchett B, Kujawa M, Young R, Turner N, Mahmoud R, Frye M, **Ketter T**: Frequently-relapsing bipolar disorder: characterization of psychiatric resource utilization by patients in a large healthcare database, in 7<sup>th</sup> International Conference on Bipolar Disorder. Pittsburgh, June 7-9, 2007. Abstract P87. Bipolar Disorders 2007;9(Suppl 1):43-4.
- 348) **Ketter TA**, Wang P, Nowakowska C, Chandler R, Hill S, Nam J, Culver J, Keller KL: Divalproex-extended release monotherapy and adjunctive therapy in bipolar II

depression, in 7<sup>th</sup> International Conference on Bipolar Disorder. Pittsburgh, June 7-9, 2007. Abstract P127. *Bipolar Disorders* 2007;9(Suppl 1):58.

- 349) **Ketter TA**, Warrington L, Loebel AD, Siu C: Early onset of antipsychotic effect and time course in the treatment of acute bipolar mania, in 7<sup>th</sup> International Conference on Bipolar Disorder. Pittsburgh, June 7-9, 2007. Abstract P128. *Bipolar Disorders* 2007;9(Suppl 1):58-9.
- 350) Mansour H, Chowdari KV, Wood J, Pless L, McClendon TB, King AJ, Allen M, Bowden CL, Calabrese J, El-Mallakh RS, Fagiolini A, Faraone SV, Fossey MD, Friedman ES, Gyulai L, Hauser P, **Ketter TA**, Loftis JM, Marangell LB, Miklowitz DJ, McQueen MB, Nierenberg AA, Patel J, Sachs GS, Sklar P, Smoller JW, Thase ME, Frank E, Kupfer DJ, Devlin B, Nimgaonkar VL: Circadian gene polymorphism and liability to bipolar I disorder, in 7<sup>th</sup> International Conference on Bipolar Disorder. Pittsburgh, June 7-9, 2007. Abstract P172. *Bipolar Disorders* 2007;9(Suppl 1):73-4.
- 351) Nierenberg AA, Marangell LB, Calabrese JR, **Ketter TA**, Bowden CL, Reilly-Harrington N, Freedman ES, Ostacher MJ, Dennehy EB, Thase ME: NIMH bipolar trials network: an infrastructure for collaboration, in 7<sup>th</sup> International Conference on Bipolar Disorder. Pittsburgh, June 7-9, 2007. Abstract P200. *Bipolar Disorders* 2007;9(Suppl 1):83-4.
- 352) Kerrick-Walker J, **Ketter TA**, Warrington L, Loebel AD, Siu C: Early onset of antipsychotic action and time course in the treatment of acute bipolar mania, in 47<sup>th</sup> Annual New Clinical Drug Evaluation Unit Meeting. Boca Raton, June 11-14, 2007. Abstract I-59.
- 353) **Ketter TA**, Wang P, Nowakowska C, Chandler R, Hill S, Nam J, Culver J: Divalproex-extended release monotherapy and adjunctive therapy in bipolar II depression, in 47<sup>th</sup> Annual New Clinical Drug Evaluation Unit Meeting. Boca Raton, June 11-14, 2007. Abstract II-51.
- 354) Nierenberg AA, Marangell LB, Calabrese JR, **Ketter TA**, Bowden CL, Reilly-Harrington N, Freedman ES, Ostacher MJ, Dennehy EB, Thase ME: NIMH bipolar trials network: an infrastructure for collaboration, in 47<sup>th</sup> Annual New Clinical Drug Evaluation Unit Meeting. Boca Raton, June 11-14, 2007. Abstract II-58.
- 355) Chandler RA, Young HJ, Wang PW, **Ketter TA**, Goodwin GM. A new US-UK diagnostic project: Symptoms of depression, mood elevation and psychotropic use in first year undergraduates at Oxford and Stanford Universities. *British Association for Psychopharmacology Summer Meeting*, Harrogate, UK, July 22-25, 2007. Abstract.
- 356) Gersing K, Burchett B, Kujawa M, Young R, Turner N, Mahmoud R, Frye M, **Ketter T**: Frequently-relapsing bipolar disorder: characterization of psychiatric resource utilization by patients in a large healthcare database, in 59<sup>th</sup> Institute on Psychiatric Services. New Orleans, October 11-14, 2007. Abstract 203.
- 357) Culver JL, Nam JY, Keller KL, Wang PW, Bonner J, **Ketter TA**: Mindfulness in euthymic bipolar disorder patients, in 41<sup>st</sup> Annual Convention of the Association for Behavioral and Cognitive Therapies. Philadelphia, November 15-18, 2006. Abstract 8B-18.
- 358) Keller KL, Johnson SL, Culver JL, Nam JY, Carver CS, **Ketter TA**: BIS/BAS sensitivity in bipolar disorder patients, in 41<sup>st</sup> Annual Convention of the Association for Behavioral and Cognitive Therapies. Philadelphia, November 15-18, 2006. Abstract 8B-25.
- 359) Pratchett L, Culver JL, Nam JY, Luce KH, Lett H, **Ketter TA**: Social support and mood symptoms in euthymic bipolar disorder patients, in 41<sup>st</sup> Annual Convention of the

Association for Behavioral and Cognitive Therapies. Philadelphia, November 15-18, 2007. Abstract 8B-27.

- 360) Nam JY, Culver JL, Keller KL, Ullal A, Wang PW, **Ketter TA**: Temperament compared to personality in bipolar disorder patients, in 41<sup>st</sup> Annual Convention of the Association for Behavioral and Cognitive Therapies. Philadelphia, November 15-18, 2006. Abstract 8B-30.
- 361) Stemmler PG, Rasgon NL, Kenna HA, Wang PW, Hill SJ, **Ketter TA**: Insulin Resistance and Hyperlipidemia in Women with Bipolar Disorder, in 46<sup>th</sup> Annual Meeting of the American College of Neuropsychopharmacology. Boca Raton, Florida, December 9-13, 2007 Abstract 8.
- 362) Goldberg JF, Brooks JO, 3<sup>rd</sup>, Kurita K, Hoblyn JC, **Ketter TA**, Ghaemi S, Pelis RH, Miklowitz DA, Sachs GS, Thase ME: Use of Complex Polypharmacy Regimens for Bipolar Disorder Among STEP-BD Entrants, in 46<sup>th</sup> Annual Meeting of the American College of Neuropsychopharmacology. Boca Raton, Florida, December 9-13, 2007 Abstract 147.
- 363) **Ketter TA**, Ahn YM, Nam JY, Culver JL, Marsh WK, Bonner JC: Acute Effectiveness of Lamotrigine Plus Quetiapine Therapy in Bipolar Disorder Patients with Syndromal or Subsyndromal Depression, in 46<sup>th</sup> Annual Meeting of the American College of Neuropsychopharmacology. Boca Raton, Florida, December 9-13, 2007 Abstract 155.
- 364) Nierenberg AA, Thase ME, **Ketter TA**, Smoller JW, Insel TR: Update on STEP-BD Results and the Bipolar Trials Network, in 46<sup>th</sup> Annual Meeting of the American College of Neuropsychopharmacology. Boca Raton, Florida, December 9-13, 2007 Abstract MPM31.
- 365) **Ketter TA**, Perlis RH, Ostacher MJ, Marangell LB, Nierenberg AA, Reilly-Harrington NA, Thase ME, Sachs GS: Longitudinal Course of Bipolar Disorder: Results from STEP-BD, in 46<sup>th</sup> Annual Meeting of the American College of Neuropsychopharmacology. Boca Raton, Florida, December 9-13, 2007 Abstract MPM34.
- 366) Nierenberg AA, **Ketter TA**: Bipolar II depression: a critical review, in 3<sup>rd</sup> Biennial Conference of the International Society for Bipolar Disorders. Delhi, India, January 27-30, 2008. Abstract. Bipolar Disord 2008;10(Suppl 1):4.
- 367) Nierenberg AA, Marangell LB, Bowden CL, **Ketter TA**, Calabrese JR, Thase ME, Friedman E, Ostacher MJ, Reilly-Harrington N, Iosifescu D, Leon AC: Lithium use for bipolar disorder study (LiTMUS): rationale, design, and innovations, in 3<sup>rd</sup> Biennial Conference of the International Society for Bipolar Disorders. Delhi, India, January 27-30, 2008. Abstract. Bipolar Disord 2008;10(Suppl 1):8-9.
- 368) Parsons B, **Ketter TA**, Loebel AD, Kremer C, Lombardo I, Siu C, Romano S: Early onset of antipsychotic action and time course in the treatment of acute bipolar mania, in 3<sup>rd</sup> Biennial Conference of the International Society for Bipolar Disorders. Delhi, India, January 27-30, 2008. Abstract. Bipolar Disord 2008;10(Suppl 1):51-2.
- 369) Brooks JO, 3<sup>rd</sup>, Hoblyn JC, Woodard SA, Rosen AC, **Ketter TA**: Corticolimbic metabolic dysregulation in euthymic older adults with bipolar disorder. In: 55th Annual Convention and Scientific Program of the Society of Biological Psychiatry; 2008; Washington, May 1-3; 2008. Abstract 567. Biol Psychiatry 2008;63(7S):181S.
- 370) Wang PW, Keller KL, Hill S, Childers M, **Ketter TA**: Effectiveness of open adjunctive ziprasidone in obese and overweight bipolar disorder patients. In: 55th Annual

Convention and Scientific Program of the Society of Biological Psychiatry; 2008; Washington, May 1-3; 2008. Abstract 606. Biol Psychiatry 2008;63(7S):192S-193S.

- 371) **Ketter TA**: Effective treatment for bipolar disorder: an elusive goal? In: 161<sup>st</sup> Annual Meeting of the American Psychiatric Association. Washington, DC, May 3-8, 2008. Industry Symposium Abstract 18D, Page 28.
- 372) **Ketter TA**: Evidence-based approaches to tailoring individual treatment plans, in: 161<sup>st</sup> Annual Meeting of the American Psychiatric Association. Washington, DC, May 3-8, 2008. Industry Symposium Abstract 27D, Page 42.
- 373) **Ketter TA**, Wang PW, Culver JL: Evolving relationships between bipolar disorder and borderline personality disorder. In: 161<sup>st</sup> Annual Meeting of the American Psychiatric Association. Washington, DC, May 3-8, 2008. Symposium Abstract 37F, Page 136.
- 374) Wang PW, Keller KL, Hill S, Childers M, **Ketter TA**: Effectiveness of open adjunctive ziprasidone for obese and overweight in patients with bipolar disorder. In: 161<sup>st</sup> Annual Meeting of the American Psychiatric Association. Washington, DC, May 3-8, 2008. Abstract NR3-096. Page 133.
- 375) **Ketter TA**, Romano S, Siu C: Early onset of antipsychotic action and outcome of ziprasidone treatment in placebo-controlled bipolar mania trials. In: 161<sup>st</sup> Annual Meeting of the American Psychiatric Association. Washington, DC, May 3-8, 2008. Abstract NR3-122. Page 146.
- 376) **Ketter TA**, Wang PW, Keller KL, Hill S, Childers M: Adjunctive ziprasidone in obese and overweight bipolar disorder patients. In 48<sup>th</sup> Annual New Clinical Drug Evaluation Unit Meeting. Phoenix, AZ, May 27-30, 2008. Abstract II-23.
- 377) Culver JL, Pratchett LC, Nam JY, Keller KL, **Ketter TA**: Bipolar disorder: Is there a silver lining? In 42<sup>nd</sup> Annual Meeting of Association for Behavioral and Cognitive Therapies, Orlando, FL, November 13-16, 2008.
- 378) Erban RL, Culver JL, Cordova M, Keller KL, **Ketter TA**: Quality of life in recovered bipolar disorder patients. In 42<sup>nd</sup> Annual Meeting of Association for Behavioral and Cognitive Therapies, Orlando, FL, November 13-16, 2008.
- 379) Brooks JO, Goldberg JF, **Ketter TA**, Miklowitz DJ, Calabrese JR, Bowden CL, Thase ME: Safety and tolerability associated with second generation antipsychotic polytherapy in bipolar disorder: findings from STEP-BD, in 47<sup>th</sup> Annual Meeting of the American College of Neuropsychopharmacology. Phoenix, Arizona, December 7-11, 2008. Abstract I-75.
- 380) Kenna H, Powers B, Keller K, Wang P, **Ketter TA**, Rasgon N: Effects of ziprasidone on insulin sensitivity and glucose utilization in overweight and obese patients with bipolar disorders, in 47<sup>th</sup> Annual Meeting of the American College of Neuropsychopharmacology. Phoenix, Arizona, December 7-11, 2008. Abstract I-153.
- 381) **Ketter TA**, Hwang SHJ, Childers, M, Wang PW, Nam JY, Keller KL, Shelley Hill S: Higher prevalence of bipolar I disorder among Asian and Latino compared to Caucasian patients receiving treatment, in 47<sup>th</sup> Annual Meeting of the American College of Neuropsychopharmacology. Phoenix, Arizona, December 7-11, 2008. Abstract III-89.
- 382) Rasgon N, Kenna H, Stemmler P, Reynolds M, Vemuri M, Wang P, **Ketter TA**: Metabolic function in bipolar women and controls, in 47<sup>th</sup> Annual Meeting of the American College of Neuropsychopharmacology. Phoenix, Arizona, December 7-11, 2008. Abstract III-90.

- 383) **Ketter TA**, Johnson K, Childers M, Srivastava S, Brooks JO, Hoblyn JC: The long term effectiveness of quetiapine plus lamotrigine therapy in bipolar patients. In 49<sup>th</sup> Annual New Clinical Drug Evaluation Unit Meeting. Hollywood, FL, June 29-July 2, 2009. Abstract.



## PART II: PUBLICATIONS

### PART II.1 ARTICLES IN PEER REVIEWED JOURNALS

- 1) **Ketter TA**, Lehrer GI: On Conjugacy Classes in Certain Isogenous Groups. Bull Austral Math Soc 1976;14(3):371-377.
- 2) **Ketter TA**: Cultural stylization and mental illness in Bali. Transcultural Psychiatric Research Review 1983;20(2):87-106.
- 3) Louie AK, Lannon RA, **Ketter TA**: Treatment of cocaine induced panic disorder. Am J Psychiatry 1989;146(1):40-44.
- 4) Kanas N, Stewart P, Deri J, **Ketter T**, Haney K: Group process in short-term outpatient therapy groups for schizophrenics. Group 1989;13(2):67-73.
- 5) Nakajima T, Post RM, Pert A, **Ketter TA**, Weiss SR: Perspectives on the mechanism of action of electroconvulsive therapy: anticonvulsant, peptidergic, and c-fos proto-oncogene effects. Convulsive Therapy 1989;5(3):274-295.
- 6) Kanas N, Deri J, **Ketter T**, Fein G: Short-term outpatient therapy groups for schizophrenics. Int J Group Psychotherapy 1989;39(4):517-522.
- 7) Post RM, Kramlinger KG, Altshuler LL, **Ketter TA**, Denicoff K: Treatment of rapid cycling bipolar illness. Psychopharmacology Bulletin 1990;26(1):37-47.
- 8) Post RM, **Ketter TA**, Joffe RT, Kramlinger KL: Lack of beneficial effects of l-baclofen in affective disorder. International Clinical Psychopharmacology 1991;6(4):197-207.
- 9) **Ketter TA**, Post RM, Worthington K: Principles of clinically important drug interactions with carbamazepine. Part I. J Clin Psychopharmacol 1991;11(3):198-203.
- 10) **Ketter TA**, Post RM, Worthington K: Principles of clinically important drug interactions with carbamazepine. Part II. J Clin Psychopharmacol 1991;11(5):306-313.
- 11) Brown DW, **Ketter TA**, Crumlish J, Post RM Carbamazepine-induced increases in total serum cholesterol: clinical and theoretical implications. J Clin Psychopharmacol 1992;12(6):431-437.
- 12) Bromfield EB, Altshuler L, Leiderman DB, Balish M, **Ketter TA**, Devinsky O, Post RM, Theodore WH: Cerebral metabolism and depression in patients with complex partial seizures. Arch Neurol 1992;49(6):617-623.
- 13) **Ketter TA**, Pazzaglia PJ, Post RM: Synergy of carbamazepine and valproic acid in affective illness: case report and review of the literature. J Clin Psychopharmacol 1992;12(4):276-281.
- 14) George MS, **Ketter TA**, Post RM: SPECT and PET imaging in mood disorders. J Clin Psychiatry 1993;54(11 Suppl):6-13.
- 15) Gill DS, **Ketter TA**, Post, RM Antidepressant response to sleep deprivation as a function of time into depressive episode in rapidly cycling bipolar patients. Acta Psychiatr Scand 1993;87(2):102-109.
- 16) Potter WZ, **Ketter TA**: Pharmacologic issues in the treatment of bipolar disorder: focus on mood stabilizing compounds. Can J Psychiatry 1993;38(3 Suppl 2):S51-S56.

- 17) Post RM, **Ketter TA**, Pazzaglia PJ, George MS, Marangell L, Denicoff K: New developments in the use of anticonvulsants as mood stabilizers. *Neuropsychobiology*, 1993;27(3):132-137.
- 18) George MS, **Ketter TA**, Gill DS, Haxby JV, Ungerleider LG, Herscovitch P, Post RM: Brain regions involved in recognizing facial emotion or identity: an oxygen-15 PET study. *J Neuropsychiatry Clin Neurosci* 1993;5(4):384-394.
- 19) Pazzaglia PJ, Post RM, **Ketter TA**, George MS, Marangell LB: Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation. *Psychiatry Research* 1993;49(3):257-272.
- 20) Lee C, Unser M, **Ketter TA**: A global approach to multivariate correlation analysis of PET brain images. *Proc SPIE* 1994;2299:305-315.
- 21) **Ketter TA**, Malow BA, Flamini R, White SR, Post RM, Theodore WH: Anticonvulsant withdrawal-emergent psychopathology. *Neurology* 1994;44(1):55-61.
- 22) George MS, **Ketter TA**, Parekh P, Gill DS, Huggins T, Marangell LB, Pazzaglia PJ, Post RM: Spatial ability in affective illness: differences in regional brain activation during a spatial matching task ( $H_2^{15}O$  PET). *Neuropsychiatry Neuropsychol Behav Neurol* 1994;7(3):143-153.
- 23) George MS, **Ketter TA**, Parekh P, Rosinsky N, Ring H, Casey BJ, Trimble MR, Horwitz B, Herscovitch P, Post RM: Regional brain activity when selecting a response despite interference: an  $H_2^{15}O$  PET study of the Stroop and an emotional Stroop. *Human Brain Mapping* 1994;1:194-209.
- 24) Del Zompo M, Bocchetta A, Loviselli A, Martino E, Post RM, **Ketter TA**: Thyroid function during carbamazepine. *Biol Psychiatry* 1994;36(2):135-136.
- 25) George MS, **Ketter TA**, Post RM: Prefrontal cortex dysfunction in clinical depression. *Depression* 1994;2:59-72.
- 26) **Ketter TA**, George MS, Ring HA, Pazzaglia PJ, Marangell LB, Kimbrell T, Post RM: Primary mood disorders: structural and resting functional studies. *Psychiatric Annals* 1994;24(12):637-642.
- 27) George MS, **Ketter TA**, Post RM: Activation studies in mood disorders. *Psychiatric Annals* 1994;24(12):648-652.
- 28) George MS, Wassermann EM, Williams WA, Callahan A, **Ketter TA**, Basser P, Hallett M, Post RM: Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression. *NeuroReport* 1995;6(14):1853-1856.
- 29) George MS, **Ketter TA**, Parekh PI, Horwitz B, Herscovitch P, Post RM: Brain activity during transient sadness and happiness in healthy women. *Am J Psychiatry* 1995;152(3):341-351.
- 30) Parekh PI, Spencer JW, George MS, Gill DS, **Ketter TA**, Andreason PJ, Herscovitch P, Post RM: Procaine-induced increases in limbic rCBF correlate positively with increases in occipital and temporal EEG fast activity. *Brain Topography* 1995;7(3):209-216.

- 31) McDermut W, Pazzaglia P, Huggins T, Mikalauskas K, Leverich G, **Ketter TA**, Bartko J, Post RM: Use of single case analyses in on-off-on trials in affective illness: a demonstration of the efficacy of nimodipine. *Depression* 1995;2:259-271.
- 32) **Ketter TA**, Post RM, Parekh P, Worthington K: Addition of monoamine oxidase inhibitors to carbamazepine: preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression. *J Clin Psychiatry* 1995;56(10):471-475.
- 33) Theodore WH, Albert P, Stertz BE, Malow B, Ko D, White S, Flamini R, **Ketter TA**: Felbamate monotherapy: implications for antiepileptic drug development. *Epilepsia* 1995;36(11):1105-1110.
- 34) **Ketter TA**, Jenkins JB, Schroeder DH, Pazzaglia PJ, Marangell LB, George MS, Callahan AM, Hinton ML, Chao J, Post RM: Carbamazepine but not valproate induces bupropion metabolism. *J Clin Psychopharmacol* 1995;15(5):327-333.
- 35) Lee C, Unser M, **Ketter TA**: Automated recognition of corpus callosum from sagittal brain MR images. *Proc SPIE* 1995;2564:528-534.
- 36) **Ketter TA**, Flockhart DA, Post RM, Denicoff K, Pazzaglia PJ, Marangell LB, George MS, Callahan AM: The emerging role of cytochrome P450 3A in psychopharmacology. *J Clin Psychopharmacol* 1995;15(6):387-398.
- 37) Post RM, **Ketter TA**, Pazzaglia PJ, Denicoff KD, George MS, Callahan AM, Leverich G, Frye M: Rational polypharmacy in the bipolar affective disorders. *Epilepsy Res Suppl* 1996;11:153-180.
- 38) **Ketter TA**, George MS, Kimbrell TA, Benson BE, Post RM: Functional brain imaging, limbic function, and affective disorders. *The Neuroscientist* 1996;2(1):55-65.
- 39) Lee C, **Ketter TA**, Unser M: Automated connectivity-based thresholding segmentation of midsagittal brain MR images. *Proc SPIE* 1996;2727:713-724.
- 40) **Ketter TA**, Malow BA, Flamini R, Ko D, White SR, Stertz BE, Post RM, Theodore WH: Felbamate monotherapy has stimulant-like effects in patients with epilepsy. *Epilepsy Research* 1996;23(2):129-137.
- 41) George MS, Parekh PI, Rosinsky N, **Ketter TA**, Kimbrell TA, Heilman KM, Herscovitch P, Post RM: Understanding emotional prosody activates right hemisphere regions. *Arch Neurology* 1996;53(7):665-670.
- 42) **Ketter TA**, Andreason PJ, George MS, Lee C, Gill DS, Parekh P, Willis MW, Herscovitch P, Post RM: Anterior paralimbic mediation of procaine-induced emotional and psychosensory experiences. *Arch Gen Psychiatry* 1996;53(1):59-69.
- 43) Callahan AM, Marangell LB, **Ketter TA**: Evaluating the clinical significance of drug interactions: a systematic approach. *Harvard Rev Psychiatry* 1996;4(3):153-158.
- 44) George MS, **Ketter TA**, Parekh PI, Herscovitch P, Post RM: Gender differences in regional cerebral blood flow during transient self-induced sadness or happiness. *Biological Psychiatry* 1996;40(9):859-871.
- 45) Little JT, **Ketter TA**, Kimbrell TA, Danielson A, Benson BE, Willis MW, Post RM: Venlafaxine or bupropion responders but not nonresponders show baseline prefrontal and paralimbic hypometabolism compared with controls. *Psychopharmacol Bull* 1996;32(4):629-635.

- 46) Post RM, **Ketter TA**, Denicoff K, Pazzaglia PJ, Leverich GS, Marangell LB, Callahan AM, George MS, Frye MA: The place of anticonvulsant therapy in bipolar illness. *Psychopharmacology (Berl)* 1996;128(2):115-129.
- 47) Post RM, **Ketter TA**, Denicoff KD, Frye MA, Levirich GS: Re-evaluating carbamazepine prophylaxis in bipolar disorder. *Br J Psychiatry* 1997;170:202-204.
- 48) Marangell LB, **Ketter TA**, George MS, Pazzaglia PJ, Callahan AM, Parekh P, Andreason PJ, Horwitz B, Herscovitch P, Post RM: Inverse relationship of peripheral thyroid-stimulating hormone levels to brain activity in mood disorders. *Am J Psychiatry* 1997;154(2):224-230.
- 49) Callahan AM, Frye MA, Marangell LB, George MS, **Ketter TA**, L'Herrou T, Post RM: Comparative antidepressant effects of intravenous and intrathecal thyroid releasing hormone: confounding effects of tolerance and implications for therapeutics. *Biol Psychiatry* 1997;41(3):264-272.
- 50) Marangell LB, George MS, Callahan AM, **Ketter TA**, Pazzaglia PJ, L'Herrou TA, Leverich GS, Post RM: Effects of intrathecal thyrotropin-releasing hormone (protirelin) in refractory depressed patients. *Arch Gen Psychiatry* 1997;54(3):214-222.
- 51) George MS, **Ketter TA**, Parekh PI, Rosinsky N, Ring HA, Pazzaglia PJ, Marangell LB, Callahan AM, Post RM: Blunted left cingulate activation in mood disorder subjects during a response interference task (the Stroop). *J Neuropsychiatry Clin Neurosci* 1997;9(1):55-63.
- 52) George MS, Post RM, **Ketter TA**, Kimbrell TA, Speer AM: Neural mechanisms of mood disorders. *Current Review of Mood Disorders* 1997;1(2):71-83.
- 53) **Ketter TA**, George MS, Kimbrell TA, Benson BE, Post RM: Functional imaging in mood and anxiety disorders. *Current Review of Mood Disorders* 1997;1(2):95-112.
- 54) Post RM, Weiss SRB, **Ketter TA**, Denicoff KD, George MS, Frye M, Smith MA, Leverich GS: The kindling model: implications for the etiology and treatment of mood disorders. *Current Review of Mood Disorders* 1997;1(2):113-126.
- 55) Ali SO, Denicoff KD, **Ketter TA**, Smith-Jackson EE, Post RM: Psychosensory symptoms in bipolar disorder. *Neuropsychiatry Neuropsychol Behav Neurol* 1997;10(4):223-31.
- 56) George MS, **Ketter TA**, Parekh PI, Gill DS, Marangell LB, Pazzaglia PJ, Herscovitch P, Post RM: Depressed subjects have decreased rCBF activation during facial emotion recognition. *CNS Spectrums* 1997;2(10):45-55.
- 57) Pazzaglia PJ, Post RM, **Ketter TA**, Callahan AM, Marangell LB, Frye MA, George MS, Kimbrell TA, Levirich GS, Corá-Locatelli G, Luckenbaugh D: Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness. *J Clin Psychopharmacol* 1998;18(5):404-413.
- 58) Parekh PI, **Ketter TA**, Altshuler L, Frye M, Callahan A, Marangell L, Post RM: Relationships between thyroid hormone and antidepressant responses to total sleep deprivation in mood disorder patients. *Biol Psychiatry* 1998;43(5):392-394.
- 59) Frye MA, **Ketter TA**, Altshuler LL, Denicoff K, Dunn RT, Kimbrell TA, Corá-Locatelli G, Post RM: Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics. *J Affect Disord* 1998;48(2-3):91-104.

- 60) Lee C, Huh S, **Ketter TA**, Unser M: Unsupervised connectivity-based thresholding segmentation of midsagittal brain MR images. *Comput Biol Med* 1998; 28(3):309-338.
- 61) Frye MA, Kimbrell TA, Dunn RT, Piscitelli SC, Grothe DR, Vanderham E, Corá-Locatelli G, Post RM, **Ketter TA**: Gabapentin does not alter single dose lithium pharmacokinetics. *J Clin Psychopharmacol* 1998;18(6):461-4.
- 62) **Ketter TA**, Kimbrell, TA, George MS, Willis MW, Benson BE, Danielson A, Frye MA, Herscovitch P, Post RM: Baseline cerebral hypermetabolism associated with carbamazepine response, and hypometabolism with nimodipine response in mood disorders. *Biol Psychiatry* 1999; 46(10):1364-74.
- 63) Little JT, **Ketter TA**, Mathé AA, Frye MA, Luckenbaugh D, Post RM: Venlafaxine but not bupropion decreases cerebrospinal fluid 5-hydroxyindoleacetic acid in unipolar depression. *Biol Psychiatry* 1999;45(3):285-9.
- 64) **Ketter TA**, Frye MA, Corá-Locatelli G, Kimbrell T, Post RM: Metabolism and excretion of mood stabilizers and new anticonvulsants. *Cell Mol Neurobiol* 1999;19(4):511-32.
- 65) Kimbrell TA, George MS, Parekh PI, **Ketter TA**, Podell DM, Danielson AL, Repella JD, Benson BE, Willis MW, Herscovitch P, Post RM: Regional brain activity during transient self-induced anxiety and anger in healthy adults. *Biol Psychiatry* 1999;46(4):454-65.
- 66) **Ketter TA**, Post RM, Theodore WH: Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. *Neurology* 1999;53(5 Suppl 2):S53-67.
- 67) Wang PW, **Ketter TA**: Biology and recent brain imaging studies in affective psychoses. *Curr Psychiatry Rep* 2000; 2(4):298-304.
- 68) Chang KD, **Ketter TA**: Mood stabilizer augmentation with olanzapine in acutely manic children. *J Am Assoc Child Adol Psychiatry* 2000;10(1):45-49.
- 69) Frye MA, **Ketter TA**, Leverich GS, Huggins T, Lantz C, Denicoff KD, Post RM: The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. *J Clin Psychiatry* 2000;61(1):9-15.
- 70) Winsberg ME, Sachs N, Tate DL, Adalsteinsson E, Spielman DM, **Ketter TA**: Decreased dorsolateral prefrontal *N*-acetyl aspartate in bipolar disorder. *Biol Psychiatry* 2000;47(6):475-81.
- 71) Chang KD, Steiner H, **Ketter TA**: Psychiatric phenomenology of child and adolescent bipolar offspring. *J Am Acad Child Adolesc Psychiatry* 2000;39(4):453-60.
- 72) Lee C, Huh S, **Ketter TA**, Unser M: Automated segmentation of the corpus callosum in midsagittal brain magnetic resonance images. *Optical Engineering* 2000;39(4):924-35.
- 73) Frye MA, **Ketter TA**, Kimbrell TA, Dunn RT, Speer AM, Osuch EA, Luckenbaugh DA, Corá-Locatelli G, Leverich GS, Post RM: A placebo controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. *J Clin Psychopharmacol* 2000;20(6):607-14.
- 74) Calabrese JR, Suppes P, Bowden CL, Sachs GS, Swann AC, McElroy SL, Kusumakar V, Ascher JA, Earl NL, Greene PL, Monaghan ET. Lamictal 614 Study Group [Includes

- Ketter TA**. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid cycling bipolar disorder.. J Clin Psychiatry 2000;61(11):841-50.
- 75) Pande AC, Crockatt J, Janney CA, Werth JL, Tsaroucha G. Gabapentin Bipolar Disorder Study Group [Includes **Ketter TA**]. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Bipolar Disord 2000; 2(3 pt 2):249-255.
- 76) Osuch EA, **Ketter TA**, Kimbrell TA, George MS, Benson BE, Herscovitch MW, Post RM: Regional cerebral metabolism associated with anxiety symptoms in affective disorder patients. Biol Psychiatry 2000; 48(10):1020-1023.
- 77) Osuch EA, Cora-Locatelli G, Frye MA, Huggins T, Kimbrell TA, **Ketter TA**, Callahan AM, Post RM: Post-dexamethasone cortisol correlates with severity of depression before and during carbamazepine treatment in women but not men. Acta Psychiatr Scand 2001; 104(5):397-401.
- 78) Winsberg ME, DeGolia SG, Strong CM, **Ketter TA**: Divalproex therapy in medication-naive and mood stabilizer-naive bipolar II depression. J Affective Disord 2001;67(1-3):207-12.
- 79) **Ketter TA**, Kimbrell TA, George MS, Dunn RT, Speer AM, Willis MW, Benson BE, Danielson A, Frye MA, Herscovitch P, Post RM: Effects of mood and subtype on cerebral glucose metabolism in treatment-refractory bipolar disorders. Biol Psychiatry 2001;49(2):97-109.
- 80) Chang KD, **Ketter TA**. Special issues in the treatment of paediatric bipolar disorder. Expert Opin Pharmacother 2001; 2(4):613-622.
- 81) Chang KD, Blasey C, **Ketter TA**, Steiner H: Family environment of children and adolescents with bipolar parents. Bipolar Disord 2001;3(2):73-78.
- 82) Chang KD, Soutullo CS, Steiner H, **Ketter TA**: SSRI-induced mania in children and adolescents. Psychiatric Networks 2001;4(1-2):55-63.
- 83) Huh S, **Ketter TA**, Sohn KH, Lee C: Automated Cerebrum Segmentation of Three-Dimensional Sagittal Brain MR Images. Comput Biol Med 2002;32(5):311-28.
- 84) Lembke A, **Ketter TA**: Impaired recognition of facial emotion in mania. Am J Psychiatry 2002; 159(2):302-304.
- 85) Kimbrell TA, **Ketter TA**, George MS, Little JT, Benson BE, Willis MW, Herscovitch P, Post RM: Regional cerebral glucose utilization in patients with a range of severities of unipolar depression. Biol Psychiatry 2002;51(3):237-52.
- 86) Obrocea GV, Dunn RT, Frye MA, **Ketter TA**, Luckenbaugh DA, Leverich GS, Speer AM, Osuch EA, Jajodia K, Post RM: Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Biol Psychiatry 2002;51(3):253-60.
- 87) Wang PW, **Ketter TA**: Pharmacokinetics of mood stabilizers and new anticonvulsants. Psychopharmacol Bull 2002;36(1):44-66.
- 88) Willis MW, **Ketter TA**, Kimbrell TA, George MS, Herscovitch P, Danielson A, Benson BE, Post RM: Age, gender, and laterality effects on cerebral glucose metabolism in healthy adults. Psychiatry Res 2002;114(1):23-37.

- 89) **Ketter TA**, Calabrese JR: Stabilization of mood from below versus above baseline in bipolar disorder: proposal for a new nomenclature. *J Clin Psychiatry* 2002;63(2):146-51.
- 90) Dunn RT, Kimbrell TA, **Ketter TA**, Frye MA, Willis MW, Luckenbaugh DA, Post RM: Principal components of the Beck depression inventory and regional cerebral metabolism in unipolar and bipolar depression. *Biol Psychiatry* 2002;51(5):387-99.
- 91) **Ketter TA**, Kimbrell TA, George MS, Sachs N, Wang PW, Post RM: Predictors of treatment response in bipolar disorder: evidence from clinical and PET studies. *J Clin Psychiatry* 2002;63(Suppl 3):21-5.
- 92) Tohen M, Baker RW, Altshuler LL, Zarate CA, Suppes T, **Ketter TA**, Milton DR, Risser R, Gilmore JA, Brier A, Tollefson GD: Divalproex versus olanzapine in the treatment of acute mania. Olanzapine HGHQ Study Group. *Am J Psychiatry* 2002;159(6):1011-7.
- 93) Wang PW, Santosa CM, Schumacher M, Winsberg ME, Strong CM, **Ketter TA**: Gabapentin augmentation in bipolar depression. *Bipolar Disord* 2002;4(5):296-301.
- 94) Janenawasin S, Wang PW, Lembke A, Schumacher M, Das B, Santosa CM, Mongkolkeep J, **Ketter TA**: Olanzapine in diverse syndromal and subsyndromal exacerbations of bipolar disorders. *Bipolar Disord* 2002;4(5):328-38.
- 95) **Ketter TA**, Wang PW, Janenawasin S, Becker OV, Wang A: The emerging role of olanzapine in bipolar disorders. *Psychiatric Annals* 2002;32(12):753-62.
- 96) Li X, **Ketter TA**, Frye MF: Synaptic, intracellular, and neuroprotective mechanisms of anticonvulsants: are they relevant for the treatment and course of bipolar disorders? *J Affect Disord* 2002;69(1-3):1-14.
- 97) **Ketter TA**, Drevets WC: Neuroimaging studies of bipolar depression: functional neuropathology, treatment effects, and predictors of clinical response. *Clin Neurosci Res* 2002;2(3-4):182-92.
- 98) **Ketter TA**, Wang PW: The emerging differential roles of GABAergic and antiglutamatergic agents in bipolar disorders. *J Clin Psychiatry* 2003;64(Suppl 3):15-20.
- 99) Chang K, Steiner H, Dienes K, Adleman N, **Ketter T**: Bipolar offspring: a window into bipolar disorder. *Biol Psychiatry* 2003;53(11): 945-51.
- 100) Sachs GS, Thase ME, Otto MW, Bauer M, Miklowitz D, Wisniewski SR, Lavori P, Lebowitz B, Rudorfer M, Frank E, Nierenberg AA, Fava M, Bowden C, **Ketter T**, Marangell L, Calabrese J, Kupfer S, Rosenbaum JF: Rationale, design, and methods of the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). *Biol Psychiatry* 2003;53(11):1028-42.
- 101) Chang KD, Adleman N, Dienes K, Barnea-Goraly N, Reiss AL, **Ketter T**: Decreased N-acetyl aspartate in children with familial bipolar disorder. *Biol Psychiatry* 2003;53(11):1059-65.
- 102) Boylan LS, Devinsky O, Barry JJ, **Ketter TA**: Psychiatric uses of antiepileptic drugs. In: *Therapy for Cognitive and Behavioral Disorders in Epilepsy*. *Epilepsy Behav* 2003;3(5S):54-59.
- 103) Tohen M, **Ketter TA**, Zarate CA, Suppes T, Frye M, Altshuler L, Zajecka J, Schuh LM, Risser RC, Brown E, Baker RW: Olanzapine versus divalproex sodium for the treatment

- of acute mania and maintenance of remission: a 47-week study. *Am J Psychiatry* 2003;160(7):1263-71.
- 104) Chang K, Dienes K, Blasey C, **Ketter TA**, Steiner H: Divalproex monotherapy in the treatment of bipolar offspring with mood and behavioral disorders and at least mild affective symptoms. *J Clin Psychiatry* 2003;64(8):936-42.
- 105) **Ketter TA**, Wang PW, Becker OV, Nowakowska C, Yang YS: The diverse roles of anticonvulsants in bipolar disorders. *Ann Clin Psychiatry* 2003;15(2):95-108.
- 106) **Ketter TA**, Manji HK, Post RM: Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders. *J Clin Psychopharmacology* 2003;23(5):484-95..
- 107) Chang KD, Blasey CM, **Ketter TA**, Steiner H: Temperament characteristics of child and adolescent bipolar offspring. *J Affect Disord* 2003;77(1):11-19.
- 108) Chang K, Steiner H, **Ketter T**: Studies of offspring of parents with bipolar disorder. *Am J Med Genetics Pt C: Seminars in Med Genetics* 2003;123C(1):26-35.
- 109) Tohen M, Vieta E, Calabrese J, **Ketter TA**, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tollefson GD, Brier A: Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. *Arch Gen Psychiatry* 2003;60(11):1079-88.
- 110) Zubieta JK, **Ketter TA**, Bueller JA, Xu Y, Kilbourn MR, Young EA, Koeppe RA: Regulation of human affective responses by anterior cingulate and limbic {micro}-opioid neurotransmission. *Arch Gen Psychiatry* 2003; 60(11):1145-53.
- 111) Wang PW, **Ketter TA**, Becker OV, Nowakowska C: New anticonvulsant medication uses in bipolar disorders. *CNS Spectrums* 2003;8(12):930-47.
- 112) Wang PW, **Ketter TA**: Emerging roles of new antipsychotics in bipolar disorders. *Current Psychosis and Therapeutics Reports* 2003;1(2):55-61.
- 113) **Ketter TA**, Wang PW, Becker OV, Nowakowska C, Yang YS: Psychotic bipolar disorders: dimensionally similar to or categorically different from schizophrenia? *J Psychiatry Res* 2004;38(1):47-61.
- 114) Marangell LB, Martinez JM, **Ketter TA**, Bowden CL, Goldberg JF, Calabrese JR, Miyahara S, Miklowitz DJ, Sachs GS, Thase ME: Lamotrigine treatment of bipolar disorder: data from the first 500 patients in STEP-BD. *Bipolar Disord* 2004;6(2):139-43.
- 115) Weisler RH, Kalali AH, **Ketter TA**,: A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy in patients with manic or mixed bipolar disorder. *J Clin Psychiatry* 2004;65(4):478-84.
- 116) **Ketter TA**, Kalali AH, Weisler RH: A 6-month, multicenter, open-label evaluation of beaded, extended-release carbamazepine capsule monotherapy in bipolar disorder patients with manic or mixed episodes. *J Clin Psychiatry* 2004;65(5):668-73.
- 117) Benson BE, Carson RE, Kiesewetter DO, Herscovitch P, Eckelman WC, Post RM, **Ketter TA**: A potential cholinergic mechanism of procaine's limbic activation. *Neuropsychopharmacology* 2004;29(7):1239-50.
- 118) Lembke A, Miklowitz DJ, Otto MW, Zhang H, Wisniewski SR, Sachs GS, Thase ME, **Ketter TA**: Psychosocial service utilization by patients with bipolar disorders: data from



- the first 500 participants in the Systematic Treatment Enhancement Program. *J Psychiatr Pract* 2004; 10(2):81-7.
- 119) **Ketter TA**, Wang PW, Nowakowska C, Marsh WK: New medication treatment options for bipolar disorders. *Acta Psychiatr Scand* 2004;110(Suppl 422):18-33.
- 120) Becker O, Rasgon N, Marsh W, Glenn T, Ketter T: Lamotrigine therapy in treatment-resistant menstrually-related rapid cycling bipolar disorder: a case report. *Bipolar Disord* 2004; 6(5):435-439.
- 121) Schneck CD, Miklowitz DJ, Calabrese JR, Allen MH, Thomas MR, Wisniewski SR, Miyahara S, Shelton MD, **Ketter TA**, Goldberg JF, Bowden CL, Sachs GS: Phenomenology of rapid-cycling bipolar disorder: data from the first 500 participants in the systematic treatment enhancement program. *Am J Psychiatry* 2004; 161(10):1902-1908.
- 122) Kogan JN, Otto MW, Bauer MS, Dennehy EB, Miklowitz DJ, Zhang HW, **Ketter T**, Rudorfer MV, Wisniewski SR, Thase ME, Calabrese J, Sachs GS: Demographic and diagnostic characteristics of the first 1000 patients enrolled in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). *Bipolar Disord* 2004;6(6):460-9.
- 123) Baker RW, Brown E, Akiskal HS, Calabrese JR, **Ketter TA**, Schuh LM, Trzepacz PT, Watkin JG, Tohen M: Efficacy of olanzapine combined with valproate or lithium in the treatment of dysphoric mania. *Br J Psychiatry* 2004; 185:472-478.
- 124) Little JT, **Ketter TA**, Kimbrell TA, Dunn RT, Benson BE, Willis MW, Luckenbaugh DA, Post RM: Bupropion and venlafaxine responders differ in pretreatment regional cerebral metabolism in unipolar depression. *Biol Psychiatry* 2005;57(3):220-8.
- 125) Nowakowska C, Strong CM, Santosa CM, Wang PW, **Ketter TA**: Temperamental commonalities and differences in euthymic mood disorder patients, creative controls, and healthy controls. *J Affect Disord* 2005;85(1-2):207-15.
- 126) Weisler RH, Keck PE, Swann AC, Cutler AJ, **Ketter TA**, Kalali AH: Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial *J Clin Psychiatry* 2005;66(3):323-30.
- 127) Wang PW, Suppes T, **Ketter TA**. Pharmacotherapy in bipolar depression. *Depression: Mind and Body* 2005;1(3):89-97.
- 128) Keck PE, Jr, Corya SA, Altshuler LL, **Ketter TA**, McElroy SL, Case M, Briggs SD, Tohen M. Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression. *J Clin Psych* 2005;66:611-6.
- 129) **Ketter TA**, Wang PW, Chandler RA, Alarcon AM, Becker OV, Nowakowska C, O'Keeffe CM, Schumacher MR. Dermatology precautions and slower titration yield low incidence of lamotrigine treatment-emergent rash. *J Clin Psychiatry* 2005;66:642-5.
- 130) Calabrese JR, Keck PE, Jr., Bowden CL, **Ketter TA**, Sachs G, Findling RL, Sajatovic M: A US perspective of the CANMAT bipolar guidelines. *Bipolar Disord* 2005; 7 Suppl 3:70-72.
- 131) **Ketter TA**, Akiskal HS, Keck PE, Jr, Fuller MA, Weisler RH, Hirschfeld RMA: Reassessing carbamazepine in the treatment of bipolar disorder: clinical implications of new data. *CNS Spectrums* 2005;10(6 Suppl 5):1-13.

- 132) Calabrese JR, Keck PE, Jr., Macfadden W, Minkwitz M, **Ketter TA**, Weisler RH, Cutler AJ, McCoy R, Wilson E, Mullen J: A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. *Am J Psychiatry* 2005;162(7):1351-60.
- 133) Evans DL, Charney DS, Lewis L, Golden RN, Gorman JM, Krishnan KRR, Nemeroff CB, Bremner JD, Carney RM, Coyne JC, DeLong MR, Frasure-Smith N, Glassman AH, Gold PW, Grant I, Gwyther L, Ironson G, Johnson RL, Kanner AM, Katon WJ, Kaufman PG, Keefe FJ, **Ketter T**, Laughren TP, Leserman J, Lyketsos CG, McDonald WM, McEwen BS, Miller AH, Musselman D, O'Connor C, Petitto JM, Pollock BG, Robinson RG, Roose SP, Rowland J, Sheline Y, Sheps DS, Simon G, Spiegel D, Stunkard A, Sunderland T, Tibbits P Jr, Valvo WJ: Mood disorders in the medically ill: scientific review and recommendations. *Biol Psychiatry* 2005;58(3):175-89.
- 134) Chang K, Barnea-Goraly N, Karchemskiy A, Simeonova DI, Barnes P, **Ketter T**, Reiss AL: Cortical magnetic resonance imaging findings in familial pediatric bipolar disorder. *Biol Psychiatry* 2005; 58(3):197-203.
- 135) Suppes T, Dennehy EB, Hirschfeld RM, Altshuler LL, Bowden CL, Calabrese JR, Crismon ML, **Ketter TA**, Sachs GS, Swann AC: The Texas Implementation of Medication Algorithms: Update to the Algorithms for Treatment of Bipolar I Disorder. *J Clin Psychiatry* 2005;66(7):870-886.
- 136) Simeonova DI, Chang KD, Strong C, **Ketter TA**: Creativity in familial bipolar disorder. *J Psychiatr Res* 2005; 39(6):623-631.
- 137) Dunn RT, Willis MW, Benson BE, Repella JD, Kimbrell TA, **Ketter TA**, Speer AM, Osuch EA, Post RM: Preliminary findings of uncoupling of flow and metabolism in unipolar compared with bipolar affective illness and normal controls. *Psychiatry Res* 2005;140(2):181-198.
- 138) Mansour HA, Talkowski ME, Wood J, Pless L, Bamne M, Chowdari KV, Allen M, Bowden CL, Calabrese J, El-Mallakh RS, Fagiolini A, Faraone SV, Fossey MD, Friedman ES, Gyulai L, Hauser P, **Ketter TA**, Loftis JM, Marangell LB, Miklowitz DJ, Nierenberg AA, Patel J, Sachs GS, Sklar P, Smoller JW, Thase ME, Frank E, Kupfer DJ, Nimgaonkar VL: Serotonin gene polymorphisms and bipolar I disorder: focus on the serotonin transporter. *Ann Med* 2005;37(8):590-602.
- 139) **Ketter TA**, Houston JP, Adams DH, Risser RC, Meyers AL, Williamson DJ, Tohen M: Differential efficacy of olanzapine and lithium in preventing manic or mixed recurrence in patients with bipolar I disorder based on number of previous manic or mixed episodes. *J Clin Psychiatry* 2006; 67(1):95-101.
- 140) Nierenberg AA, Ostacher MJ, Calabrese JR, **Ketter TA**, Marangell LB, Miklowitz DJ, Miyahara S, Bauer MS, Thase ME, Wisniewski SR, Sachs GS: Treatment-resistant bipolar depression: a STEP-BD equipose randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. *Am J Psychiatry* 2006; 163(2):210-216.
- 141) Perlis RH, Ostacher MJ, Patel JK, Marangell LB, Zhang H, Wisniewski SR, **Ketter TA**, Miklowitz DJ, Otto MW, Gyulai L, Reilly-Harrington NA, Nierenberg AA, Sachs GS, Thase ME: Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). *Am J Psychiatry* 2006; 163(2):217-224.

- 142) Weisler RH, Hirschfeld R, Cutler AJ, Gazda T, **Ketter TA**, Keck PE, Swann A, Kalali A: Extended-release carbamazepine capsules as monotherapy in bipolar disorder: pooled results from two randomised, double-blind, placebo-controlled trials. *CNS Drugs* 2006; 20(3):219-31.
- 143) Sachs G, Bowden C, Calabrese JR, **Ketter T**, Thompson T, White R, Bentley B: Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder. *Bipolar Disord* 2006; 8(2):175-181.
- 144) **Ketter TA**, Greist JH, Graham JA, Roberts JN, Thompson TR, Nanry KP: The effect of dermatologic precautions on the incidence of rash with addition of lamotrigine in the treatment of bipolar I disorder. *J Clin Psychiatry* 2006;67(3):400-6.
- 145) Fenn HH, Sommer BR, **Ketter TA**, Alldredge B: Safety and tolerability of mood-stabilising anticonvulsants in the elderly. *Expert Opin Drug Saf* 2006;5(3):401-16.
- 146) **Ketter TA**, Suppes T, Morrell MJ, Rasgon N, Cohen LS, Viguera AC: Reproductive health and bipolar disorder. *CNS Spectr* 2006; 11(5 Suppl 5):1-16.
- 147) Brooks JO, 3rd, Wang PW, Strong C, Sachs N, Hoblyn JC, Fenn R, **Ketter TA**: Preliminary evidence of differential relations between prefrontal cortex metabolism and sustained attention in depressed adults with bipolar disorder and healthy controls. *Bipolar Disord* 2006; 8(3):248-54.
- 148) Calabrese JR, Goldberg JF, **Ketter TA**, Suppes T, Frye M, White R, Deveaugh-Geiss A, Thompson TR: Recurrence in bipolar I disorder: a post hoc analysis excluding relapses in two double-blind maintenance studies. *Biol Psychiatry* 2006; 59(11):1061-1064.
- 149) Bowden CL, Calabrese JR, **Ketter TA**, Sachs GS, White RL, Thompson TR: Impact of lamotrigine and lithium on weight in obese and nonobese patients with bipolar I disorder. *Am J Psychiatry* 2006; 163(7):1199-1201.
- 150) Wang PW, Sailasuta N, Chandler RA, **Ketter TA**: Magnetic resonance spectroscopic measurement of cerebral gamma-aminobutyric acid concentrations in patients with bipolar disorders. *Acta Neuropsychiatrica* 2006; 18(2):120-126.
- 151) **Ketter TA**, Wang PW, Chandler RA, Culver JL, Alarcon AM: Adjunctive aripiprazole in treatment-resistant bipolar depression. *Annals Clin Psychiatry* 2006;18(3):169-72.
- 152) Nasrallah HA, **Ketter TA**, Kalali AH. Carbamazepine and valproate for the treatment of bipolar disorder: a review of the literature. *J Affective Disord* 2006;95(1-3):69-78.
- 153) **Ketter TA**, Nasrallah HA, Fagiolini A: Mood stabilizers and atypical antipsychotics: bimodal treatments for bipolar disorder. *Psychopharmacol Bull* 2006;39(1):120-46.
- 154) Weisler RH, Cutler AJ, Ballenger JC, Post RM, **Ketter TA**: The use of antiepileptic drugs in bipolar disorders: a review based on evidence from controlled trials. *CNS Spectr* 2006;11(10):788-99.
- 155) **Ketter TA**, Haupt DW: Current perceptions of weight gain and bipolar pharmacotherapy: results of a 2005 survey of physicians in clinical practice. *Curr Med Res Opin* 2006;22(12):2345-53.
- 156) Wang PW, Sachs GS, Zarate CA, Marangell LB, Calabrese JR, Goldberg JF, Sagduyu K, Miyahara S, **Ketter TA**: Overweight and obesity in bipolar disorders. *J Psychiatr Res* 2006;40(8):762-4.

- 157) Marangell LB, Suppes T, **Ketter TA**, Dennehy EB, Zboyan H, Kertz B, Nierenberg A, Calabrese J, Wisniewski SR, Sachs G: Omega-3 fatty acids in bipolar disorder: clinical and research considerations. *Prostaglandins Leukot Essent Fatty Acids* 2006;75(4-5):315-21.
- 158) Frye MA, Yatham LN, Calabrese JR, Bowden CL, **Ketter TA**, Suppes T, Adams BE, Thompson TR. Incidence and time course of subsyndromal symptoms in patients with bipolar I disorder: an evaluation of two placebo-controlled maintenance trials. *J Clin Psychiatry* 2006;67(11):1721-8.
- 159) Post RM, **Ketter TA**, Uhde T, Ballenger JC: Thirty years of clinical experience with carbamazepine in the treatment of bipolar illness: principles and practice. *CNS Drugs* 2007;21(1):47-71.
- 160) Culver JL, Arnow B, **Ketter TA**: Bipolar disorder: improving diagnosis and optimizing integrated care. *J Clin Psychol* 2007;63(1):73-92.
- 161) Cookson J, Keck PE, **Ketter TA**, Macfadden W: Number needed to treat and time to response/remission for quetiapine monotherapy efficacy in acute bipolar depression: evidence from a large, randomized, placebo-controlled study. *Int Clin Psychopharmacol* 2007;22(2):93-100.
- 162) Sommer, BR, Fenn HH, **Ketter TA**: Safety, tolerability and efficacy of anticonvulsants in older patients with psychiatric disorders: oxcarbazepine, topiramate, and gabapentin. *Expert Opin Drug Saf* 2007;6(2):133-45.
- 163) Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L, Friedman ES, Bowden CL, Fossey MD, Ostacher MJ, **Ketter TA**, Patel J, Hauser P, Rapport D, Martinez JM, Allen MH, Miklowitz DJ, Otto MW, Dennehy EB, Thase ME: Effectiveness of Adjunctive Antidepressant Treatment for Bipolar Depression. *N Engl J Med* 2007;356(17):1711-22.
- 164) Santosa CM, Strong CM, Nowakowska C, Wang PW, Rennie CM, **Ketter TA**: Enhanced creativity in bipolar disorder patients: a controlled study. *J Affect Disord* 2007;100(1-3):31-39.
- 165) Strong CM, Nowakowska C, Santosa CM, Wang PW, Kraemer HC, **Ketter TA**: Temperament-creativity relationships in mood disorder patients, healthy controls and highly creative individuals. *J Affect Disord* 2007;100(1-3):41-48.
- 166) **Ketter TA**: Introduction - Advancing the treatment of acute mania: Evidence for the efficacy and safety of quetiapine. *J Affect Disord* 2007;100(Suppl 1):S1-S3.
- 167) **Ketter TA**, Jones M, Paulsson B: Rates of remission/euthymia with quetiapine monotherapy compared with placebo in patients with acute mania. *J Affect Disord* 2007;100(Suppl 1):S45-S53.
- 168) Malhi GS, Lagopoulos J, Sachdev PS, Ivanovski B, Shnier R, **Ketter TA**: Is lack of disgust something to fear? A functional magnetic resonance imaging facial emotion recognition study in euthymic bipolar disorder patients. *Bipolar Disord* 2007;9(4):345-57.
- 169) Goldberg JF, Bowden CL, Calabrese JR, **Ketter TA**, Dann RS, Frye MA, Suppes T, Post RM: Six-month prospective life charting of mood symptoms with lamotrigine monotherapy versus placebo in rapid cycling bipolar disorder. *Biol Psychiatry* 2008;63(1):125-30.

- 170) Marsh WK, Templeton A, **Ketter TA**, Rasgon NL: Increased frequency of depressive episodes during the menopausal transition in women with bipolar disorder: Preliminary report. *J Psychiatr Res* 2008;42(3):247-51.
- 171) Konarski JZ, McIntyre RS, Kennedy SH, Rafi-Tari S, Soczynska JK, **Ketter TA**: Volumetric neuroimaging investigations in mood disorders: bipolar disorder versus major depressive disorder. *Bipolar Disord* 2008;10(1):1-37.
- 172) Wang PW, Yang YS, Chandler RA, Nowakowska C, Alarcon AM, Culver J, **Ketter TA**. Adjunctive zonisamide for weight loss in euthymic bipolar disorder patients: A pilot study. *J Psychiatr Res* 2008;42(6):451-7.
- 173) El-Mallakh RS, **Ketter TA**, Weisler RH, Hirschfeld R, Cutler AJ, Gazda T, Keck P, Swann AC, Kalali AH: Switching from other agents to extended-release carbamazepine in acute mania. *Psychopharmacol Bull* 2008;41(1): 52-8.
- 174) Nowakowska C, Sachs GS, Zarate, CA, Marangell LB, Calabrese JR, Goldberg JF, **Ketter TA**: Increased rate of non-right handedness in patients with bipolar disorder. *J Clin Psych* 2008;69(5):866-7.
- 175) Chandler RA, Wang PW, **Ketter TA**, Goodwin GM. A new US-UK diagnostic project: mood elevation and depression in first year undergraduates at Oxford and Stanford universities. *Acta Psychiatr Scand* 2008;118:81-5.
- 176) Perlick, DA, Rosenheck, RA, Miklowitz, DJ, Kaczynski, R, Link, BG, **Ketter, T**, Wisniewski, S, Wolff, N, Sachs, G: Caregiver burden and health in bipolar disorder: A cluster analytic approach. *J Nerv Met Disord* 2008;196(6):484-91.
- 177) **Ketter TA**, Brooks JO, 3<sup>rd</sup>, Hoblyn JC, Champion LM, Nam JY, Culver JL, Marsh WK, Bonner JC: Effectiveness of lamotrigine in bipolar disorder in a clinical setting. *J Psychiatr Res* 2008;43(1):13-23.
- 178) Willis MW, Benson BE, **Ketter TA**, Kimbrell TA, George MS, Speer AM, Herscovitch P and Post RM: Interregional cerebral metabolic associativity during a continuous performance task, part I: Healthy adults. *Psychiatry Res Neuroimaging* 2008;164(1):16-29.
- 179) Benson BE, Willis MW, **Ketter TA**, Speer AM, Kimbrell TA, George MS, Herscovitch P and Post RM: Interregional cerebral metabolic associativity during a continuous performance task, part II: Differential alterations in bipolar and unipolar disorders. *Psychiatry Res Neuroimaging* 2008;164(1):30-47.
- 180) **Ketter TA**. Monotherapy versus combined treatment with second-generation antipsychotics in bipolar disorder. *J Clin Psychiatry* 2008;69(Suppl 5):9-15.
- 181) **Ketter TA**. Combination therapy versus monotherapy in bipolar disorder. *J Clin Psychiatry* 2008;69(12):e34.
- 182) Brooks JO, 3<sup>rd</sup>, Wang PW, Bonner JC, Rosen AC, Hoblyn JC, Hill SJ, **Ketter TA**: Decreased prefrontal, anterior cingulate, insula, and ventral striatal metabolism in medication-free depressed outpatients with bipolar disorder. *J Psychiatr Res* 2009;43(3):181-8.
- 183) Gruber J, Harvey AG, Wang PW, Brooks JO, 3<sup>rd</sup>, Thase ME, Sachs GS, **Ketter TA**: Sleep functioning in relationship to mood, function, and quality of life at entry to the Systematic

- Treatment Enhancement Program for Bipolar Disorder (STEP-BD). *J Affect Disorder* 2009;114(1-3):41-9.
- 184) Citrome L, **Ketter TA**. Teaching the philosophy and tools of evidence-based medicine: misunderstandings and solutions. *Int J Clin Pract* 2009;63(3):353-9.
- 185) Goldberg, JF, Brooks, JO, 3<sup>rd</sup>, Kurita K, Hoblyn JC, Ghaemi SN, Perlis RH, Miklowitz DJ, **Ketter TA**, Gary S. Sachs GS, Thase ME: Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: findings from the STEP-BD. *J Clin Psychiatry* 2009;70(2):155-62.
- 186) **Ketter TA**. Treating bipolar disorder: monotherapy versus combination therapy. *J Clin Psychiatry* 2009;70(2):e42.
- 187) Brooks JO, 3<sup>rd</sup>, Hoblyn JC, Woodard SA, Rosen AC, **Ketter TA**. Corticolimbic metabolic dysregulation in euthymic older adults with bipolar disorder. . *J Psychiatr Res* 2009;43(5):497-502.

#### **PART II.1A ARTICLES IN PEER REVIEWED JOURNALS - IN PRESS**

- 188) Brooks JO, 3<sup>rd</sup>, Bonner JC, Rosen AC, Wang PW, Hoblyn JC, Hill SJ, **Ketter TA**. Dorsolateral and dorsomedial prefrontal gray matter density changes associated with bipolar depression. *Psychiatry Res Neuroimag* (In Press).
- 189) Goldberg JF, Calabrese JR, Saville BR, Frye MA, **Ketter TA**, Suppes T, Post RM, Goodwin FK: Mood stabilization during continuation phase treatment for bipolar I disorder with lamotrigine or placebo. *J Clin Psychiatry* (In Press).
- 190) Frye MA, Yatham L, **Ketter TA**, Goldberg J, Suppes S, Calabrese JR, Bowden CL, Bourne E, Bahn RS, Adams B: Depressive relapse during lithium treatment associated with increased serum thyroid-stimulating hormone: results from two placebo-controlled bipolar I maintenance studies. *Acta Psych Scand* (In Press).
- 191) Gruber J, Culver JL, Johnson SL, Nam JY, Keller KL, **Ketter TA**. Do positive emotions predict symptomatic change in bipolar disorder? *Bipolar Disord* (In Press).
- 192) Marsh WK, **Ketter TA**, Rasgon NL. Increased depressive symptoms in menopausal age women with bipolar disorder compared to similar age men and younger women and men. *J Psychiatric Res* (In Press).
- 193) Houston JP, Mauricio Tohen M, Degenhardt EK, Jamal HH, Liu LLL, **Ketter TA**. Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study. *J Clin Psychiatry* (In Press).

#### **PART II.1B ARTICLES IN PEER REVIEWED JOURNALS - IN REVIEW**

- 194) Autio KA, Frye MA, Leverich GS, Danielson A, **Ketter TA**, Vanderham E, Post RM: Gender differences in suicidality and TSH in refractory mood disorders. *J Affective Disord* (In Review).
- 195) Sachs G, Collins MA, Altshuler L, **Ketter TA**, Suppes T, Rasgon N, Frye M, Wozniak P, Tracy K, Sommerville K: Divalproex sodium versus placebo for the treatment of bipolar depression. *Bipolar Disord* (In Review).

- 196) Frye MA, Yatham L, **Ketter TA**, Goldberg J, Suppes S, Calabrese JR, Bowden CL, Bourne E, Adams B: Lithium associated change in serum TSH associated with time to depression relapse in two placebo-controlled bipolar I maintenance studies of lamotrigine monotherapy. (In Review).
- 197) Hwang SHJ, Childers M, Wang PW, Nam JY, Keller KL, Hill S, Culver JL, **Ketter TA**: Higher prevalence of bipolar I disorder among Asian and Latino compared to Caucasian patients receiving treatment. Psychiatr Serv (In Review).
- 198) Singh MK, **Ketter TA**, Chang KD. Atypical antipsychotics for acute manic and mixed episodes in children and adolescents with bipolar disorder: a review of efficacy and tolerability. Pediatric Drugs (In Review).
- 199) Mansour HA, Talkowski ME, Wood J, Chowdari KV, McClain L, Montrose KPD, Fagiolini A, Friedman F, Allen M, Bowden CL, Calabrese J, El-Mallakh RS, Faraone MESV, Fossey MD, Gyulai L, Loftis JM, Hauser P, **Ketter TA**, Marangell LB, Miklowitz DJ, Nierenberg AA, Patel J, Sachs GS, Sklar P, Smoller JW, Laird N, Keshavan M, Thase ME, Axelson D, Birmaher B, Lewis D, Monk T, Frank E, Kupfer DJ, Nimgaonkar VL. Association study of twenty one circadian genes with bipolar I disorder, schizoaffective disorder and schizophrenia. Bipolar Disord (In Review).

## PART II.1B ARTICLES FOR PEER REVIEWED JOURNALS - IN PREPARATION

None currently

## PART II.2 LETTERS IN PEER REVIEWED JOURNALS

- 1) **Ketter TA**, Chun D, Lu FG: Alprazolam in the treatment of compulsive symptoms. [letter] J Clin Psychopharmacol 1986;6(1):59-60.
- 2) George MS, Post RM, **Ketter TA**, Marangell LB, Pazzaglia PJ: A clarification of alpidem as an antidepressant. [letter] J Clin Psychiatry 1992;53(2):68-69.
- 3) Callahan AM, **Ketter TA**, Crumlish J, Parekh P, Brown DW, Post RM: Reply to letter from Swartz on "Mania and lower serum cholesterol levels". [letter] J Clin Psychopharmacol 1996;16(1):95-97.
- 4) **Ketter TA**, Callahan AM, Post RM: Nefazodone relief of alprazolam interdose dysphoria: a potential therapeutic benefit of 3A3/4 inhibition. [letter] J Clin Psychiatry 1996;57(7):307.
- 5) **Ketter TA**, Post RM, Parekh P, Worthington K: Dr. Ketter and colleagues reply (Reply to: MAOI-carbamazepine combination and statistical power). [letter] J Clin Psychiatry 1996;57(7):312.
- 6) **Ketter TA**, Malow BA, Post RM, Theodore WH: Psychiatric effects of felbamate. [letter] J Neuropsychiatry Clin Neurosci 1997;9(1):118-119.
- 7) **Ketter TA**, Andreason PJ, Lee C, Gill DS, Parekh PI, Willis MW, Herscovitch P, Post RM, George MS: Dr. Ketter and colleagues reply (Reply to: Anterior paralimbic mediation of procaine-induced emotional and psychosensory experiences). [letter] Arch Gen Psychiatry 1997;54(8):763-765.

- 8) **Ketter TA**, Callahan AM, Post RM: Dr. Ketter and colleagues reply (Reply to: Antiepileptic drug augmentation for treatment-resistant depression). [letter] *J Clin Psychiatry* 1997;58(8):362-363.
- 9) **Ketter TA**, Winsberg ME, DeGolia SG, Dunai M, Tate DL, Strong CM: Rapid efficacy of olanzapine augmentation in nonpsychotic bipolar mixed states. [letter] *J Clin Psychiatry* 1998;59(2):83-85.
- 10) **Ketter TA**, Winsberg ME, DeGolia SG, Dunai M, Tate DL, Strong CM: Dr. Ketter and colleagues reply (Reply to: Comments on efficacy of olanzapine in mood disorders). [letter] *J Clin Psychiatry* 1998;59(10):538.
- 11) Frye MA, Luckenbaugh D, Kimbrell TA, Constantino C, Grothe D, Corá-Locatelli G, **Ketter TA**: Possible gabapentin-induced thyroiditis. [letter] *J Clin Psychopharmacol* 1999;19(1):94-5.
- 12) Kimbrell TA, **Ketter TA**, George MS, Little JT, Benson BE, Willis MW, Herscovitch P, Post RM: Reply to "Comment on regional cerebral glucose metabolism utilization in patients with a range of severities of unipolar depression" [letter]. *Biol Psychiatry* 2002; 52(10):1031-2.
- 12) **Ketter TA**: Is neuroimaging relevant to the diagnosis and treatment of bipolar disorder? [letter] *J Bipolar Disord* 2003;2(3):3.
- 13) Nowakowska C, Sachs GS, Zarate, CA, Marangell LB, Calabrese JR, Goldberg JF, **Ketter TA**: Increased rate of non-right handedness in patients with bipolar disorder. *J Clin Psych* 2008;69(5):866-7.
- 14) Stemmler PG, Kenna HA, Wang PW, Hill SJ, **Ketter TA**, Rasgon NL. Insulin resistance and hyperlipidemia in women with bipolar disorder. *J Psychiatr Res* 2009;43(3):341-3.

### PART II.3 BOOK CHAPTERS

- 1) Post RM, Altshuler LL, **Ketter TA**, Denicoff K, Weiss SR: Antiepileptic drugs in affective illness: clinical and theoretical implications. In: Smith DB, Treiman DM, Trimble MR, eds. *Neurobehavioral Problems in Epilepsy. Advances in Neurology, Volume 55*. Raven Press, New York 1991:239-277.
- 2) Post RM, Weiss SR, Clark M, Nakajima T, **Ketter TA**: Seizures as an evolving process: implications for neuropsychiatric illness. In: Theodore WH, Devinsky O, eds. *Epilepsy and Behavior*. Wiley-Liss, New York 1991:361-387.
- 3) Post RM, Weiss SR, **Ketter TA**, George MS, Clark M, Rosen J: The temporal lobes and affective disorders. In: Bolwig T, Trimble M, eds. *The Temporal Lobes and Limbic System: Basic and Clinical Perspectives*. Wrightson Biomedical Publishing Limited, England 1992:247-265.
- 4) Post RM, **Ketter TA**, Denicoff K, Leverich G, Mikalaukas K: Assessment of anticonvulsant drugs in patients with bipolar affective illness. In: Hindmarch I, Stonier PD, eds. *Human Psychopharmacology: Methods and Measures, Volume 4*. John Wiley & Sons, Limited, New York 1993:211-245.
- 5) Post RM, George MS, **Ketter TA**, Denicoff K, Leverich G, Mikalaukas K: Mechanisms underlying recurrence and cycle acceleration in affective disorders: implications for long-



- term treatment. In: Montgomery SA, Corn TH, eds. *Psychopharmacology of Depression*. Oxford University Press, Oxford 1994:141-169.
- 6) Post RM, Weiss SRB, Chuang DM, **Ketter TA**: Mechanisms of action of carbamazepine in seizure and affective disorders. In: Joffe RT, Calabrese JR, eds. *Anticonvulsants in Psychiatry*. Marcel Dekker, Inc., New York 1994:43-92.
  - 7) **Ketter TA**, Post RM: Clinical pharmacology and pharmacokinetics of carbamazepine. In: Joffe RT, Calabrese JR, eds. *Anticonvulsants in Psychiatry*. Marcel Dekker, Inc., New York 1994:147-187.
  - 8) Post RM, **Ketter TA**, Pazzaglia PJ, Denicoff K, Marangell L, George MS: Anticonvulsants in refractory mood disorders. In: Nolan WA, Zohar J, Roose SP, Amsterdam JD, eds. *Refractory Depression: Current Strategies and Future Directions*. John Wiley & Sons, Limited, New York 1994:97-113.
  - 9) Post RM, Weiss SRB, Leverich, **Ketter TA**: Modeling of affective illness: implications for treatment. In: *Depression as a Lifetime Disorder*, Lundbeck Monograph 1994:25-50.
  - 10) George MS, **Ketter TA**, Kimbrell TA, Speer AM, Steedman JM, Post RM: What functional imaging has revealed about the brain basis of mood and emotion. In: Panksepp J: *Advances in Biological Psychiatry, Volume 2*. JAI Press Inc., Greenwich, CT 1996:63-113.
  - 11) Post RM, Weiss SRB, Leverich GS, George MS, Frye M, **Ketter TA**: Developmental psychobiology of cyclic affective illness: implications for early therapeutic intervention. In: Chichetti D, Tucker D (eds.) *Development and Psychopathology* Cambridge University Press, Cambridge 1996;8:273-305.
  - 12) **Ketter TA**, George MS, Kimbrell TA, Willis MW, Benson BE, Post RM: Neuroanatomical models and brain imaging studies. In: Joffe RT, Young LT (eds.) *Bipolar Disorder: Neurobiology and Clinical Applications*. Marcel Dekker, Inc., New York 1997:179-217.
  - 13) George MS, **Ketter TA**, Kimbrell TA, Post RM: Brain imaging in mania. In: Goodnick P (ed.) *Mania: Clinical and Research Perspectives*. American Psychiatric Press, Washington 1998:191-238.
  - 14) **Ketter TA**, Post RM, Denicoff K, Pazzaglia PJ, Marangell LB, George MS, Callahan AM: Carbamazepine. In: Goodnick P (ed.) *Mania: Clinical and Research Perspectives*. American Psychiatric Press, Washington 1998:263-300.
  - 15) George MS, Post RM, **Ketter TA**, Kimbrell TA, Speer AM: Neural mechanisms of mood disorders. In: Rush AJ (ed.) *Mood and Anxiety Disorders*. Williams & Wilkins, Baltimore 1998:1-21
  - 16) Post RM, Weiss SRB, **Ketter TA**, Denicoff KD, George MS, Frye M, Smith MA, Leverich GS: The kindling model: implications for the etiology and treatment of mood disorders. In: Rush AJ (ed.) *Mood and Anxiety Disorders*. Williams & Wilkins, Baltimore 1998:22-42.
  - 17) Post RM, **Ketter TA**, Speer AM, Leverich GS, Weiss SRB: Predictive validity of the sensitization and kindling hypothesis. In: Soares JC, Gershon S (eds) *Bipolar Disorders*. Marcel Dekker, New York 2000:387-432.
  - 18) Post RM, Pazzaglia PJ, **Ketter TA**, Denicoff KD, Weiss SRB, Hough C, Chuang DM, Stein R, Frye M: Carbamazepine and nimodipine in refractory bipolar illness: efficacy and

- mechanisms. In: Montgomery SA, Halbreich U (eds) *Pharmacotherapy for Mood, Anxiety and Cognitive Disorders*. American Psychiatric Press, Washington. 2000:77-110.
- 19) **Ketter TA**, Bench CJ, George MS, Kimbrell T, Post RM: Structural and functional brain imaging in resistant mood disorders. In: Amsterdam JD, Nierenberg A, Hornig M (eds) *Textbook of Refractory Mood Disorders*. Cambridge University Press, Cambridge 2001:111-41.
- 20) George MS, **Ketter TA**, Kimbrell TA, Speer AM, Lorberbaum J, Liberatos CC, Nahas Z, Post RM: Neuroimaging approaches to the study of emotion. In: Borod JC (ed.) *The Neuropsychology of Emotion*. Oxford University Press, Oxford 2001:106-134.
- 21) **Ketter TA**, Wang PW, Li X: Psychotropic medications in bipolar disorder: pharmacodynamics, pharmacokinetics, drug interactions, adverse effects and their management. In: Yatham LN, Kusumakar V, Kutcher SP (eds.), *Bipolar Disorder: A Clinician's Guide To Biological Treatments*. Brunner-Routledge, New York 2002:265-306.
- 22) **Ketter TA**, Wang PW, Lembke A, Sachs N: Physiological and pharmacological induction of affect. In: Davidson RJ, Scherer KR, Goldsmith HH (eds), *The Handbook of Affective Science*. Oxford University Press, New York. 2002:930-62
- 23) **Ketter TA**, Wang PW, Dieckmann N, Lembke A, Becker OV, Camilleri C: Brain anatomic circuits and the pathophysiology of affective disorders. In: Soares JC (ed) *Brain Imaging in Affective Disorders*. Marcel Dekker, Inc., New York 2002:79-118.
- 24) **Ketter TA**, Wang PW, Post RM: Carbamazepine and oxcarbazepine, in *The American Psychiatric Press Textbook of Psychopharmacology (Third Edition)*. Edited by Schatzberg AF, Nemeroff CB. American Psychiatric Press, Washington, DC 2003:581-606.
- 25) **Ketter TA**: Gabapentin. In: Kaplan BJ, Sadock VA (eds) *Kaplan & Sadock's Comprehensive Textbook of Psychiatry (8<sup>th</sup> edition)*. Lippincott Williams & Wilkins, Philadelphia, PA 2005:2746-9.
- 26) **Ketter TA**: Lamotrigine. In: Kaplan BJ, Sadock VA (eds) *Kaplan & Sadock's Comprehensive Textbook of Psychiatry (8<sup>th</sup> edition)*. Williams & Wilkins, Philadelphia, PA 2005:2749-53.
- 27) **Ketter TA**: Topiramate. In: Kaplan BJ, Sadock VA (eds) *Kaplan & Sadock's Comprehensive Textbook of Psychiatry (8<sup>th</sup> edition)*. Williams & Wilkins, Philadelphia, PA 2005:2753-6.
- 28) **Ketter TA**, Sachs GS, Bowden CL, Calabrese JR, Chang KD, Rasgon NL: Introduction. In: T. A. Ketter (ed.) *Advances in the Treatment of Bipolar Disorder*. American Psychiatric Publishing, Inc., Washington, DC. 2005:1-9.
- 29) **Ketter TA**, Wang PW, Nowakowska C, Marsh WK, Bonner JC: Advances in the treatment of acute mania. In: T. A. Ketter (ed.) *Advances in the Treatment of Bipolar Disorder*. American Psychiatric Publishing, Inc., Washington, DC. 2005:11-55.
- 30) Wang PW, **Ketter TA**: [Structural and functional imaging]. In Bauer M, Berghofer A, Adli M: [Acute and Treatment-Resistant Depression]. Springer Medizin Verlag, Heidelberg. 2005:127-148.

- 31) **Ketter TA** – Collaborator (authored Chapter 15 “Neuroanatomy and neuroimaging”) In Goodwin F, Jamison KR: Manic Depressive Illness, second edition. Oxford University Press, Oxford UK 2007:609-58.
- 32) **Ketter TA**, Wang PW: Management commentary. In G Parker (ed.) Bipolar II Disorder. Modelling, Measuring, and Managing. Cambridge University Press, Cambridge, UK. 2008:217-31.

#### **PART II.3A BOOK CHAPTERS - IN PRESS**

- 33) Parker G, **Ketter TA**: Management of bipolar II disorder. In Yatham LN, Maj M (eds.) Bipolar Disorder: Clinical and Neurobiological Foundations. Blackwell Publishing, Ltd., Oxford UK (In Press).
- 34) **Ketter TA** (ed): Clinical Manual of Bipolar Disorder. Arlington, VA, American Psychiatric Publishing (In Press).

#### **PART II.4 OTHER PUBLICATIONS**

- 1) **Ketter TA**: A computer study of conjugacy classes in certain isogenous groups. University of Sydney Department of Mathematics Technical Reports 1976.
- 2) **Ketter TA**: Review of L. Connor's article "Ships of fools and vessels of the divine". Transcultural Psychiatric Research Review 1983;20(3):207-210.
- 3) **Ketter TA**: Review of L. Suryani's article "Culture and mental disorder: The case of bebainan in Bali". Transcultural Psychiatric Research Review 1985;22(2):135-138.
- 4) Post RM, **Ketter TA**, George MS: Psychiatric syndromes and the limbic system. In: Mesulam MM, ed. Behavioral Neurology: Limbic System in Neurology and Psychiatry. Course Syllabus 246. American Academy of Neurology, Minneapolis 1993:79-99.
- 5) Post RM, **Ketter TA**, Callahan AM: Treating a manic episode that breaks through lithium prophylaxis. International Drug Therapy Newsletter 1994;29(3):13-16.
- 6) **Ketter TA**: Anatomy and pharmacology of depression I. Audio Digest Psychiatry 1995;24(8):2.
- 7) **Ketter TA**: Anatomy and pharmacology of depression II. Audio Digest Psychiatry 1995;24(9):1-2.
- 8) **Ketter TA**, Chang KD, Post RM: Carbamazepine in child and adolescent psychiatry. Child and Adolescent Psychopharmacology News 1997;2(1):1:4.
- 9) **Ketter TA**: Bipolar pharmacology. Audio Digest Psychiatry 2000;29(18):1-3.
- 10) **Ketter TA**: New treatment options in bipolar disorders. American Society of Clinical Psychopharmacology Progress Notes 2000.
- 11) **Ketter TA**: Diagnosis of bipolar II disorder. 14 National DMDA Outreach 2001;(Summer):8.

- 12) Chang KD, Barnea-Goraly N, Adleman N, **Ketter TA**: Brain imaging in bipolar disorder. *Contemporary Psychiatry* 2002;1(4):1-10.
- 13) **Ketter TA**: A 54-year-old man with treatment-resistant bipolar I disorder: management of adverse effects resulting from medications used during maintenance treatment can be an ongoing challenge to the clinician. *Psychiatric Annals* 2004;34(2):90-3.
- 14) Wang PW, **Ketter TA**: The emerging role of GABAergic mechanisms in mood disorders. *Psychiatric Times* 2005;22(10):90-95.
- 15) Wang PW, **Ketter TA**: Clinical use of carbamazepine for bipolar disorders. *Expert Opin Pharmacother* 2005; 6(16):2887-2902.
- 16) **Ketter TA**: Diagnosis and acute treatment of bipolar I disorder. *Physician's Weekly* 2007;24(15):1. <http://www.physweekly.com>.
- 17) **Ketter TA**: Preventing recurrence in bipolar I disorder. *Physician's Weekly* 2007;24(22):1. <http://www.physweekly.com>.
- 18) **Ketter TA**: Emerging concepts in management strategies for bipolar II disorder. *Physician's Weekly* 2007;24(30):1. <http://www.physweekly.com>.
- 19) **Ketter TA**: Update on diagnosis and treatment of bipolar depression (Part II): An interview with Terence A Ketter MD. *Currents in Affective Illness* 2007;26(9):5-9..
- 20) **Ketter TA**: Update on diagnosis and treatment of bipolar depression (Part III): An interview with Terence A Ketter MD. *Currents in Affective Illness* 2007;26(10):5-9.
- 21) **Ketter TA**, Wang PW, Culver JL, Hill S, Nam JY: Creativity and mood disorder: the case of Edvard Munch. *Cantor Arts Center Journal* 2006-2007;5:76-85.
- 22) **Ketter TA**: Incorporating trial data into bipolar disorder management. *J Clin Psychiatry* 2008;69[7]:e21.
- 23) **Ketter TA**. Monotherapy versus combination treatment in bipolar disorder. *Prim Care Companion J Clin Psychiatry* 2008;10(5):393-5.

#### **STANFORD AND COMMUNITY OUTREACH**

- 1) **Ketter TA**: The biology of mood disorders. Presentation to students of Nueva School, Psychiatry Building, Stanford, CA, January 5, 1996.
- 2) **Ketter TA**: Recent research in brain imaging and medication treatment of mood disorders. Presentation to San Francisco Depressive and Manic Depressive Association, Saint Francis Hospital, San Francisco, CA, January 24, 1996.
- 3) **Ketter TA**: New research findings in brain imaging and medication treatment of mood disorders. Presentation to Berkeley Bipolar Support Group, Herick Hospital, Berkeley, CA, February 1, 1996.
- 4) **Ketter TA**: Recent research findings in brain imaging and medication treatment of mood disorders. Presentation to Mood Disorders Support Group, Psychiatry Building, Stanford, CA, May 15, 1996.

- 5) **Ketter TA:** Recent medication and brain imaging research in mood disorders. Presentation to Los Altos Depressive and Manic Depressive Association, Christ Episcopal Church, Los Altos, CA, June 5, 1996.
- 6) **Ketter TA:** Brain imaging and medication and research in mood disorders. Presentation to West Valley Mental Health Services, Santa Clara Valley Mental Health Department, Los Gatos, CA, July 25, 1996.
- 7) **Ketter TA:** New research in brain imaging and treatment of mood disorders. Presentation to Alliance for the Mentally Ill of Marin County, Saint Sebastian's Church, San Rafael, CA, September 5, 1996.
- 8) **Ketter TA:** Update on research in brain imaging and treatment of mood disorders. Presentation to Alliance for the Mentally Ill of Monterey County, Crossroads Shopping Center, Carmel, CA, September 11, 1996.
- 9) **Ketter TA:** Research in treatment and brain imaging in mood disorders. Presentation to Family Alliance for the Mentally Ill of Alameda County, Eden Hospital, Castro Valley, CA, September 12, 1996.
- 10) **Ketter TA:** Recent research in brain imaging and medication treatment of mood disorders. Presentation to Fremont Depressive and Manic Depressive Association, Evangelical Free Church, Fremont, CA, September 30, 1996.
- 11) **Ketter TA:** Research in treatment and brain imaging in mood disorders. Presentation to Family Alliance for the Mentally Ill of Napa County, Queen of the Valley Hospital, Napa, CA, October 1, 1996.
- 12) **Ketter TA:** New research in treatment and brain imaging in mood disorders. Presentation to National Alliance for the Mentally Ill of San Francisco, Family Services Agency Building, San Francisco, CA, October 16, 1996.
- 13) **Ketter TA:** Research in treatment and brain imaging in mood disorders. Presentation to Alliance for the Mentally Ill of Contra Costa County, Mount Diablo Hospital, Concord, CA, October 24, 1996.
- 14) **Ketter TA:** Update on research in brain imaging and treatment of mood disorders. Presentation at Fall Meeting of the California Alliance for the Mentally Ill, San Francisco Airport Marriott Hotel, Burlingame, CA, November 1, 1996.
- 15) **Ketter TA:** Recent research in brain imaging in mood disorders. Presentation to the 7th Annual Conference of the California Depressive and Manic Depressive Association, Cathedral Hill Hotel, San Francisco, CA, November 3, 1996.
- 16) **Ketter TA:** Recent research in brain imaging and treatment in mood disorders. Presentation to Alliance for the Mentally Ill - American Schizophrenia Association of Alameda County, University Christian Church, Berkeley, CA, January 22, 1997.
- 17) **Ketter TA:** New research in brain imaging and medication treatment in mood disorders. Presentation to Alliance for the Mentally Ill of Santa Clara County, Hewlett Packard Auditorium, Santa Clara, CA, March 11, 1997.
- 18) **Ketter TA:** Management of bipolar disorders. Presentation to Consumers' Group of Family Alliance for the Mentally Ill of Fresno, Mental Health Department, Fresno, CA, April 22, 1997.

- 19) **Ketter TA:** Research in brain imaging and medication treatment in bipolar disorders. Presentation to Family Alliance for the Mentally Ill of Fresno, Trinity Lutheran Church, Fresno, CA, April 22, 1997.
- 20) **Ketter TA:** Treatments for bipolar disorders. Presentation to Mental Health Association of Santa Clara County, Psychiatry Building, Stanford, CA, September 9, 1997.
- 21) **Ketter TA:** New treatments for bipolar disorders. Presentation to Family Alliance for the Mentally Ill of Alameda County, Eden Hospital, Castro Valley, CA, September 11, 1997.
- 22) **Ketter TA:** Mood and attention-deficit/hyperactivity disorders: commonalities and dissociations. Presentation to Marin Children and Adults with Attention Deficit Disorders, Marin Community Mental Health Building, Greenbrae, CA, June 9, 1998.
- 23) **Ketter TA:** Creativity, temperament, and treatment in bipolar disorders. Presentation to Summer Meeting of California Alliance for the Mentally Ill, Santa Clara, CA, August 28, 1998.
- 24) **Ketter TA:** New treatment advances for bipolar disorders. Presentation to Alliance for the Mentally Ill of Sonoma County, Sonoma County Public Health Services Administration Building, Santa Rosa, CA, October 22, 1998.
- 25) **Ketter TA:** New treatment options for bipolar disorders. Keynote presentation to the 8<sup>th</sup> Annual Conference of the California Depressive and Manic Depressive Association, Double Tree Hotel, Modesto, CA, October 24, 1998.
- 26) **Ketter TA:** New treatments for bipolar disorders. Presentation to the Tri-Valley Support Group for Families of the Mentally Ill, Valley Care Health System Hospital, Pleasanton, CA, February 1, 1999.
- 27) **Ketter TA:** Recent research in bipolar disorders. Presentation for the Stanford Help Center, Tressider Union Building, Stanford, CA, February 22, 1999.
- 28) **Ketter TA:** New treatments for bipolar disorders. Presentation for the Annual Conference of the National Depressive and Manic-Depressive Association, Adam's Mark Hotel, Houston, TX, October 3, 1999.
- 29) **Ketter TA:** Creativity in bipolar disorders. Presentation for Stanford Annual Reunion Homecoming, Building 370, Stanford, CA, October 15, 1999.
- 30) **Ketter TA:** Update on bipolar disorders. Presentation to United Consumer Advocacy Network of Fresno, W. Gary Cannon Psychological Service Center, Fresno, CA, June 8, 2000.
- 31) **Ketter TA:** New anticonvulsants for bipolar disorders. Presentation for the Annual Conference of the National Depressive and Manic-Depressive Association, Royal Sonesta Hotel, Cambridge, MA, August 12, 2000.
- 32) **Ketter TA:** Research in treatment and brain imaging in mood disorders. Presentation to Alliance for the Mentally Ill of Contra Costa County, Mount Diablo Hospital, Concord, CA, February 15, 2001.
- 33) **Ketter TA:** Medical comorbidity in bipolar disorders. Presentation for the Annual Conference of the National Depressive and Manic-Depressive Association, Renaissance Hotel, Cleveland, OH, August 19, 2001

- 34) **Ketter TA:** Mood, temperament, and creativity. In: Creativity and Madness: A Symposium, Building 320, Stanford, CA, April 6, 2002.
- 35) Seligman TK, Delaney C, Hui M, Shanks M, **Ketter TA:** Creativity: Beyond the Genius Myth. Panel for Stanford "Think Again" Alumni Event, Hilton Hotel, Chicago, IL, May 4, 2002.
- 36) Seligman TK, Delaney C, Hui M, Shanks M, **Ketter TA:** Creativity: Beyond the Genius Myth. Panel for Stanford Annual Reunion Homecoming, Building 420, Stanford, CA, October 17, 2002.
- 37) **Ketter TA:** New treatment options for bipolar disorders. Presentation for the 12<sup>th</sup> Annual Conference of the California Depressive and Manic Depressive Association, Cathedral Hill Hotel, San Francisco, CA, October 19, 2002.
- 38) **Ketter TA:** Creativity in bipolar disorders. Presentation for the Academy of Art College, San Francisco, CA, May 20, 2003.
- 39) **Ketter TA:** New treatments for bipolar disorders. Presentation for the Annual Conference of the National Depression and Bipolar Support Alliance, Hyatt Regency Hotel, Long Beach, CA, August 16, 2003.
- 40) **Ketter TA:** Creativity in bipolar disorders. Presentation for the Art Institute of California-San Francisco, San Francisco, CA, September 4, 2003.
- 41) **Ketter TA:** Creativity in bipolar disorders. Presentation for the California College of Art, Oakland, CA, September 15, 2003.
- 42) **Ketter TA:** Creativity in bipolar disorders. Presentation for Stanford Annual Reunion Homecoming, Economics Building, Room 140, Stanford, CA, October 17, 2003.
- 43) **Ketter TA:** Early detection and intervention in bipolar disorders. Presentation for Student Counseling Services, San Jose State University, San Jose, CA, November 20, 2003.
- 44) **Ketter TA:** Early detection and intervention in bipolar disorders. Presentation for Student Counseling Services, Santa Clara University, Santa Clara, CA, January 20, 2004.
- 45) **Ketter TA:** Creativity, mood, and temperament. Presentation for Stanford Annual Alumni Day, Building 200, Room 205, Stanford, CA, March 6, 2004.
- 46) **Ketter TA:** Bipolar disorders – differences in diagnosis and treatment compared to unipolar major depression. Presentation for the Stanford Help Center, 100 Encina Commons, Stanford, CA, March 18, 2004.
- 47) **Ketter TA:** Creativity, mood, and temperament. Presentation for Stanford Community Lecture Series, Clark Center Auditorium, Stanford, CA, October 6, 2004.
- 48) **Ketter TA:** Creativity, mood, and temperament. Presentation for Stanford Annual Alumni Day, Building 200, Room 002, Stanford, CA, October 22, 2004.
- 49) **Ketter TA:** Advances in bipolar disorders research. Presentation in: A New Era in Psychiatry- Knowledge, Treatments & Hope, Frances C. Arrillaga Alumni Center, Stanford, CA, March 7, 2005.

- 50) **Ketter TA:** Brain imaging in mood disorders. Presentation in: The Human Brain – Neuropsychiatric Conditions, Cubberley Auditorium, Education Building, Stanford, CA, April 9, 2005.
- 51) **Ketter TA:** Differential diagnosis of schizophrenia and bipolar disorders. Presentation in: Stanford Schizophrenia and Bipolar Disorder Education Day, Fairchild Auditorium, Stanford, CA, July 30, 2005.
- 52) **Ketter TA:** New treatments for bipolar disorders. National Alliance for the Mentally Ill of Marin County, Marin General Hospital, Greenbrae, CA, November 14, 2005.
- 53) **Ketter TA:** Creativity and mood disorder: the case of Edvard Munch. Presentation in: Cantor Center Edvard Munch Symposium, Annenberg Auditorium, Stanford, CA, JuAprilly 29, 2006.
- 54) **Ketter TA:** Latest advances in treatment of bipolar disorders. California National Alliance for the Mentally Ill, Marriott Hotel, Burlingame, CA, August 26, 2006.
- 55) **Ketter TA:** Differential diagnosis of schizophrenia and bipolar disorders. Presentation in: Second Annual Stanford Schizophrenia and Bipolar Disorder Education Day, Fairchild Auditorium, Stanford, CA, October 1, 2006.
- 56) **Ketter TA:** Differential diagnosis of bipolar disorder – distinguishing bipolar disorder from unipolar depression. Presentation in: Third Annual Stanford Bipolar Disorder Education Day, Fairchild Auditorium, Stanford, CA, July 14, 2007.
- 57) **Ketter TA:** Update on the treatment of bipolar disorder. Presentation to National Alliance for the Mentally Ill of San Francisco, Family Services Agency Building, San Francisco, CA, September 20, 2007.
- 58) **Ketter TA:** Diagnostic challenges in bipolar disorder. Presentation in: Fourth Annual Stanford Bipolar Disorder Education Day, William R. Hewlett Teaching Center, Stanford, CA, July 26, 2008.
- 59) **Ketter TA:** New treatments for bipolar disorders. Presentation for the 18<sup>th</sup> Annual Conference of the California Depression and Bipolar Support Alliance, Park Plaza Hotel, Oakland, CA, October 4, 2008.
- 60) **Ketter TA:** Creativity and mood disorders. Presentation for the Depression and Creativity Symposium, Library of Congress, Washington, DC, February 3, 2009.